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Abstract
ABSTRACT
Lung cancer is a leading cause of cancer death in Western countries.
Although most cases are due to tobacco smoking, complex genetics may
modulate this disease, as suggested by epidemiological studies and findings
obtained in mouse models.
Systematic population-based association studies testing several
thousands of genetic markers dispersed genome-wide have recently
become a powerful and widely-used approach to identify genetic factors
affecting common diseases.
In this thesis, the role of genetic polymorphisms and risk of cancer
were investigated through a case-control association study in Italian lung
adenocarcinoma (ADCA) patients and unrelated controls from general
population and through a case-control association family-based study in
lung cancer patients and unaffected sibs as controls. I confirmed the
relevance of a polygenic model characterized by additive and
interchangeable effects of rare alleles in the modulation of individual risk of
lung ADCA identifying multiple inherited susceptibility alleles linked to lung
cancer.
Additionally, I studied the role of genetic polymorphisms modulating
individual lung cancer prognosis through a case-only association study in
lung ADCA patients with clinical stage I versus higher clinical stage. In
particular, I identify two genes (FCN3 and TMEM100) down-regulated up to
1.8-fold in normal lung of stage>I as compared to stage I patients. These
results suggest that clinical stage may be genetically determined as
Abstract
reflected in germ-line variations as well as in the transcriptional profile of
normal lung tissue.
Although clinical application of these results awaits replication in
independent and large populations, I found that genetic variants may be
involved in the modulation of not only individual risk of lung cancer but also
clinical staging. The newly identified individual genetic profiles associated
with risk and/or prognosis of lung cancer may thus represent new
diagnostic tools and suggest molecular targets for the development of new
therapies against lung cancer.
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1.Introduction
1. INTRODUCTION
1.1 EPIDEMIOLOGY
The word "epidemiology" derives from the Greek language "epi
demos logos" in which "epi" means "on", "among" or "upon"; "demos" =
"people" and "logos" = "study of" and so is defined "the study of what is
upon the people", suggesting that it applies only to human populations (1).
It is now widely recognised as the tool used to measure the public health
impact of disease and to study the distribution and determinants of a
disease, injury, and other health outcomes in human populations. It is the
basic science of preventive medicine involving studying groups of people in
order to identify causal or/and risk factors of a disease or trait (2). These
factors may be a characteristic of individuals (e.g., their genetic
background) or the exposure to external agents.
According to Buck et al. (1988) the first published use of the word
"epidemiology" was the Spanish "epidemiologia" in a study of bubonic
plague in Spain in 1598 (3). Originally used as the term for the study of
epidemic disease, epidemiology is a continually evolving discipline
evidenced by the changing definitions. It concerns itself with populations
rather than individuals (4). The subject of epidemiology has developed and
can be applied to the control of health conditions, disease distribution and
threats to public health thanks to the methodological development of
techniques such as statistics and clinical epidemiology (5, 6).
5
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The observation that patterns of disease observed in a community
are often caused by interaction of several factors in a multiple causation or
multi-factorial aetiology of disease (4) gives the opportunity of
epidemiological approaches to describe the natural history of specific
diseases in populations analysing the aetiological determinants of disease
(2). The field of epidemiology has then expanded considerably in scope to
cover the description and causation of not only epidemic disease, but of
disease in general, and even many common non-disease health-related
conditions, such as high blood pressure and obesity.
The history of epidemiology has been documented in 1978 by
Lilienfeld (7), which investigated the origins of epidemiology, and described
it as the coming together of clinical and statistical sciences. The
establishment of epidemiology as a science was also shown to have
progressed in tandem with public health developments (8). In 1850 the
science of epidemiology was officially "born" by the clinicians when they
founded the London Epidemiological Society. These clinicians included John
Snow, the "father of epidemiology", who firstly investigated the cholera
epidemic in Soho London in 1854 by plotting cases on a map of the area
(7). During the first half of the 20th century the field of epidemiology and
public health were consolidated on monitoring and tackling major diseases,
and began to move towards cancer research. The first case-control study
was carried out in 1926 in london and Glasgow by the investigation of
aetiology of breast cancer (9). Also during the second half of the 20th
century, with improved sanitation, vaccination, and antibiotics, attention
turned to chronic diseases such as cancer and coronary heart disease. Doll
6
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and Hill's carried out case-control and cohort studies establishing the
aetiological link between smoking and lung cancer (10-12). Towards the
end of the 20th century and in the third millennium, the field has further
developed and has been applied to pursuit genetic, lifestyle and biomedical
phenomena (13); and exploring the wider, social determinants of health
and disease (14).
The history of the topic of cancer epidemiological research has been
intricately detailed by dos Santos Silva (15), where she noted that the
concept of cancer incidence, as a formal topic for scientific study, is
relatively new. Until the nineteenth and twentieth centuries, cancer was a
relatively rare since it mainly occurs in older people (7). At the beginning of
the 19th century life expectancy was around 35 years in Europe. Thus many
of those who may have got cancer later in life had died at earlier ages due
to infectious diseases, malnutrition, or accidents (7). By the 20th century,
however, pathogenesis of cancer was studied, and epidemiologists sought
to describe the distribution of the disease in populations and to analyse
potential causes (15). The principal purposes of cancer epidemiology are to
describe the burden of the disease in various human population groups,
generate and test hypotheses on its cause, and testing effectiveness of
treatments and interventions (13). With the sequencing of human genome,
the huge challenge to understand the complex interactions among genes,
environment, and behaviours, in the causation of cancer became central in
cancer epidemiology.
Typically, epidemiology is divided into three main branches:
descriptive, analytic and experimental epidemiology.
7
J .Introduction
- Descriptive epidemiology describes the distribution and the
frequency of sanitary events (deaths, disease, etc.) in terms of person,
place, and time (2). These three pillars correspond to the questions "who?",
"where?", and "when?" and are used to describe and explain health events.
Person characteristics include socio-demographic data such as age,
ethnicity, education, income, occupational status, and marital status as well
as behaviours such as diet, substance abuse, use of health care services,
etc. They are used to describe whether a particular risk factor or outcome is
more prevalent in one population than another. Place characteristics include
geographic location, population density, different features of the geography,
and location of worksites, schools, and health facilities. Finally, time
characteristics include cyclical changes, long term secular trends, and even
daily or hourly occurrences during an epidemic. Sometimes descriptive
epidemiology investigated also the questions "what?", and "how many?"
(13). Since epidemiology jointly considers person, place, and time, it
advances the idea that health and disease as result from the interaction
between individuals and their environment. The aims of descriptive
epidemiology are to describe the extent and spectrum of disease; describe
the natural history of disease; identify disease aetiological factors through
generating hypotheses for further study; predict disease trends; identify
health needs of a community; and evaluate public health intervention
programmes (4). A series of methods have been developed for study
design, statistical analyses, data collection, classification, synthesis,
tabulation and presentation, followed by inference, and interpretation (13).
Descriptive epidemiology has an important surveillance role, particularly in
8
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terms of cancer surveillance. Interpretation of findings from descriptive
epidemiology needs to be done with caution and all potential sources of
bias, confounding, and artefacts in the data need to be explored. To these
ends, it is important that the methods of data collection, collation, and
processing are understood (15). Descriptive epidemiology should not be
considered an end in itself but should be regarded as a means of monitoring
the burden of disease in the population, in addition to generating
hypotheses or highlighting areas for further study and investigation. These
areas could subsequently be explored using methods of analytical
epidemiology.
- Analytical epidemiology takes hypotheses generated by descriptive
means and tests them through an analytical approach. The main aim is to
determine causal factors in the form of aetiological risk factors for a
disease, through investigation of exposure and disease outcome at the
individual level (2). Analytical studies aims to determine whether particular
exposures (variables) such as environmental or behavioural factors
(including physical, chemical, or biological agents) are associated to a
disease outcome (13). Such an association does not necessarily indicate
causation, as chance, confounding and bias need to be considered as
possible sources of the relationship (16). Thus mathematical tools and
appropriate statistical analytical methods were developed for quantifying
and minimizing the uncertainty in the relationship between exposure and
outcome. Epidemiologists further test possible bias by teasing out spurious
or indirect causes described as confounders by increasing certainty through
repetition of observations in different populations; by increasing the number
9
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of subjects under observation which reduces the effects of random variation
and uncertainty and through developing a better understanding of the
underlying biological mechanisms. The criteria for causation in public health
and epidemiology were set down originally by Hill (17). Hills' nine criteria
for associations to be considered as causes were: strength, consistency,
temporality, specificity, biologic gradient (dose-response ratio), plausibility
(biological explanation), coherence (with previous research), experiment
(e.g., further indication from removing exposure), analogy (with previous
results in other settings) (17). These criteria have been adopted by
epidemiologists as a pragmatic approach to assess associations and
causation. Finally, it is important to consider and minimize bias that
includes any systematic error in an epidemiologic study due to an incorrect
estimate of the association (18). Bias comes in many forms and is a
particular challenge in case-control studies (see paragraph 1.7) where
selection bias can be related to the controls' selection, the comparability
between cases and controls, and the statistical efficiency (18).
- Experimental epidemiology aims to evaluate sanitary interventions
either with preventive objective (e.g., vaccinations, sanitary educational) or
therapeutic objective (e.g., testing of new drugs, new surgical techniques)
using intervention studies that explore the associations between
interventions and outcomes such as clinical trials (2).
1.2 CANCER GENETICS AND TUMOUR PROGRESSION
The origins of the term 'cancer' are in the writings of the early
Ancient Greek physician and philosopher Hippocrates (460-377 BC) who
10
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used the Greek word for crab, "karkinoma", to describe the radiating
antennae-like growths of the blood vessels extending "out of control in all
directions" from some breast tumours (19).
Cancer is a common and devastating disease that represents one of
the major public health problems in industrialized countries (20). The
disease accounted worldwide to about 7.9 million deaths (around 13% of all
deaths) in 2007, with an estimation of 12 million deaths in 2030 (World
Health Organization - WHO: http://www.who.int/cancer/enl). The most
prevalent form of cancer is lung carcinoma, representing about 29% and
26% of all cancer in men and women, respectively (Fig. 1). Among women,
breast cancer is the second most prevalent cause of cancer-related deaths,
while among men, the second most prevalent form of cancer is prostate
cancer (www. cancer.org; (20); Fig. 1).
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Fig. 1 Cancer related death rates in the United States, from 1930 until 2006 (20).
Cancer is characterized by uncontrolled growth and spread of
transformed malignant cells which are capable of invasion and destruction
of the adjacent tissue, and metastasizing far from the primitive origin
through blood or lymphatic vessels. Since the middle of 1900, cancer has
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been understood as genetic disease resulting from the dynamic
accumulation of several changes that can affect structure and expression of
key genes (review in (21)). The list of potentially factors, as we will see,
leading to genetic alterations and associated with cancer includes genetics
(e.g., family history), behaviour (e.g., tobacco habit) and environment
(e.g., radiation).
Tumours grow from a single cell as the result of one or more
mutations which confer a selective growth advantage on its progeny
through a clonal evolution process (22). The transition of a normal cell
towards a neoplastic and malignant phenotype is a multistep process
influenced by several factors that can occur spontaneously inside the cell or
can be induced by external agents (carcinogens) and that can alter either
the probability of transformation or the effects of the transforming events.
(23). Internal spontaneous changes can occur through various genetic and
epigenetic mechanisms, such as point mutation, gene amplification,
translocation, deletion, chromosomal loss, somatic recombination, gene
conversion, or DNA methylation (24). Internal influences include defects in
cell-cycle control and DNA repair mechanisms, defects in regulation of
epigenetic events, variations in metabolism of exogenous carcinogens and
in production or destruction of endogenous mutagens (23). External factors
are instead represented by environmental exposures to exogenous
carcinogens, interaction with surrounding cells and microenvironment,
mechanisms of immune system cellular defence against tumour cells, and
levels of circulating hormones or growth factors (23). All these causal
events may act together or in sequence to initiate or promote
12
1.Introduction
carcinogenesis. Two or more events are necessary before a cell becomes
malignant. It has been estimated, for example, that between four and
seven rate-limiting genetic events are required for common epithelial
cancers development (25). The pattern of alterations that transform a cell is
~1"1I1l;':_ .. lIi·d, 1111 tumor ph"lItll.' P"
lulu-ritcrl f"rl1l" or.-alln·"
tlallJili,,1 '\ 'Idroll'.",
\\",," dli-d ....till tumor "Iwllot, lie'
ill,h ••'..d 11\ IIJ I 'Iii t iou ....ill \II'(~
huli\ idll,il 'lI'II'plihilih ;((111
itllli-I'illWI'I' <11"11'::""'1"111""
---r===-=r=:'-'1
...... . ..-F,~~;:;':i;~,;ii'i'~~~'li;':~:lrl\,:'~i~,;;~;~:~';)j;:h:~-l
'1'11111111'lIIodifi,'l' "I'ltl"
{T\J(; I ,..
{,'\ll'illsi.' ,\ illirill,in
.-----~----
••
Fig. 2 Genetic predisposition to cancer (26).
not random and is peculiar not only to each type of cancer but can also
differ between cancers of the same type. Tumour development seems to be
analogous to a Darwinian evolution process in which each genetic change,
that confers a growth advantage, is maintained and leads to a progressive
switch of normal cells into cancer cells (22). The entire process of
transformation can take years to decades in humans (23).
There are two main categories of genes that influence the appearance
of cancer (26): major cancer genes with frequent somatic mutations
exerting a strong and evident effect on tumour development (Major Cancer
Predisposition Genes or MPG) and cancer modifier genes (Tumour Modifier
Genes or TMG) that are characterized by naturally occurring germ line
13
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variants playing a less perceptible role on tumour phenotypes (Fig. 2).
Somatic changes in MPG genes have strong effects on tumour
phenotype. These genes can be further divided in oncogenes and tumour
suppressor genes.
- Oncogenes are characterized by gain-of-function events. They
become the constitutionally and inappropriately activated counterparts of
normal cellular genes, named "proto-oncogenes", that control normal
cellular growth and differentiation (review in (21». In this way, oncogenes
encode proteins that strongly promote cell proliferation, increasing the
chance that a normal cell will develop into a tumour cell. Mechanisms of
oncogene activation range from single-point mutations to chromosomal
abnormalities, such as translocation and amplification (24). Oncogenes and
their products are highly unregulated in many cancer cells.
- Tumour suppressor genes (anti-oncogenes) are involved in
tumourigenesis by loss-of-function events. They normally functions to limit
cell proliferation, so in this case the loss of function takes away the control
and facilitates cancer development, usually in combination with other
genetiC changes (28). Functional activity of tumour suppressor genes can
be lost through several mechanisms such as introduction of inactivating
mutations, loss of chromosomal material, epigenetic silencing and
haploinsufficiency (29). Kinzler and Vogelstein (30) proposed a new
subdivision of this vast gene family in two different categories: gatekeepers
(such as pS3, RB and APe) that directly control cellular proliferation by
inhibiting growth or promoting cell death; and caretakers (such as Mismatch
Repair Genes and Nucleotide Excision Repair Genes) that maintain genome
14
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integrity during DNA replication, repair or recombination, in telomeres
maintenance, or in chromatin assembly thus controlling cell proliferation
and cell apoptosis indirectly. Inactivation of a gatekeeper gene is a limiting
step in the initiation of cancer, whereas inactivation of caretakers indirectly
promotes tumourigenesis through genome instability that results in an
elevated mutation rate of a" genes, including gatekeeper genes or
oncogenes (30).
Germ line mutations in TMG genes have instead a weak effect and
fine-tuning in tumour phenotype modulation, influencing the expression or
activity of other genes through allele-specific effects. These genes are
capable of either affecting the probability that cancer wlll develop
(conferring susceptibility or resistance), influencing the severity of tumour
phenotypes as we" as the differential response to environmental
compounds or drug treatments (26). They are involved in a variety of
functions, such as control of the cellular properties, exposure to carcinogen,
diet or lifestyle factors, systemic molecules (e.g., hormones and growth
factors), local events affecting cancer cells (e.g., chronic inflammation), or
the vulnerability to viruses and bacteria recognized as risk factors for cancer
(26). The modifier genes often have at least two alleles, one of which that
has no effects on tumour phenotype and one that exacerbates or
suppresses disease. The first evidence of the existence of cancer modifier
genes was obtained in mouse models characterized for their genetic
susceptibility or resistance to spontaneous and induced tumourigenesis. In
laboratory animals, modifier effects are usually attributed to genetic
background and can be inherited as Mendelian or polygenic traits. At
15
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Fig.3 Relationship between the allele frequency of disease susceptibility locus and
their estimated effect size (35).
present, more than 100 mouse loci have been detected that can affect
different types of tumourigenesis and at different tumour phenotypes
(number, size, stage, latency period, survival time) (31). First indirect
evidence for the existence of cancer modifier genes also in humans derived
from epidemiological studies reporting the increase in relative risk values for
first-degree relatives of cancer patients consistent with a polygenic model of
inherited predisposition to cancer (32, 33) and from Crabtree's study (34)
reporting segregation in families that could not be explained by germ line
mutations. Functional allele var-iants of major cancer predisposing genes
associated with increased or decreased tumour development risk are
present in general population and the modulation of tumour phenotype is
often due to different combinations of multiple allelic variant of
predisposition or resistance (see paragraph 1.3). Identification of cancer
16
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modifier genes could be very important in order to understand the
biochemical mechanisms of inherited resistance/susceptibility to cancer.
The interest in genetic predisposition to common cancers has
constantly increased in the last decades. At the start of the 1990's first
findings supported the potential role of hereditary components in
determining the risk of cancer. Genetic predisposition is based on the role of
one or more genes or genetic variants, and of the interplay of these genes
or variants with other genetic, environmental and/or lifestyle factors. The
degree of involvement of genetic factors depends on penetrance (Fig. 3
(35».
- High penetrance is due to rare variants (with frequency <1%) with
a high effect on risk (e.g., BRCA1,Odds Ratio (OR)1V5) (35).
- Low penetrance is due to common variants (with frequency >1%)
that individually confer a low effect on risk (ORIV1.3-1.8). Low-penetrance
genetic factors characterize the bulk of inherited cancer risk according to
the polygenic model (see paragraph 1.3) and to the hypothesis of "common
disease, common variant", which suggests that genetic influences on
common traits are at least partially due to a limited number of allelic
variants with a frequency more than 1-5% in a population (35).
Based on familial clustering, three main categories of cancer genetic
predisposition can be distinguished: inherited cancer syndromes, familiar
cancer and predisposition without evident family clustering (23).
- Inherited cancer syndromes account less than 5% of all cancer
cases consist of rare cancers or combination of cancers with strong familiar
history. Examples are retinoblastoma, familial adenomatous polyposis,
17
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Wilms' tumour syndrome, and U- Fraumeni syndrome. The genetic changes
are confined to a particular tissue and take place over several cell
generations with specific phenotypic abnormalities. An inherited cancer
predisposing genetic mutation is present in somatic cell and germ line cells,
and therefore can be passed onto a proportion of the offspring through a
well-defined pattern of inheritance as the effect of a single highly penetrant
.. .. .. CANCER
" DEVELOPMENTDElETlON
a) Familial Cancer
INHERITED
GERMUNE
MUTATION
.. .......CANCER".....,.. DEVELOPMENT
DElETlON
1st-hit" 2nd-hit"
b) Sporadic Cancer
1st-hit"
Fig.4 Knudson's two-hit hypothesis for tumourigenesis.
autosomal dominant allele according to the Mendelian dominant inheritance
(36). Knudson explained the genetic mechanism underlying predisposition
by highly-penetrant variants studying retinoblastoma (37). Knudson
proposed the "two-hits model" (Fig. 4) where the first "hit" affecting the
gene responsible for the development of familial retinoblastoma is inherited
through the germ line and the second "hit" occurs somatically in the other
allele of the same gene (38). Studies have been shown that this second
somatic event may arise by a variety of molecular mechanisms, for example
18
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new intragenic mutations, gene deletions, chromosomal loss or somatic
recombination (37, 38). The model extends also to sporadic forms of cancer
that are explained to initiate only after two somatic "hits" arise
independently in the two alleles. Knudson's hypothesis was confirmed when
the RB gene was cloned on human chromosome 13 and both copies were
found to be mutated in the tumours (39). It was understandable that people
who inherit an inactivated copy of a tumour suppressor gene had a higher
risk of developing the associated form of cancer than people born with two
normal copies, as postulated in "two-hit model".
Indeed, it was shown that in the tumours of these predisposed
patients, the remaining wild-type copy of the tumour suppressor gene was
lost, a process referred to as loss of heterozygosity (LOH) (38). LOH leads
to either deletion of the tumour suppressor locus or "reduction to
homozygosity" (40, 41). Later studies confirmed that this concept is also
suitable for other tumour suppressor genes. Genetic variants responsible of
these cancer syndromes are very rare (1:1000 or less) but confer a high
risk to develop cancer and the age at onset of hereditary cases is, on
average, earlier since the inheritance of predisposing genetic mutations
through the germ line can accelerate the process of carcinogenesis (42).
- Familial cancers are characterized by evident clustering in families
of common cancers. The main clinical features of familial cancers are two or
more close relatives affected, early age at onset, cancer of specific type
occurring together, multiple or bilateral cancers in one individual. The
pattern in families is generally consistent with dominant inheritance (23).
However, large epidemiological population-based studies on breast cancer
19
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indicate that only 15-20% of the observed familial risk depends on
mutations in strong predisposing genes, such as BRCAl and BRCA2 (43).
The remaining 80-85% of the familial risk is attributable to other genetic
determinants conferring a low relative risk and to environmental origin.
- Inherited predisposition without family clustering, also named as
sporadic, is a common trait of the great majority of cancer cases (about
95%). However, the adjective "sporadic" does not mean that there is no
hereditary genetic determinant of predisposition, but only that there is no
family history. Predisposition to non-hereditary sporadic forms of cancer can
be described by polygenic model in which the combination of multiple
genetic predisposing factors and environmental risk factors has a main role
in the pathogenesis of the disease (44) (see paragraph 1.3). In the last
years, the scientific community focuses its attention on the hypothesis of
"common disease, common variant" in which susceptibility to common
diseases, as cancer, is the result of a joint "work" of several common
genetiC variants each with a low effect (low penetrant variants), rather than
a result of rare genetiC variants with high effect (high penetrant variants,
under the hypothesis of "common disease, rare variant") (see paragraph
1.2).
In the last few years the genetics of cancer predisposition has
experienced great progress. The greatest discoveries in the genetics of
common inherited cancers relate to breast, ovarian and colorectal cancer.
Of particular note are mutations in two genes for breast and ovarian cancer
(BRCAl and BRCA2), in the APC gene for familial adenomatous polyposis
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and in several mismatch repair genes for hereditary non-polyposis colon
cancer (HNPCC).
Fig. 5 Acquired Capabilities of Cancer during
progression (45).
The malignant cell can be distinguished from its normal healthy
counterpart because of abnormal properties, shared by almost all cancer
cells and that determine the transition towards a more aggressive
behaviour. These are known as the "hallmarks of cancer" (45-47) (Fig. 5):
- Genome instability: cancer cells escape the mechanisms aimed at
the maintenance of genome integrity to acquire an increased mutability and
raise the possibility of further mutations (48). Genome instability is
attributed to loss of function of genes involved in sensing and repairing DNA
damages, in assuring correct chromosomal segregation during mitosis and
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in cell cycle checkpoints (49).
- Limitless replicative potential: normal cells have a finite replicative
potential, named as Hayflick limit (SO). After a certain number of divisions,
cells stop proliferating and become non-proliferative going into senescence,
presumably because the telomeres reach a critical length due to the inability
of DNA polymerase to completely replicate the 3'-ends of chromosomes
during 5 phase. The progressive shortening of telomeres during successive
cycles of replication leads to chromosomal anomalies, such as end-to-end
chromosomal fuslons. karyotypic disarray and ultimately to cell death.
Tumour cells acquire the capability to proliferate without limit since they
maintain telomeres through up-regulation of expression of the telomerase
enzyme that adds hexanucleotide repeats at telomerase ends or the
Alternative Lengthening of Telomeres method (ALT) that maintains
telomeres with inter-chromosomal recombination events. As a consequence
tumour cells undergo an immortalization process (51).
Loss of differentiation: metabolic functions necessary for
specialized activities often disappear or decrease in tumour cells that seems
to evade from anti-proliferative and pro-differentiation signals as they
acquire self-sufficiency in growth signals and insensitive to anti-growth
signals.
- Evasion of apoptosis: the capability of tumour cells to expand is
determined by the imbalance of both cell proliferation and cell death.
Apoptosis (programmed cell death) represents a major barrier to cancer
growth and defects in this mechanism play important roles in a wide variety
of tumour types. Resistance to apoptosls can be acquired through several
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strategies including increase of growth factor secretion, loss of tumour
suppressor genes and oncogene activation. One of the most affected
pathways involves the p53 tumour suppressor gene that represents a key
sensor in detecting DNA damages and inducing the cascade of apoptotic
effectors (52).
- Sustained angiogenesis: cancer progression, in the case of solid
tumours, is invariably dependent on the formation of new blood vessels
from the pre-existing vessels (angiogenesis) because oxygen and nutrients,
supplied by the vasculature, are crucial for cell function and survival. It has
been recognized that the tumour vasculature often exhibits distinct
morphological and biochemical properties as compared to the normal
vasculature, including the increased expression of various cell surface
proteins (integrins and adhesion molecules), growth factor receptors, and
matrix metalloproteinases (45).
- Tissue invasion and metastasis: the acquisition of the capacity to
escape the primary tumour, invade surrounding tissues and colonize distant
new sites is the fundamental definition of malignancy (46). Invasion and
metastasis are complex and not completely understood processes that
comprise the activation of extracellular proteases and the involvement of
numerous cell-cell adhesion and cell-extracellular matrix molecules (CAMs,
integrins and cadherins) and cell-microenvironment interactions. All these
processes help tumour cells to acquire the capability to detach from the
primary tumour, penetrate the basement membrane and the vascular
lumen, and survive outside of their normal microenvironment through
different adaptation mechanisms (53). Metastasis causes 90% of human
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cancer deaths (45).
- Acquisition of drug resistance: treatment of malignancies with
chemotherapy can be limited by drug resistance of cancer cells. Important
mechanisms of drug resistance include apoptosis regulation, cellular stress
response, and cell survival signals. Tumours can be either intrinsically
resistant to many of cytotoxic agents used in cancer therapy or acquire this
property during late stages of development so that therapeutic agents are
no longer effective (54);
- Escape from the host immune system: the capacity of tumour cells
to evade the host immune surveillance involves multiple pathways and
mechanisms: reduction of MHC class I expression, loss of costimulatory
factors, suppression of the immune response and tolerance development in
the host versus tumour antigens (SS).
These capabilities are shared by most types of human tumours. The
paths, however, which cells take on their way to becoming malignant, are
highly variable. Mutations in certain oncogenes and tumour suppressor
genes can occur early in some tumour progression pathways and late in
others, so that the acquisition of specific biological capabilities may appear
at different times during progression (56). Neoplastic cells can remain in a
quiescent state or evolve towards more aggressive clinical behaviour and
malignant characteristics.
Tumour progression is a dynamic multistep and complex process,
which starts with the transformation of a benign into a malignant cell and
potentially leads to surrounding tissue destruction and invasion, metastasis
and finally death (47). Each step is characterized by the acquisition of new
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properties on the level of either single tumour cells or whole tumour tissue
(Fig. 6) (NIH, modified from (28)).
Fig. 6 Stages of tumor progression {NIH, modified from (2S».
Cell migration is the result of a continuous cycle of repetitive steps.
First, the cell becomes polarized and it elongates. Cell protrusions
containing filamentous actin and structural and signalling proteins are
formed, which initiate the recognition of and interaction with the
extracellular matrix (ECM). Then, the leading edge or the whole cell
contracts, and moves forward. Now the cell has to survive in the blood
stream and finally extravasates again to colonize the secondary organ and
grow out (57). The acquisition of features above described are the same for
all forms of cancer cell, but the molecular mechanism may vary from one
invasion pattern to another and the entire process may be quite variable,
thus determining the differences in aggressiveness and malignancy among
tumours. Indeed, there are tumours that acquire the properties of advanced
malignancy before reaching macroscopic size; tumours that may persist for
years in a large well-differentiated quiescent state before shifting to a more
25
1..Introduction
malignant state and tumours characterized by a strong heterogeneity with
part of the cell population showing a later degree of tumour progression
than other components. Changes in the cell-cycle control and
immortalization are more significant during early stages, while the
alteration on migration and adhesion resulting in the acquisition of an
invasive and metastatic phenotype is typically associated with later events
(47).
Recently, a new hypothesis attempts to describe the establishment
and maintenance of tumour heterogeneity with the existence of cancer
stem cells (CSCs). Cancer stem cell population is defined as a particular
rare subset of undifferentiated tumour cells with stem cell-like properties
that are thought to be responsible of tumour initiation, progression,
maintenance, spreading, resistance to therapy, recurrence, and metastasis.
They are also called cancer initiating cells CCICs). This type of cells is
characterized, as normal stem cells, by self-renewal capacity and the ability
to differentiate leading to the production of all cell types of a tumour, and
thus generating tumour heterogeneity (58). Cancer stem cells are thought
to arise from normal stem or non-stem progenitor cells of an organ and to
persist in a tumour as a small side population of cells that sustains tumour
growth. Although some similarities are evident in cancer stem cell theory
and clonal evolution model (22), several differences are evident. CSCs
explain tumour heterogeneity with different mechanisms, either by a
program of aberrant differentiation or by a competition among neighbours.
Under this hypothesis, normal stem and progenitor cells are considered the
most likely targets of transformation. The cancer stem cell hypothesis states
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that only the "cancer stem cells," contribute to tumour progression, while
the clonal evolution model supposes that any tumour cell has the potential
to become more aggressive, since all may further mutate. The two theories
also explain therapeutic resistance differently: either cancer stem cells are
inherently drug resistant or therapy selects for resistant clones (59).
However, it has been hypothesized that an integration of the two models
should be more successful in oncological research in the next future (60).
Finally, it is important also to focus on the fundamental role of
microenvironment in affecting the efficiency of tumour formation, growth,
invasiveness and metastatic potential. A typical example of the
microenvironment leading to cancer is chronic inflammatory status in
response to tissue injury (e.g., irradiation) or infection. In fact, many
cancers arise from sites of infection such as stomach cancer caused by
Helicobacter pylori infection in stomach and liver cancer after chronic
inflammation caused by hepatitis C infection of the liver (61) (see
paragraph 1.4). The hypothesis is that inflammatory cells act as powerful
tumour promoters facilitating genomic instability and DNA damages through
their generation of reactive oxygen and nitrogen species to fight infection
(61). In other experiments, injection of non-transformed mammary
epithelial cells into irradiated mammary stromal fat pads resulted in
increased tumour growth when compared to those injected into
contralateral, non irradiated mammary fat pads (62). The authors
concluded that irradiation induces no reversible changes in stromal cells
altering the microenvironment and leading to tumour promotion. In some
cases, the trigger for neoplastic progression is speculated to come from
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signals within the stromal microenvironment (62). Summarizing the
described data suggest that microenvironment is crucial not only in tumour
invasion and metastasis, but also in the earlier steps of tumourigenesis.
Cancer is a heterogeneous disease difficult to treat. For that reason it
is necessary to understand the metabolic pathways that are altered in
cancer cells in order to adapt therapies with targeting of multiple and/or
specific pathways. The primary objectives of cancer treatment are cure,
prolongation of life and improvement of the quality of life. Treatment of
cancer usually includes surgery, radiotherapy, hormonal treatment,
immunotherapy and chemotherapy, often used in combination. Despite
recent progress in its treatments, so far few types are curable. Thus, cancer
is under intense research because of the high prevalence and severe
consequences leading to death. Most research aims to apply the knowledge
about cancer in order to allow early diagnosis and understanding the
mechanism of tumour development.
Two complementary analytical methods are used to detect the
specific genetic regions and genes that are involved in the disease process:
linkage analyses and association studies.
- Linkage analyses identify chromosomal regions that co-segregate
with the disease in many affected families or over many generations of an
extended pedigree. The hypothesis is that the disease locus will lie in the
region of the genome that is shared by all affected members of a family or
pedigree. Generally, the number of observed crossovers is small unless to
have numerous families, or very large multi-generation pedigrees, with the
resulting gene being mapped to a large interval (63). This approach is
28
1.Introduction
useful for Mendelian diseases but is particularly unhelpful for complex
diseases where the involvement of many genes and the possible influence
of environmental factors in the pathogenesis mean that large multi-
generation pedigrees or wide detailed family histories are harder to recover.
An analysis by Risch and Merikangas (64) suggested that, in a linkage
study, the number of pedigrees required to map the genes of minor effect
that probably underlie susceptibility to common diseases would be
prohibitively large.
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Fig.7 Estimated efficiency of association and linkage
analysis in relationship to the allele frequency of disease
susceptibility locus (63).
- Association studies (see paragraph 1.7) perform a "genetic
dissection of complex traits" without involving familial inheritance patterns
but comparing frequency of genetic variants in diseased individuals (cases)
and healthy subjects (controls) (65). Generally, tests of association are
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more powerful than linkage studies when the disease alleles are common
(Fig. 7 (63)).
1.3 POLYGENIC MODEL OF INHERITED PREDISPOSITION TO
CANCER
Polygenic traits or diseases controlled by a single major gene or
biochemical pathway are called Mendelian or single-gene traits.
Complicating factors, such as incomplete penetrance and variable age of
onset, are often present in single-gene traits, but they show basic
Mendelian segregation patterns. By contrast, the polygenic model of
inherited predisposition to cancer is based on the assumption that the
combination of multiple genetic predisposing factors and environmental risk
factors has a main role in the pathogenesis of the disease (44).
In the past, there was no consensus regarding the genetic model that
can account for this increased risk, in particular whether it is caused by
aggregation of multiple rare alleles in a subset of genes that have strong
effects ("common disease, rare variant model"), by combination of common
alleles with weak effects ("common disease, common variant model"), or by
some mixture of these hypotheses (43, 66). More recently, complex
polygenic diseases and traits result principally from genetic common
variants in the population rather than being due to specific and relatively
rare mutations, under the hypothesis of "common disease, common
variant". The combined effects of many genetic variants, each with an
individual modest effect, determine the major portion of susceptibility to
cancer. The polygenic model predicts in fact a very high risk for individuals
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inheriting the appropriate combination of susceptibility alleles associated
with a specific disease, but only a marginal increase in the relative risk of
the same disease in the progeny carrying a half of the genetic background
of the affected parent. The phenotype is genetically controlled, but it does
not run in families, as actually observed for common cancers (44).
Moreover, this model is in good agreement with epidemiological studies
reporting that the risk of cancer for people with affected first-degree
relatives is about 2- to 4-fold higher as compared to those without a family
history (44).
Polygenic inheritance models of predisposition to diseases is difficult
to demonstrate in humans since genetic heterogeneity, epistasis and gene-
environment interactions may mask the role of genetic factors but it has
been successfully and extensively studied and demonstrated in animal
models (67).
The list of complex diseases controlled by the polygenic model in
humans embraces a large fraction of the common causes of morbidity and
death and includes atherosclerosis, hypertension, psychiatric disorders,
Alzheimer disease, type I and type II diabetes, asthma, rheumatoid
arthritis, and cancer (68-73). The difference between Mendelian and
complex traits is not in the fact that the involved genes in complex diseases
disobey the rules of Mendelian inheritance, but that the pattern of
inheritance is not simple (74).
The main challenge for medical genetiCS in the last decade was to
systematically search and identify genes or genetiC determinants
responsible for the hereditary contributions to complex polygenic traits.
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Indeed, the problems in defining specific gene variants that contribute to
the propensity for common complex disorders are multiple and difficult. In
1994 and 1995, Lander and Schork (67) and also Weissman (75) in their
reviews about the genetics of complex diseases gave a partial list of
difficulties, the main of these are the following:
- incomplete penetrance and phenocopy: some individuals can
inherit a predisposing allele without manifesting the disease (incomplete
penetrance), whereas others can manifest the disease without the
predisposing allele but as a result of environmental or random causes
(phenocopy). The genotype at a given locus may therefore affect the
probability of disease but not fully determine the outcome (67).
- heterogeneity of causation: the same genes may not be
contributing to the disease process in all the affected individuals, thus non
overlapping combinations of gene variants may contribute to the increased
propensity for the same disease in different individuals (e.g., in breast
cancer) (75).
1.4 ENVIRONMENTAL CONTRIBUTION TO CANCER
Differential rates of cancer incidence between different populations
and the observation that immigrants tend to acquire the same cancer risk of
their new country led epidemiologists to conclude that an important cause
of cancer is environmental and that changes in lifestyle and environment
could be helpful for prevention (76). Lung cancer also occurs in non-
smokers and only about 10% of smokers develop lung cancer. Additional
genetic, environmental, hormonal factors and chance (mutation is to some
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extent a stochastic process) determine the ultimate development of cancer
in mutation carriers (77). Humans are in fact daily exposed to a wide range
of potential natural or synthetic toxicants that are carcinogens and so can
increase the incidence of cancer. Many environmental causes of cancer are
now ascertained, the best characterized being smoking as a risk factor for
lung cancer (see paragraph 1.5), alcohol consumption for liver cancer, and
intense exposure to sunlight for skin cancer. Generally, the known
environmental causes indicated as major etiologic factors in the
development of sporadic tumours include exogenous chemicals, diet,
workplace, radiation, oxidative agents, chronic inflammation and infections
(78-81).
The most relevant environmental and lifestyle factors that playa
role in tumour development are briefly summarized below (Fig. 8) (81):
- Diet and nutrition: it is a general consensus that about 35% of
cancers may be preventable by changing our diet. However, no single
dietary factor have shown a strong and consistent effect to establish it
unequivocally as an important carcinogen or anti-carcinogen, except for
drinking alcohol and consumption of foods contaminated with aflatoxin (82).
There is a general consensus that some types of cancer are commoner in
people who are overweight such as cancers of the oesophagus, colorectal,
endometrial, breast, and kidney. A high intake of red meat and fats has
been related to increased risk of several cancers such as stomach, and
colorectal cancers, whereas alcohol consumption is associated with cancers
of the oral cavity, pharynx, larynx, oesophagus, and liver. On the contrary,
adequate consumption of fresh fruits and vegetables is regarded as a
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protective cancer factor since they contain important antioxidants (76, 83);
- Oxidative agents: oxidant by-products of normal metabolism, such
as reactive oxygen species (ROS), cause extensive damage to DNA,
proteins and lipids. The damages are mostly repaired by enzymes and occur
naturally several times per cell and day. Unrepaired damage or modification
of DNA bases may cause genetic mutation in semi-conservative replication
processes of DNA. Oxidative stress is an important mutagenic or
carcinogenic lesion in vivo and is associated with as many as half of all
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Fig. 8 Proportion of cancer mortality attributable
to environmental and lifestyle factors (81).
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disrupt normal cellular replication and lead to double-strand breaks and
further chromosome abnormalities. Oxidative endogenous damage is also
estimated to be a major contributor to aging and to degenerative diseases
of aging, since antioxidant defences remove most, but not all, of these
lesions that accumulate in macromolecules with time (78);
- Chronic infection and inflammation: different pathogens have been
clearly correlated to specific cancer risks. For instance, chronic gastric
infection caused by Helicobacter pylori (H. Pylori) causes gastric ulcers and
is a contributing factor in the development of stomach cancer; a subgroup
of sexually transmitted human papillomavirus (HPV) is detectable in
virtually all cervical cancers (8S); hepatitis Band C viruses (HBV and HCV)
are a major cause of chronic inflammation leading to hepatocellular cancer
(78). Other ascertained pathogens include Epstein-Barr virus (HHV-EBV) for
B-cell rnaliqnancies and nasopharyngeal cancer, malaria for Burkitt's
lymphoma, human immunodeficiency virus (HIV) for non-Hodgkin's
lymphoma and Kaposi sarcoma, human herpes simplex virus (H5V) for
Kaposi's sarcoma, schistosomiasis for inflammation associated with bladder
and colon cancer (79). In addition, it has been demonstrated that
inflammatory conditions predispose to cancer since stimulate cytokines and
chemokines that contribute to development of malignant disease influencing
survival, growth, mutation, proliferation, differentiation, interaction with the
extracellular matrix, and movement of cells (61);
- Environmental chemical carcinogens: the environment contains
many potentially carcinogenic compounds including polycyclic aromatic
hydrocarbons (PAHs), heterocyclic amines, and aromatic amines that
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represent important classes of carcinogens (85). Like most other xenobiotic
substances, these chemical compounds are not carcinogenic per se but
undergo metabolic activation producing reactive intermediate metabolites
that can bind covalently DNA and form DNA adducts leading to genetic
mutations. Activation is performed by the phase I enzymes and consists
mainly of an oxidation reaction catalyzed by the enzymes of the cytochrome
P4S0 (CYP) or by microsomal epoxide hydroxylase (mEH). If DNA adducts
escape cellular repair mechanisms and persist, they may lead to miscoding,
resulting in permanent mutations (86). Detoxification is performed by the
phase II enzymes, such as the glutathione-S-transferases (GSTs) and the
N-acetyl transferases (NATs), which favour the elimination of reactive
intermediates by conjugating them with endogenous molecules. Some of
these enzymes could playa dual role in detoxification and activation;
- Radiation: a small fraction of all neoplasia seems to be correlated to
DNA damages of exposure to radiations (e.g., ultraviolet for skin cancer and
ionizing radiations for many forms of cancer) (79).
Often ten or more years pass between exposure to environmental
factors and detectable cancer. The interaction of susceptibility factors and
exposure to carcinogenic environmental agents may lead to the initiation of
cancer development. Inherited genetic variants can affect genes that are
involved in metabolism of xenobiotics and DNA repair. Additional genes that
contribute to carcinogenic process belong to the DNA modification and cell
proliferation control groups.
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1.5 LUNG CANCER
Lung cancer is an important public health problem and the most
common form of cancer in the world accounting for approximately 1.5
million new cases in 2006, 12% of total cancer diagnoses (87), and is a
major cause of cancer deaths in the Western countries (20) (Fig. 1). It is
characterized by late diagnosis and poor prognosis and therapeutic
strategies have shown only a limited effect. Indeed, most cases are
diagnosed at late stages often related to metastases. The overall five-year
survival rates are only 5-15% (88) and it has not significantly improved in
the last 20 years. However, long-term survival of patients who undergo
resection of lung tumours at early stages are higher than 80% (89).
Fig. 9 Incidence of lung histologic subtypes (Modified from
(90) and (91». sec indicates SCLC.
Lung cancer is generally classified in two major histological types:
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (Fig.
9, modified from (90) and (91)).
SCLC or microcytoma (also named 'oat cell' carcinoma), is so defined
because of the characteristic shape of its cells. The incidence of this
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histology is about 20% of all newly diagnosed lung cancers. SCLC is most
frequent in males and in heavy smokers. SCLC mostly arises centrally in a
large bronchus and tends to be more aggressive than the NSCLC. It is
characterised by rapid growth and is more likely to spread to other organs
and it is usually disseminated at time of presentation (92). Just because of
its aggressivity, surgical resection is generally not indicated and systemic
therapy is required, especially chemotherapy and radiation therapy. SCLC
responds very well to chemotherapy, but nevertheless the disease is
recurrent after a period which varies from person to person (92). In almost
all cases this type of tumour has a severe prognosis with a 3-year survival
of less than 10%.
NSCLC is the most common type and accounts for 75-80% of all lung
cancers. Generally it is a localized tumour which develops and spreads out
more slowly than SCLC, so that surgical resection is the preferred treatment
(90). NSCLCis further subdivided into three major histological subtypes:
- squamous cell carcinoma (SQCC or epidermoid or spinocellular
carcinoma) generally arises centrally within the lungs inside a large
bronchus although the tumour may sometimes be located peripheral and
involves the squamous epithelium of lung. SQCC most widespread in men
and accounts for approximately 30-40% of all lung tumours (90);
- adenocarcinoma (ADCA or AD or AC) tends to occur in more
peripheral locations arising from smaller airways but it can be found
centrally in a main bronchus and involves glandular tissue forming
recognizable glandular patterns. ADCA accounts about 30-40% of all lung
cancers and it is the most frequent among never smokers, women, and
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young people (93). Today ADCA is the most frequent form of lung cancer in
the world, and the frequency of adenocarcinoma is constantly increasing,
probably due to a change in cigarette production and composition (94).
- large cell carcinoma (LCC) is composed of round large-sized poorly-
differentiated cells and lacks the diagnostic features of the other subtypes.
It accounts for about 15% of all lung cancers.
The histological distinction between NSCLC and SCLC is also
important for therapeutic choices, since there are substantial differences
between the two groups in both treatment and prognosis (95).
Lung cancer cells originate from airway epithelia of bronchi,
bronchioles or alveoli. Differences in site of origin of lung cancer reflect
histological differences. Indeed, the NSCLC histological types all have the
phenotypic features of the differentiated cell types in normal or injured
bronchial epithelium, whereas SCLC cells have neuroendocrine markers
common to endocrine cells that are found in normal bronchial mucosa.
Thus, one possibility is that each of the four major histological types arises
from alterations in its pre-existing normal counterpart. An alternative
hypothesis is that the four types of lung cancer arise from a common stem
cell and are related through a common differentiation pathway (96).
Cancer staging describes the anatomical extent or spread of a
cancer at the time of diagnosis and attempts to group together patients
with similar prognosis. Proper staging is essential to determine the type of
therapy and to assess the prognosis. The staging system for lung cancer is
based on the TNM (tumour size, lymph nodes, metastasis) classification
system, according to UICC (International union against cancer) criteria, and
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takes into account the degree of spread of the primary tumour (T), the
extent of regional lymph node involvement (N), and the presence or
absence of distant metastases (M). Information on each parameter is
attributed separately and later combined together to assign an overall stage
of I, II, III or IV. Tumours of stage I have a maximum primary tumour size
of 5 cm with the exclusion of local or distant metastasis (Tl-2 NOMO). For
Stage II cases, the primary tumour has a minimum dimension of 5 cm or
extends to the breast wall or skin (T3-4 NOMO). Stage III includes primary
tumours of any size with local metastases affecting lymph nodes (Tl-4 Nl-2
MO). The highest stage tumours (Stage IV) present distant metastases in
liver, skeleton, brain or adrenal glands (Tl-4 NO-3 Ml) (97).
There are limitations in the use of the TNM classification. For
example, recent reports observed that Nl patients actually behave as a
heterogeneous subgroup with different lymph node involvement. Indeed,
patients with microscopic Nl and single-node Nl diseases show the same
survival of patients with pathologic NO disease, whereas patients with
multiple-node Nl disease are similar to N2 patients (98). Such
heterogeneity of Nl lung cancer could lead to an underestimation of the
effects of genetic variants affecting nodal status, as the "good prognosis"
variant could be over-represented in Nl patients. These problems make it
necessary to revise regularly the staging system since the development of
more accurate diagnostic methodologies can lead to the identification of
discrepancies among patients belonging to the same group and allow
performing a more homogenous classification. Indeed, TNM system
currently in use for the classification of NSCLCwas first proposed several
40
I.Introduction
decades ago and has been modified and refined over the years until the last
revision was approved in 1997 (99).
Genetic changes acquired by lung cancers are complex and
heterogeneous. There are molecular lesions that are common to different
lung tumour types and others that are relatively specific to only one of
them. For instance, alterations of c-MYC, E2Fl and RB genes are more
frequent in SCLC, whereas alterations in EGFR, K-RAS and p16/Ink4 genes
are mainly detected in NSCLC, while mutations of pS3 can be detected in
both histological types (100). Besides smoking, a small number of genetic
polymorph isms have been associated with modest increases in lung cancer
risk, thus excluding existence of highly-penetrant, strongly-predisposing
genetic variants for this type of cancer (101). The main deregulated
signalling pathways in lung cancer cells include positive and negative
signallers of cell growth and proliferation, apoptosis, senescence,
angiogenesis, invasion, metastasis, genomic instability, DNA repair
pathways, autocrine and paracrine growth factor circuits (102).
Epidemiological research has convincingly established that tobacco
smoking is the main cause of lung cancer (10, 11, 103, 104); today we
know that about 85% of lung cancer cases arises in current or former
cigarette smokers (105). Overall risk of lung cancer for smokers depends on
several factors. A lifetime smoker has a 20- to 3D-fold increased risk of
developing lung cancer compared to a lifetime non-smokers. Risk increases
with both the duration of smoking and the number of cigarettes smoked per
day, although the former is predicted to have a much stronger effect (106).
Smoking cessation results in decreased risk after a lag period of about 7
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years (107). However, the decreased risk never reaches baseline levels and
risk of lung cancer among former smokers remains elevated as compared to
never smokers.
Tobacco smoke contains an array of biologically active components:
carbon monoxide, benzene, nicotine, polycyclic aromatic hydrocarbons
(PAHs), aromatic amines, N-nitrosamines, aldehydes, oxidative radicals,
butadiene, and heavy metals. Tobacco-specific nitrosamines and PAHs are
the major risk factors (108). Most tobacco carcinogens require metabolic
activation to exert their carcinogenic effects forming mutagenic DNA
adducts. Although the predominant cause of lung cancer is well-ascertained
(i.e., tobacco smoking), there are other factors known to increase the risk
of lung cancer. Exposure to xenobiotics may also increase the risk of
cancer. Occupational agents (e.g., asbestos), some metals (e.g., nickel,
arsenic, cadmium, chromium), chemical elements (e.g., beryllium), ionizing
radiation (e.g., radon), and outdoor and indoor air pollution play an
important role in the causality of lung cancer (109-112). Some of these
agents act in concert with smoking to synergistically increase the risk.
Although 80-90% cases of lung cancer develops among smokers,
only about 10-15% of heavy smokers develop lung cancer and lung cancer
are also observed among non-smokers (113, 114) suggesting that genetic
factors have effects on lung cancer susceptibility.
The first evidence for a genetic control of lung cancer susceptibility
and progression comes from mouse inbred strains that provide an essential
tool for the dissection of the determinants underlying the complex genetic
nature of lung cancer. Several susceptibility and resistance loci have been
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mapped in several crosses between different strains. The major locus
affecting lung cancer susceptibility, the Pulmonary Adenoma Susceptibility 1
(Pasl), was identified in the distal region of mouse chromosome 6 and it is
linked to both tumour multiplicity and volume; therefore, it can affect both
lung cancer risk and lung cancer growth (115). The Lasl gene and the
Kras2 gene were then indicated as primary candidates for the Pasl locus,
the former affecting lung tumour multiplicity and the latter determining lung
tumour progression (116). More recently it has been hypothesized that Pasl
constitutes a genetic cluster composed of six candidate tumour modifier
genes (Bcatl, Lrmpl, Lasl, Ghiso, Kras2 and Lmna-rsl) and it has been
demonstrated that polymorph isms in these genes might confer susceptibility
or resistance to lung tumourigenesis (117). Population-based association
studies were carried out using genetic markers in the human homologous
region on chromosome 12 and demonstrated this locus to be most likely
involved in the genetic control of human lung carcinogenesis (118, 119).
Mapping in other genetic crosses identified Pulmonary adenoma resistance
(Par) loci that inhibit genetic predisposition to lung cancer provided by the
Pasl susceptibility allele: Parl on chromosome 11 (120), Par2 on
chromosome 18, and Par4 on chromosome 6 (121). In addition, a locus
specifically associated with lung tumour growth was mapped on the central
region of mouse chromosome 4 and named Pulmonary adenoma
progression 1 (Papgl) (121). Besides the major susceptibility and
resistance genes, other minor loci have been mapped confirming that lung
cancer in mice is a complex trait controlled by multiple genes with additive
and/or counteracting effects (122).
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In humans, the inherited genetic susceptibility to lung cancer was
first suggested more than 40 years ago following epidemiological evidence
for familial aggregation of lung cancer (123). Family-based studies indicate
that relatives of lung cancer patients are 2-5 times more likely to develop
lung cancer than relatives of control participants (124). This is in agreement
with models of polygenic inheritance supporting the role of multiple
predisposing genes that modulate the development and growth of
neoplastic lesions and the response to environmental carcinogens.
Subsequent linkage analyses of high-risk families identified a locus in
chromosomal region 6q23-2S as potential lung cancer susceptibility (125,
126). Some tumour suppressor genes (e.g., p53), genes linked to the
metabolism of tobacco carcinogens, and DNA repair genes are associated
with an increase in lung cancer risk (101), however most associations have
not been robustly replicated (127, 128). In the last years, under the
hypothesis of "common disease, common variant", several genome-wide
association studies (GWASs) identified three main lung cancer susceptibility
loci at 1Sq2S (129-131), 6p21 (132, 133), and 5p15.33 (132, 134),
providing further powerful evidence of a genetic contribution to lung cancer,
even if with some discrepancies due to ethnlcltv, smoking habits, and
tumour histology (135). More recently, genetiC variants at 13q31.3 have
been interestingly reported to be associated with susceptibility to lung
cancer in never-smokers and to modify the expression of the glypican 5
(GPC5) gene (involved in cell division and cell growth regulation) (136),
providing further evidence that the genetiC factors for risk in smokers and
never-smokers may be different. Together these data strongly indicate that
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lung cancer is a complex multi-factorial disease characterized by the
interplay of environmental and genetic contribution.
Also in lung cancer progression, as for lung cancer susceptibility, it
is possible that genetic polymorph isms or other inherited genetic factors,
which occur in genes controlling basic cellular process, together with
environmental, psychological, social, and biological factors, might have a
role influencing neoplastic development and leading to differences in
patients' prognosis and in their survival rates. In addition, it has been
demonstrated that genetic factors alter treatment response, affecting
disease prognosis and outcome (137, 138). In the last years, several
inherited genetic variants, are being assessed as predictors of different
cancer outcome phenotypes such as Myel1 for cell growth (139); FGFR4for
tissue invasion (140, 141); VEGF for tumour angiogenesis (142); KRAS
(143) and p53 (144) for tumour prognosis. At the moment, except for our
work, no GWASs for the identification of lung cancer prognostic germ line
variations have been published.
In the last ten years, a lot of progress has been made in the
treatment of lung cancer such as adjuvant chemotherapy, targeted therapy,
and individualized therapy. However, lung cancer is still today the leading
cause of death due to cancer remaining a main medical, scientific, and
social problem (90) (Fig. 1).
1.6 SINGLE NUCLEOTIDE POLYMORPHISMS
In 2001 the first two reference versions of the human DNA were
published (145, 146), but both these sequences did not report genetic
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variants that differ among individuals. Subsequent studies, that completed
human genome sequencing, focused on identification of human genetic
variants. The HapMap project (147, 148, http://hapmap.ncbi.nlm.nih.gov/)
aimed to localize and validate variants throughout the genome.
The most common sequence variations in the human genome are
substitutions of a single base called SNPs or single nucleotide
polymorph isms (Fig. 10) that occur with a frequency of more than 1% in at
least one population (149). The different sequence alternatives in a SNPare
named "alleles". SNPs could be bl-, tri-, or tetra-allelic polymorphisms.
However, in humans, tri-allelic and tetra-allelic SNPs are rare almost to the
point of non-existence (reviewed in (149». Observed data indicate a clear
bias towards transitions (i.e., purine-purine or pyrimidine-pyrimidine
changes) instead of transversions (purine-pyrimidine or pyrimidine-purine
exchanges) (150, 151). One probable explanation is the high spontaneous
rate of deamination of 5-methyl cytosine to thymidine in the CpG
dinucleotides, leading to the generation of high levels of CIT SNPs, seen as
G/A SNPson the reverse strand (152, 153).
The major conceptual change arose from two critical events early in
the 1980s: Kan and Dozy (154) demonstrated how DNA polymorphisms
could be identified in non-coding DNA and Botstein et al. (155) proposed
that these DNA polymorph isms could be used as the basis for defining
molecular markers. Before 1978, all known human polymorphisms were
within gene products; however, evolutionary selection on genes does not
lead to high polymorphism. The possibility that molecular genetic methods
could be used to detect polymorphism within any arbitrary segment of DNA
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(154) was of great value since without the constraints of evolutionary
selection, polymorphism rates could be much higher in intervening regions
than within genes.
In 1980s, restriction enzymes were used to identify single base-pair
changes in genomic DNA fragment by the ability of a segment of DNA to be
cut, or not, by a specific restriction enzyme that recognises between 4-6
specific DNA base pairs (155). These nucleotide variants were called
"restriction fragment length polymorph isms" (RFLPs). The discovery of the
Polymerase Chain Reaction (peR) methodology then made possible the
rapid development of highly informative markers for genetic mapping like
single nucleotide polymorphisms. Since SNPsare stable (with a low rate of
recurrent mutation), frequent, and easy to automatically genotyped, they
are the markers of choice for a variety of genetic studies including those on
susceptibility to polygenic diseases and poor drug reactions in order to
understand disease causation and facilitate a more accurate drug
prescribing or development of new drugs (156, 157).
It has been estimated that the human genome contains at least 11
million SNPs, with about 7 million of these occurring with a minor allele
frequency (MAF) of over 5% (158). The distribution of allele frequencies can
vary greatly among different population (159). Depending on their
localization, SNPs can be defined as anonymous variants with no effect on
gene products or functional substitutions affecting either the amino acid
sequence of the protein product or the expression of the gene. Many
polymorphisms lie outside genes and are silent, with no effect on gene
products (160). It has been estimated that only between 60,000 and
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240,000 common SNPs could have a biological effect, as non-synonymous
coding variants, regulators of gene expression, or affecting RNA splicing,
mRNA stability or mRNA translation (161). Most likely there are substantial
differences in SNP densities across the genome with the great majority of
variations localized in non-coding regions and having no functional
consequences on the activity and expression of proteins (145, 146, 162) .. .
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Fig. 10 SNPs (A), haplotype blocks (B) and TagSNPs (C) (185).
It has been observed that SNPs located in the same genomic interval
are not inherited independently but often tend to be associated with each
other in a set of SNPs called haplotype block (Fig. 10). This correlation
structure is named as linkage disequilibrium (LD), and refers to the fact
that particular alleles at nearby sites can co-occur on the same haplotype
more often than expected by chance (63, 163, 164). When a particular
allele of one SNP is found together on the same chromosome with a specific
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allele of a second SNP, these alleles are said to be in disequilibrium. The
extent of LD in populations is expected to decrease with both time and
recombination distance between markers. Nevertheless stochastic factors
predominate in the behaviour of LD over short distances. Consequently,
although a trend towards decreasing disequilibrium with increasing distance
between markers has generally been observed in empirical data, closely
"linked" markers are not always in LD (165-167). By contrast, in other
instances, LD has been reported between quite distant markers (163, 168-
170). This variability is due to the fact that the factors governing LD among
any specific collection of loci are numerous, complex and only partially
understood. A range of demographic, molecular and evolutionary forces
have a significant effect on the LD patterns:
- Genetic drift: frequencies of genotypes and haplotypes change in a
population every generation owing to the random sampling of gametes that
occurs during the production of a finite number of offspring, particularly in
small populations. In general, the increased drift of small, not growing
populations tends to increase LD since haplotypes are lost from the
population. But the applicability of this phenomenon to gene mapping has
not been well characterized (63).
- Natural selection: natural selection can have a hitchhiking effect in
which an entire haplotype that flanks a favoured variant can be rapidly
swept to high frequency or even fixation (171). Selection against
deleterious variants can also inflate LD, as the deleterious haplotypes are
lost in the population. The second way in which selection can affect LD is
through epistatic selection for combination of alleles at two or more loci on
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the same chromosome (172). This form of selection has been shown to lead
to the association of particular alleles at different loci in Drosophila, not yet
in humans (173).
- Population structure: various aspects of population structure are
believed to influence LD. Population subdivision is likely to have been an
important factor in establishing the patterns of LD in humans, but most of
our limited information comes from studies of model organisms (63).
- Admixture or migration: admixture is the introduction of mates from
one previously distinct population into another. Admixture and migration
(gene flow), between populations can create LD. Initially, LD is proportional
to the allele frequency differences between the populations, and is
unrelated to the distance between markers. In subsequent generations, the
"spurious" LD between unlinked markers quickly dissipates, while LD
between nearby markers is more slowly broken down by recombination. In
theory, this would allow the mapping of disease genes in hybrid populations
without using many genetic markers (174-177). In practice, the diseases
and circumstances for which this mapping approach will be feasible might
turn out to be quite rare and exceptional.
- Variable recombination rates: recombination rates are known to
vary by more than an order of magnitude across the genome. It is even
possible that recombination is largely confined to highly localised hot spots,
with little recombination elsewhere. According to this view, LD will be strong
across the non-recombining regions and break down at hot spots. There are
indications that this reflects the situation for some regions (178), but the
generality of the hot-spot phenomenon, the strength of recombination in
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and outside hot spots, and the length distributions of these regions remain
to be determined.
- Variable mutation rates: some SNPs, such as those at CpG
dinucleotides, might have high mutation rates and therefore show little or
no LD with nearby markers, even in the absence of historical recombination.
- Gene conversion: a short stretch of one copy of a chromosome is
transferred to the other copy during meiosis process. The effect is
equivalent to two very closely spaced recombination events, and can break
down LD in a manner similar to recombination or recurrent mutation. It has
been recently shown that rates of gene conversion in humans are high and
are important in LD between very tightly linked markers (167, 179, 180).
It has been observed that LD varies across the genome. A
"haplotype-block" model has been proposed that suggests the genome
might be structured into discrete regions of high LD, with a mean size of 5-
20 kb in length, separated by regions of recombination hotspots and
breakdown of LD (160). Furthermore, LD can vary considerably also among
different populations, reflecting the effects of population size, structure and
migration history. Some results showed LD between single nucleotide
polymorph isms to be usually limited to short distances (3-5 kb) (166, 181),
although in certain populations it may extend to longer distances, up to 1
Mb (119, 182, 183).
LD is commonly measured by one of two estimators, 0' or r2, that
represent the proportion of variation in one SNP explained by another SNP,
or the proportion of observations in which two specific pairs of their alleles
occur together. 0' or r2 can range from zero (no association between the
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two SNPs) to one (perfect correlation among SNPs) but their interpretation
is slightly different (63). Of= 1, known as a complete linkage disequilibrium,
means that two markers have not been separated by recombination during
the history of sample and occurs only when some haplotypes have
frequency equals to zero. r summarizes both recombinational and
mutational history representing the statistical correlation between two sites.
In general, r=1 is used to measure the statistical association between pairs
of markers and reflects the proportion of information provided by one locus
about the other and takes into account differences in allele frequencies at
the two locus (63).
It has been determined that the majority of 7 million SNPs with a
MAF more than of 5% could be reduced about to 550,000 haplotype blocks
for European and Asian population and to 1,100,000 haplotype blocks for
African population (184). For each LO block, it is determined a tagSNP (Fig.
10) (185), a representative SNP, and its genotyping is sufficient to know
over 80% of SNPswith a MAF>5% in the same LO block.
In June 2002 Gabriel et al. (186) reported in Science, the
construction of a haplotype map (HapMap) of the human genome with the
use of common SNP markers and up to now more than 5 million human
SNPs were validated with genotyping assay by the International HapMap
Project's SNP Consortium (184). Information and data about each SNP and
LO blocks are publicly available online (http://hapmap.ncbLnlm.nih.govl).
The challenge is to determine which genetic variant is responsible for the
inherited components of certain phenotype.
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1.7 OBSERVATIONAL STUDIES
There are two primary non-experimental, observational study designs
which are the mainstay of analytical epidemiology: the cohort study and the
case-control association study (13).
Cohort studies or prospective studies are longitudinal population-
based studies, in which a group of individuals is identified based on
exposure to a suspected risk factor for a disease (exposure ~ disease)
(187). This group is selected before disease onset and then followed
forward in time, together with a group of unexposed individuals, to
ascertain the occurrence of the disease of interest, and their individual prior
exposure information can be related to the subsequent disease
development. With this basic design, there are also a number of different
variations based on whether the design is prospective from the present time
into the future, or defines a cohort and their experiences from historic
records. In addition comparison groups can be identified from within the
same cohort (internal group), i.e., those not exposed. When the whole
cohort has similar exposure experience, an external comparison group is
needed. This is particularly used in occupational cohort studies where a
cohort from one company or industry, may be compared to those from
another company outside the cohort (187). Since data are collected from a
population that is free of disease, it is possible to follow the cohorts of
exposed and unexposed individuals from exposure to outcome, and to
calculate the incidence of the outcome in both the exposed and unexposed
groups (188). Thus, in cohort study the measure of association is the ratio
of these two risks, named relative risk (RR) (see paragraph 1.9). Since the
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exposure is always assessed prior to disease development, this type of
study also allows the advantage of examine rare exposure events, multiple
disease outcomes and incidence and relative risk in exposed and
unexposed, in that way avoiding problems due to selection bias of control
population (15). The main limitations are that cohort studies are expensive
and time-consuming, particularly in prospective designs; the need to
consider changes in exposure status during the time of follow-up that
require repeated measurements; and bias from loss to follow-up, and from
outcome information being influenced by knowledge of exposures
(information bias). Finally, cohort studies have limited utility in conducting a
detailed investigation of risk factors related for outcomes which are rare or
have long induction periods. In such circumstances, where a cohort study is
not feasible, the best option is a case-control study (15). Cohort studies
allow for calculating either cumulative incidence (Le., the number of events
per number of exposed individuals per time) or incidence rate (i.e., the
number of events over a certain time of exposure) (see paragraph 1.9).
Case-control association studies (or retrospective) require two
different and quite large groups of individuals, selected on the bases of
whether they do (cases) or not (controls) develop a particular disease or
trait (disease --+ exposure) (189). Under the hypothesis that affected
individuals carrier genetic variants associated with disease, the aim of
association studies is identifying genetic determinants that make different
patients from healthy subjects and so that are more or less frequent in
patients (189). The analysis consists of a comparison of allele frequencies
between individuals with a disease or trait of interest and disease- or trait-
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free comparison group, in search of a statistical difference that can be
reflected in an estimated effect size (usually quite small, see paragraph
1.8). If most affected individuals in a population share the same mutant
allele at a causative locus in respect to control groups that allele results
"associated" with disease. A significant association with risk or prognosis of
a disease may indicate that a marker plays a role in pathogenesis or
aetiology of the disease or, if this is not a functional marker, it could be in
LD with the functional one. In this case, it is possible to perform a fine
mapping of the genetic interval around the disease locus in order to find the
functional SNP (63). Carriers of a particular disease associated variant will
not necessary develop the disease, but they have an increased/decreased
risk since the genetic variant confers susceptibility or resistance to given
disease or phenotype.
The important aspects of case-control studies are: defining the study
hypothesis; definition and selection of cases; definition and selection of
controls; measurement of exposures or presence of a genetic variant;
analyses; interpretation and reporting. The major strengths of a case-
control study include its direct application to humans, its ability to study
diseases with a very long latency period, and its "informativeness" and
efficiency, such that one study can simultaneously evaluate multiple
hypotheses and interactions (15). Another advantage of case-control
studies is that they allow the evaluation of casual significance, even with
relatively low risk factor exposure or disease prevalence. Rare diseases with
a wide-range of potential risk factors are also particularly suitable for case-
control design. The case-control study is more commonly used than the
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cohort study because it is considered relatively quicker and less expensive
to accumulate cases of an outcome of interest and subsequently gather
controls who are similar enough to the cases to allow for a comparison of
differential exposure (162). On the other hand, the main limitation of case-
control studies is their susceptibility to bias. Since case-control studies are
mounted when the disease is manifested, disease incidence cannot be
calculated and the relative risk cannot be used as a measure of association.
Instead, the measure of association between exposure and outcome used
as an approximation of the relative risk is the odds ratio (see paragraph
1.9). Two different designs of case-control association studies can be
carried out according to the selection of controls to be representative of the
study population or for their comparability with cases:
- Population-based association studies look for differences in
frequency of genetic variants between affected individuals and unrelated
healthy controls testing for the co-occurrence of a marker and disease at
the population level. Population controls are also considered more suitable
than hospital controls, as they avoid the bias arising from the factors which
lead people to use health services, although cost and effectiveness in terms
of participation are recognised issues (190). Exposure variables are
ascertained through questionnaires, interviews and examination of health
records. Interpretation of results of case-control studies should be done
taking into account the potential biases in the form of selection bias in the
choice of cases and controls, information bias in the collection of data, and
confounding factors (16). Ideally, a case-control association study should
match cases and controls by ethnlcltv, age at disease onset, gender, and
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smoking status in the case of lung cancer, since the risk of tobacco smoking
seems to be higher than any risk factor (191). A high quality case-control
study can provide informative results, if cases and controls can be selected
independently of the exposure and controls are selected at random from the
same defined study population as the cases came from, thus the results
would be unbiased and equivalent to a cohort study.
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Fig. 11 Estimated power in case-control studies and family-based designs (192).
- Family-based association studies generally test associations using
genotype information from affected individuals and both of their parents
("trio design"), estimating the frequency with which an allele is transmitted
to the affected offspring. When parents are missing, an alternative family-
based design is looking for genetic differences between affected individuals
and their unaffected sibs as control. The discordant sibling pairs (DSPs)
design is less powerful than trio in case of rare disease; but is more efficient
when the prevalence of disease is high (192) (Fig. 11). Since cases and
controls derive from the same pedigree, family-based studies are not biased
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by population admixture and stratification, and the observed DNA
differences in genetic polymorph isms are putatively responsible for the
disease status. Thus, it may represent an alternative design to population-
based association studies in studying sporadic cancer. However, the poor
feasibility of the recruitment of healthy sibs or parents for cancer patients,
due to late age at cancer onset for most of sporadic cancer cases, make
difficult to carry out such type of study (192).
In those studies aiming to identify the genetic variants correlated
with the progression of a disease (instead of risk), a case-only approach is
required since no prognostic parameters can be defined for the control
group. In this specific study design, frequencies of polymorphic markers are
compared between subsets of cases selected for their poor or favourable
prognosis.
Association studies have been widely used in the attempt to identify
genetic loci contributing to complex diseases. However, so far, negative
results have been more frequent than positive outcomes and the main
criticism of this approach relies on the lack of replication of significant
findings in independent studies (193). The absence of reproducibility is
generally ascribed to inadequate statistical power, biological and phenotypic
complexity, population-specific linkage disequilibrium patterns, population
stratification, and other biases that can lead to spurious associations (194).
Inadequate statistical power of single studies in detecting weak
effects of common variants (195) may be partially resolved using meta-
analyses that summarize data of previous independent studies (in order to
increase the sample size under analysis). Indeed, if the power is low, there
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is a low chance to detect a difference between groups (or an association) if
one exists (196). The reliability of results from meta-analyses depends on
the validity of the primary studies included and on rigorous methodology.
Meta-analyses suffer of several limitations, such as potential heterogeneity
of the studies in the diagnostic criteria, patient selection, laboratory
methods (197). However, these combined analyses present the advantage
of an overall assessment of the potential role of a given polymorphism in a
specific disease increasing the power of single studies. Indeed, most of the
confounding variables present in individual studies, such as population
stratification and population-specific LD, are expected to balance and reduce
their effects (198, 199).
The problem of population stratification (presence in population of
distinct groups with limited inbreeding) arises when cases and controls are
unknowingly sampled from different populations or variations in allele
frequency between groups are present (200). For instance, if a disease is
unique to (or more frequent in) one population and controls have a different
ethnic origin, an association study will most likely produce a positive result
at many loci throughout the genome reflecting the "genetic distance"
between the two populations rather than a real correlation between variants
and the investigated phenotype. The disparity in frequencies among
populations is a well known event and arises from genetic and social
features unique to each population. However, the amount of bias attributed
to stratification is likely to be small and not substantial in case-control
studies with unrelated controls (201). Stratification can be controlled using
either family-based controls or testing a set of unlinked genetic markers in
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the study population (202). Thus, if frequency differences are observed for
randomly selected and anonymous markers, one could infer that
populations have genetic differences consistent with stratification.
Biases affecting association studies fell into three broad categories:
recall (information) bias, selection (including response) bias, and analytical
bias (including confounding effects) (13): recall or information bias, where
the case subjects have a differential ability to remember details about their
past life history and this affects the accuracy of information; selection bias
relates to the way cases and controls are selected or not. If they are not
representative of the population from which the cases come, the results are
likely to be distorted. Analytical bias issues include the potential problems of
lack of precision and validity of results can be improved by increasing
sample size (utilising a pre-study power calculation) and by getting better
study design or efficiency (including matching control group e.g., by age)
(13).
Finally, confounding is the most important consideration in the
analysis and interpretation of case-control studies. Basically, confounding
variable is related independently to the risk factor or exposure and the
outcome variable under investigation, and can create an apparent
association or mask real one (203).
Although association studies suffer from several limitations and need
corrections in order to gain more power and reliability, positive findings
have been published and support the use of this approach (204).
As with Consolidated Standards of Reporting Trials (CONSORT)
guidelines, which are widely adopted and improved the quality of clinical
60
1.lntroduction
trial reporting internationally (205), a group of epidemiologists in Europe
have begun to develop similar guidelines with similar aims for reporting
observational studies. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines (206), set out standards for
reporting of observational studies, including case-control studies for all the
issues covered above (http://www.strobe-statement.org/).
1.8 GENOME-WIDE ANALYSIS
Genome-wide association study is the study of genetic common
variation across the entire genome that is designed to associate genetic
variations with phenotypic traits (such as blood pressure or weight) or with
the presence or absence of disease or condition (207). The National
Institute of Health defined GWAS as "Study of common genetic variation
across the entire human genome designed to identify genetic associations
with observable traits" (208).
Interest in GWASs started in 1996, when Risch Nand Merikangas K,
reviewing the statistical framework of association studies, evidenced that
association studies have greater statistical power than linkage analysis to
detect genetic variants with small or moderate effect on a disease or trait
testing a large number of variants across the genome (64).
GWASs represented the most widely used approach to study
relationship between genetic variations and phenotypic diversity (209)
based upon the "common disease, common variant" hypothesis (see
paragraph 1.2). Important disease-causing variants, that are rarer than 1-
5% in population, are not detected with GWA approach.
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As a traditional association study, a typical GWA study consists of
four principal phases: selection of individuals with the trait of interest and a
reference group for comparison; DNA isolation, genotyping and data review;
statistical analysis for association between SNPs and trait of interest and
replication of identified associations or their functional characterization (Fig.
12) (210).
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2009, of which 96 are cancer hits with frequency of more than 10%
(http://hugenavigator.net).
Most of cancer associated loci are tissue-specific, but some are also
common in different types of cancer, such as the 8q24 region in prostate,
colorectal and breast cancer, suggesting possible unsuspected relationships
and common pathways among different diseases not previously implicated,
such as the autophagy pathway in inflammatory bowel disease (211). Other
loci seem associated only with certain histological subtype. For example, the
locus Sp1S.33 was found significantly associated in ADCA histotype but not
in SQCC (212, 213). Up to now, three regions were identified with by GWA
studies associated with lung cancer (see paragraph 1.5): 15q25, 5p15 and
6p21 (reviewed in (134)).
Of course, whole genome information may offer the potential for
discovery of new regions associated with disease (individual SNPs, gene-
gene interactions, high-risk haplotype) establishing utility of genetiC
markers for risk and outcome prediction. In addition, it increased
understanding of basic biological processes and molecular pathways of
disease causation with the future promise of personalized medicine,
differential pharmacological intervention (pharmacogenetics) and new drug
targets. Once genetiC associations are identified, researchers can use the
information to develop better strategies to detect, treat and prevent the
disease.
The success of GWA study is due to the development and upgrading
of the high throughput SNP genotyping platforms commercially available,
that allow genotyping of hundreds of thousands of tagSNPs with their
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relative comprehensive annotations and that have constantly increased the
number of variants that can be typed at once. The main companies
producing SNP platforms are Affymetrix (Santa Clara, CA, USA) and
Illumina (San Diego, CA, USA) that developed a last array containing more
than one million of tagSNPs and offer a coverage of 67-89% of SNPs with a
MAF >5% in European and Asian populations and of 50% in African
population (185). Even with a very low cost for each SNP, the total cost for
genotyping 1 million of SNPs in a large sample size is prohibitive and DNA
pooling approach can be used as initial screening in order to reduce costs
as compared to the analysis of individual samples at the same power of
study and with a robust estimation of allele frequency (214, 215). In this
way, an equal amount of DNA samples from cases and controls were pooled
and genotyped together to determine imbalance among allele frequencies of
the two groups.
Despite its success, GWA studies have several limitations, that are
typical of a traditional association study (see paragraph 1.7), but more
evident in this high throughput approach. Indeed, SNP associations
identified in one population are frequently not transferable to other
populations because both allele frequencies and LD blocks are different from
population to population (216). However, most of associations found with
GWA analyses have problems on reproducibility in different series from the
discovery, even though within the same population. This could be due to the
bulk of the genetic heterogeneity or existence of phenocopies across
individuals from the same population that have not been accounted for in
GWA studies and whereby multiple variants in the same or different loci can
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contribute to the same phenotype. In this case, failure in replication does
not mean that the initial findings was spurious, but that replication series
was substantially different from the discovery and thus invalidates test for
association giving different results. In addition, population stratification
or selection for subgroups reflecting population history with different
characteristics alters association analyses, providing associations even for
unlinked loci (false-positive or spurious associations). Moreover, there is
great difficulty moving beyond statistical associations to identifying the
functional and biological explanation of link between a genomic locus
and a given complex trait. It is important also to call attention to the fact.
that GWA approach identifies significant statistical associations for a tagSNP
of entire LD block and does not give information about the exact associated
polymorphic or structural variant in the region and moving from tagSNPs to
disease causal variants is often difficult. Moreover, most associated SNPs
are not localized within a gene or regulatory regions; markers are often
located in introns or in intergenic region. For example, variants on 8q24
that were found associated with multiple solid tumours risk is 300 kb from
the nearest gene (MYC) (217, 218). Another debated topic any of GWA
studies tend to minimize false-positive associations paying attention only on
the highest statistically significant associated SNPs and carrying over from
initial screening into the replication step only these. Indeed, the most
robust findings are often not in the "top" associations and this approach can
cause false-negative results. Another hotly debated topic of GWA approach
is that variants found to be associated with a given disease have a limited
impact on its susceptibility. The mean contribution to the overall risk
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variation estimated for most of these associations is modest (OR in order of
1.1-1.3 for heterozygous genotype and 1.5-1.6 for homozygous genotype,
http://hugenavigator.net). Each variant by itself has in general a small
effect; however, the combination of several low-risk alleles could have a
strong effect and identify individuals with a substantially increased risk
(219).
On the other hand, in the last years, only a small part of inherited
risk has been explained by GWA studies (220). Estimates of residual
missing heritability suggest that numerous other variants, including rare,
structural or other common variants, remain to be found for most of
complex disease.
To perform an excellent GWA study we need to develop a robust
study design to obtain a high power to detect genes of modest risk
minimizing the potential of false association signals due to testing large
numbers of markers and to high genetic heterogeneity interindividual. The
key components are:
- Sufficient sample sizes: since the relatively modest effect sizes of
common genetic variants in modulation of complex disease
susceptibility/resistance, very large samples sizes need to detect them.
Since statistical power of a study is function of MAF, sample size and
supposed genetic effect, a GWA study from general population (with MAF >
5% and OR in order of 1.2-1.5) requires more than 10,000 individuals for
group (221). Ioannidis JPAet al. (222) estimated that a median sample size
of 15,000 participants is needed to have a power of study of 90%.
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- Rigorous phenotypes (cases and matched controls): since
misclassification of case and control participants can widely reduce study
power, the two groups should be careful defined, selected and matched for
confounding factors (gender, age, smoking, ethnicity, etc.) in order to focus
on differences really associated with the given trait and to minimize
phenotypic heterogeneity and population stratification (35). For lung cancer,
where the contribution of tobacco smoking is important in definition of risk,
it could be useful to use smokers as controls.
- Accurate high throughput genotyping technologies (comprehensive
maps, rigorous assessment of genome-wide signatures, rapid algorithms for
data analysis): quality control measures for genotyping step require a SNP
call rate > 95%, concordance in replicas > 99.5%, MAF > 5%, Hardy-
Weinberg equilibrium and Mendelian inheritance in trio studies. Statistical
analysis of dense genotyping data can be performed with publicly available
tools as SNPLims (http://www.itb.cnr.it/snplims). Genotype Library and
Utilities (GLU) or PLINK (223), that allow archiving, management and basic
analysis of datasets.
- Replication: an important step in evaluating the reliability of results
is replication of initial associations study in independent series in the same
population changing recruitment centre, genotyping platform or method and
then extending results in other population. In the last years much interest
has been focused with contrasting results on the advantages/disadvantages
of splitting the initial available series of samples in two series: a "testing
series" for GWA study and a "validation series" to perform the replication
step for the most promising SNPs (194, 224, 225). An innovative approach
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to the replication-based analysis, proposed by Skol AD et al. (226), could be
to jolntlv analyze the results from both series. The [olnt analysis provides
greater power than replication-based analysis of only the replication series,
although a more stringent significance level is required. Replication
represents the major challenge of GWA studies in the last years since the
extensive lack of reproducibility.
- Functional studies: it is important investigate the functional and
biological value of statistical associations found with a genome-wide
approach to confirm their role and increase understanding of their
mechanisms and their possible interactions with other genes or
environmental factors. Indeed, GWA studies find significant statistically
association for a tagSNP of an entire LD block and without giving
suggestions about the exact associated polymorphic or structural variant in
the region. Moreover, most associations are often located in introns or in
intergenic region, rather than within a gene or regulatory regions such as
the 5' or 3' untranslated regions (UTRs), the promoter, or the splicing
donor/acceptor sites (218, 227).
Software provided with the SNP platforms is sufficient for
management of row data while management and statistical analysis of data
post-genotyping could be done with publicly free tools (e.g., PLINK), that
allow tests for allelic, genotypic, dominant, recessive or additive model
associations with permutations, multiple testing corrections, and test for LD
and Hardy-Weinberg equilibrium (HWE) analyses.
Data from GWA studies are available consulting the Database of
Genotype and Phenotype (dbGaP) of the National Center for Biotechnologies
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Information (NCBI) (228) (http://view.ncbi.nlm.nih.gov/dbgap) and
updated information on published GWA findings are released online to the
scientific community through the National Genome Research Institute site
(http://www.genome.gov/GWAstudies/).
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AIM OF THE PROJECT
In this project I examined the genetic profile related to lung cancer
risk and prognosis. More specifically, the overall aim of this project was the
identification of genetiC profiles predictive of individual risk of lung cancer or
associated to patients' prognosis through genome-wide analysis of DNA and
RNA pools from different groups of Italian lung cancer cases and controls,
followed by individual genotyping of candidate SNPs and by individual
assessment of the transcript levels of candidate genes.
According to these aims, my project is divided in two fundamental
tasks. The first task investigates human genetiC variants that may playa
role in lung cancer risk through GWA in a case-control association studies in
Italian lung ADCA patients and unrelated controls from general population
and a case-control association family-based studies in Italian lung patients
and unaffected sibs as controls. The second task investigates a genetic
profile that can explain the differences in cancer prognosis through GWA in
a case-only association studies in Italian lung ADCA patients with clinical
stage I versus higher clinical stage and a whole-genome expression profile
in normal lung tissue of these patients.
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2. MATERIALS AND METHODS
2.1 PATIENTS AND SAMPLES CHARACTERISTICS
The entire project involved pathologically and clinically documented
Italian lung ADCA patients who underwent surgical resection at three
Institutes in Milan (Italy): Istituto Nazionale Tumori, Istituto Clinico
Humanitas and Ospedale Maggiore Policlinico. Control subjects from general
population were enrolled among healthy blood donors or subjects
participating in a computed tomography screening for lung cancer
prevention (272) at the same Istituto Nazionale Tumori (Milan, Italy) and
matched to the group of cases for their district of birth, age at diagnosis,
gender, and smoking status. Characteristics of lung ADCA patients and
control subjects used in the population-based case-control association study
are summarized in Table 1.
Table 1. Characteristicsof lung adenocarcinomapatients and control
subjects population-basedassociationstudy.
Subject characteristics Controls Cases
No. of subjects 522 482
Medianage (range) a 59 (31-77) 63 (34-77)
Gender
Male 389 361
Female 127 121
Smoker status
Never 25 68
Ever 485 398
Clinical stage
I NA 252
II NA 85
III NA 93
IV NA 43
a Age in years. NA, not applicable.
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For the family-based case-control association study, series consisted
of 80 Italian lung cancer patients and their healthy sibs as control. This
population was recruited, on a voluntary basis, with the help of Marta
Nurizzo Association (Brugherio, Italy,
http://www.martalive.org/foreign.htm) according to recruitment criteria
consisting in the non-smoking status and young age «60 years) of lung
cancer cases (Table 2).
Table 2. Characteristics of discordant sibs series in the family-
based association case-control series.
Subject characteristics Controls Cases
No. of subjects 80 80
Median age (range) * 51 (31 - 73) 52 (31 - 80)
Gender
Male 29 19
Female 51 61
Smoker status
Never 54 75
Ever 26 5
Histological type §
ADCA NA 47
NSCLC NA 30
SCLC NA 3
Clinical stage NA Unknown
* Age in years. § ADCA,adenocarcinoma;NSCLC,non-small cell lung
carcinoma; SCLC,small-cell lung carcinoma; NA, not applicable.
Lung cancer patients used in case-only association study consisted of
pathologically documented 1174 Italian lung cancer patients distributed in a
first series composed of 600 lung ADCA patients (discovery series) and in
two additional independent validation series composed of 317 lung ADCA
and 257 lung SQCCpatients (Table 3).
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Gene expression profile analysis in normal tissue was performed in a
series of RNAs from 120 lung ADCA patients derived from the discovery
seires of previous GWA, divided in two groups according to their clinical
stage (lor >1) (Table 4). We selected only smokers to avoid bias in gene
expression associated to the smoking habit (273).
Table 3. Characteristics of lung cancer patients in case-only association
study.
Subject characteristics All patients (N=1174)
Discovery Validation Validation
ADCA series ADCA series SQCCseries
No. of subjects 600 317 257
Age at diagnosis (years)
Median 63 65 67.5
Range 20 - 81 34 - 84 44 - 84
Gender
Male 442 233 233
Female 156 84 21
Smoker status
Never 98 50 7
Ever 494 262 241
Histological type
ADCA 600 317 0
SQCC 0 0 257
Clinical stage
1 300 160 109
>1 300 141 130
Follow-up at 60 months
No. patients alive 316 183 157
Median duration (months) 59.1 60 55.8
Range 4.4 - 60 1.7 - 60 1.9 - 60
For 27 out of 120 cases, we had also available the matched lung
ADCA tissue for analysis of gene expression in matched couples of lung
ADCA tissue and adjacent normal lung tissue (Table 5).
Files were recorded to get personal and clinical data. Study protocols
were approved by the institute ethics committee and written informed
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consent was obtained from each subject for the use of their biological
samples for research purposes.
Table 4. Characteristics of lung ADCA patients used in
gene expression profile analysis of normal tissue.
Parameter Values
No. of patients 120
Median age (range) a 65 (36 - 81)
Gender
Male 99
Female 21
Smoking status
Never 0
Ever 120
Clinical stage
I 60
II 15
III 35
IV 10
aAge in years.
Table 5. Characteristics of 27 out of 120 cases lung ADCA patients used
for paired analysis of the gene expression of lung ADCA tissue and
adjacent normal lung tissue.
Parameter Values
No. of patients 27
Median age (range) a 63 (44 - 76)
Gender
Male 23
Female 4
Smoking status
Never 0
Ever 27
Clinical stage
I 13
II 4
III 6
IV 3
aAgein years.
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2.1.1 Genomic DNA extraction and quantification
Genomic DNA was extracted from peripheral blood sample or from a
small piece of non-tumour lung parenchyma excised during surgery using
the DNeasy Blood & Tissue kit (QIAGEN, Valencia, CA, USA), according to
the manufacturer's instructions. Quality of genomic DNAs was checked on
1% agarose gel stained with ethidium bromide (EtBr) and DNAs were
quantified using Picogreen dsDNA Quantitation Kit (Invitrogen, Carlsbad,
CA, USA) in fluorimetry. The method allows the estimation of DNA
concentration by comparison of the fluorescent signal obtain from each
sample with that collected using a dilution of a DNA standard. Signal can be
measured with a fluorescent microplate reader using excitation wavelength
484 nm, emission wavelength 538 nm, according to the protocol. The
purified DNA was stored at -20°C.
2.1.2 Total RNA extraction and quantification
A small section of lung tumour tissue and normal lung parenchyma
distant from the macroscopic lung cancer tissue was removed at surgery
and stored frozen or in RNAlater solution (Ambion, Austin, TX, USA). Total
RNA was extracted from normal lung or ADCA tissue with the RNeasy Midi
kit (Qiagen) and quantified by Nanodrop Spettrophotometer ND-1000
(Thermo Scientific, Wilmington, DE, USA). The integrity of the total RNA
obtained was evaluated with spectrophotometric analysis using the RNA
6000 Nano Assay Kit (Agilent Technologies, Palo Alto, CA, USA). The
purified RNA was stored at -80°C.
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2.1.3 Preparation of DNA and RNA pools
A genome-wide DNA pooling strategy was used in our case-control
association studies as initial screening in order to minimize interindividual
sample variability and to reduce costs and time as compared to the analysis
of individual samples at the same power of study and with a robust
estimation of allele frequency (214). Then, we confirmed putative
associations by individual genotyping.
DNAs from patients and control series of population-based association
study (Table 1) were respectively pooled to form 4 different pools (two from
cases and two from controls), each constituted by 200 individuals
contributing 30 ng of DNA to the pool. Cases and controls in pools were
matched for gender, age and smoking habits to minimize phenotypic
heterogeneity and population stratification (Table 6) (191). We have so
applied a joint analysis of two experiments, each one including a pool of
either lung ADCA cases or matched healthy controls.
DNA of 80 discordant sibs of family-based study (Table 2) was used
to generate two pools (cases or controls) containing 30 ng of each DNA
sample.
Patients of the discovery series of case-only association study,
composed of 600 lung ADCA patients (Table 3), were divided into two
groups according to their clinical stage (lor >1). As expected, Kaplan-Meier
survival curves (Fig. 13) and Cox regression analysis of survival indicated
poorer survival among patients with higher clinical stage compared with
patients with stage 1 (P=6.47x10-6 and P=2.32x10-05 respectively). For each
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sample 15 ng of DNA was used to create a DNA pool of 300 stage I patients
and a DNA pool of 300 patients at higher clinical stages. Since the accuracy
of analyses using a DNA pooling strategy depends heavily on the estimates
of DNA concentration, we performed serial dilutions of each DNA sample
(284). DNAs were first diluted to 15 ng/ul and their concentrations re-
estimated by using Picogreen dsDNA Quantitation Kit (Invitrogen) in
fluorimetry. Samples were then diluted to 5 nq/ul, re-quantified and finally
15 ng of each DNA were combined. Pools were quantified to check their
correct concentration.
Table 6. Characteristics of Italian lung cancer patients and controls used for
DNA pools.
First ex~eriment Second experiment
Subject characteristics Cases Controls Cases Controls
No. of subjects 200 200 200 200
Median age (years) 61.0 59.0 62.0 61.0
Gender
Male 158 158 140 140
Female 42 42 60 60
Smoker status
Never 29 29 0 0
Ever 171 171 200 200
Histology a
ADCA 200 NA 200 NA
Lymph node status b
NO 128 NA 101 NA
Nl 69 NA 75 NA
Clinical stage NA
I 107 NA 102 NA
II 39 NA 29 NA
III 36 NA 42 NA
IV 15 NA 25 NA
Follow-up (months) C 89.1 (n=61) NA 87.3 NA
(n=64)
a ADCA, adenocarcinoma. b NO, absence of nodal metastasis, Nl, presence of nodal
metastasis. C Median for patients alive at the end of follow-up. NA, not
applicable.
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Fig. 13 Kaplan-Meier curves for lung ADCA patients with
stage I (red line, number of patients = 60) or with higher
clinical stage (blue line, number of patients = 60). Log-
rank test showed a significant difference between the two
curves (P=6.47 x 10-6).
Whole-gene expression analysis for initial screening of transcriptome
was performed on RNA pools obtained using equal amounts of each RNA
sample. In the first experiment (A), the 120 RNA samples from normal lung
(Table 4) were combined in 24 small pools: 12 pools constituted by patients
with stage I and 12 pools by patients with higher clinical stage (5 samples
per pool). These pools were analyzed on Sentrix Bead Chip HumanHT-12
(Iliumina). In the second experiment (B), the same 120 samples were
combined to form only two pool (60 samples per pool) representing stage I
and stage > I patients, respectively. These pools were analyzed in
quadruplicate on the Sentrix Bead Chip HumanRef_8_v2 (Ilium ina).
We used different pooling approach for the three genome-wide
scanning and for the whole-gene expression analysis ,(Table 7). This was
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due to the characteristics of each population and to the fact that each
subsequent study reflects the experience acquired in the previous study.
Table 7. Summary of pooling approaches used in the thesis.
Study Outcome N° Pool samples/ Replicas
Experiment pool
Population-based case- Risk I 2 200 2
control association
study (GWAS) II 2 200 2
Family-based case- Risk I 1 80 4
control association
study (GWAS)
Case-only association Prognosis I 1 300 12
study (GWAS)
Case-only association Prognosis I 24 5 0
study (whole
II 2 60 4transcriptome analysis)
2.2 POPULATION-BASED ASSOCIATION STUDY FOR LUNG
CANCER RISK
2.2.1 Genome-wide SNPs analysis
In order to map genetic variation across human populations to
identify variants associated with lung cancer risk or staging, we performed
genome-wide association study using Iliumina platform in collaboration with
the CNIO Genotyping Unit in Madrid, where the Iliumina platform is already
available.
Genome-wide genotyping for initial screening was carried out in DNA
pools (see paragraph 2.1.3) and 800 ng of DNA per pool was hybridized
using the Infinium II Assay 300K on the Sentrix BeadChip platform
79
2. Materials and Methods
(Illumina, San Diego, CA, USA), that allows for the analysis of more than
318,000 tagSNPs chosen from the International HapMap Project (274). The
Infinium II Whole-Genome Genotyping Assay used a single bead type and
dual colour channel approach. The DNA samples were isothermally amplified
in an overnight step using random primers and then fragmented by a
controlled enzymatic process that does not require gel electrophoresis (Fig.
14, (275)).
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Fig. 13 Diagram of Infinium II assay protocol (275).
Briefly, after alcohol precipitation and resuspension, the amplified and
fragmented DNA of 300-600 bp are hot denatured and the BeadChip is
prepared for hybridization in the capillary flow-through chamber. Samples
are applied to BeadChips and incubated overnight to permit the annealing of
these to locus-specific SO-mers covalently linked to one of over 500,000
beadtypes. One bead type corresponds to each allele per SNP locus. After
locus-specific hybridization capture, each SNP locus is "scored" by an
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enzymatic single-base extension assay using labelled nucleotides that
confers allelic specificity. These labelled products are subsequently
visualized fluorescent a sandwich-basedby withstaining
immunohistochemistry (IHe) that increases the overall sensitivity of the
assay (Fig. 15).
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Fig. 14 Whole-Genome Genotyping steps (38S).
The intensities of the beads' fluorescence are detected by the
Illumina BeadArray Reader, and are in turn analyzed using Iliumina's
software for automated genotype clustering calling (275). The software
represents samples in cluster of homozygous (red and blue points) and of
heterozygous (violet points) according to the fluorescent signals in a
diagram with normalized intensity in y and "theta" value in x axes. In case
of pool genotyping, the diagram has intermediated values (grey points)
(Fig. 16).
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Data were obtained in the form of intensity files, which were used to
determine the allele frequencies of each SNPand to reconstruct the number
of chromosomes carrying each of the two possible alleles. For each DNA
pool, SNP array analysis was carried out in duplicate to verify genotype
reproducibility and estimate technical variability.
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Fig. 15 Report of a SNP genotyping (275).
2.2.2 Independent confirmation on DNA pools
(Biotage AB, Uppsala, Sweden), according to the manufacturer's
instructions using specific primers reported in Supplementary Table 1 (at
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Pyrosequencing technology is sequencing by synthesis, a simple to
use technique for accurate and quantitative analysis of DNA sequences
performed on PSQ96MA system. PCRassays were performed with primers
(with one of them modified by addition of a biotinylated group at S'-end)
that amplified a short region contained the SNP. Then 20 1.11 of peR products
were mixed with 4 1.11 of streptavidin-coated beads (Biotage) and 36 IJI of
binding buffer and the volume is adjusted to 100 IJI with water. Samples are
then vortex at 1100 rpm for 10 min at room temperature to optimizing the
formation of complex between streptavidin-coated beads and biotinylated
PCR product. The complexes were capture on tool pins membrane by
vacuum filtration and purified by using a denaturation solution. At the end
the complexes were released in a solution with sequencing primer and
samples were analysed with Pyrosequencing assay. Briefly, samples are
denaturated at 80° e and sequencing primer is hybridized to a single-
stranded peR amplicon that serves as a template, and incubated with four
enzymes (DNA polymerase, ATP sulfurylase, luciferase and apyrase) as well
as the substrates adenosine 5' phosphosulfate (APS) and luciferin (Fig. 17,
(276». The first deoxribonucleotide triphosphate (dNTP) is added to the
reaction. DNA polymerase catalyzes the incorporation of the dNTP into the
DNA strand, if it is complementary to the base in the template strand. Each
incorporation event is accompanied by release of pyrophosphate (PPi) in a
quantity equimolar to the amount of incorporated nucleotide. ATP
(adenosine triphosphate) sulfurylase converts PPi to ATP in the presence of
adenosine 5' phosphosulfate and drives the luciferase-mediated conversion
of luciferin to oxyluciferin that generates visible light in amounts that are
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proportional to the amount of ATP (277). The light produced in the
luciferase-catalyzed reaction is detected by a charge coupled device (CCD)
chip and seen as a peak in the raw data output (Pyrogram). The height of
each peak (light signal) is proportional to the number of nucleotides
incorporated. Apyrase, a nucleotide-degrading enzyme, continuously
degrades unincorporated nucleotides and ATP. When degradation is
complete, another nucleotide is added. Addition of dNTPs is performed
c
c
PPi
ATP
sequentially. As the process continues, the complementary DNA strand is
r-
.:»
built up and the nucleotide sequence is determined from the signal peaks in
-- __--..------1--'--.---,..---
---+-.--..,f------,-'----!--
Fig. 17 Pyrosequencing: reactions and principles (276).
the Pyrogram trace (Fig. 17).
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Primers designed to confirm allele frequencies of 47 putative
associated SNPs in the same DNA pools for confirmation were listed in
Supplementary Table 1.
2.2.3 Individual genotyping
Validation of statistically significant associated SNPs in individual
samples was performed using MassARRAY Sequenom assay (Sequenom,
San Diego, CA, USA).
Genotyping of the selected SNPs was carried out following published
protocols applying the multiplex genotyping assay iPLEXTMfor use with the
MassARRAY platform (278). Briefly, multiplex PCR assays were designed
using Sequenom SpectroDESIGNER software by entering sequence
containing the SNP site and 100 bp of flanking sequence on either side of
the SNP (Fig. 18). The SNPswere grouped into multiplexes according to the
mass of the extension product over the SNP site. PCR was carried out in
384-well reaction plates in a volume of 5 j,J1 using 2.5 ng of genomic DNA.
All reactions are ended after a single base extension (SBE) into the SNP site
and SBE products are separated by their mass differences allowing to
genotype (Fig. 18, (278».
The extension products were spotted onto a 384-well spectroCHIP bioarray
before analysis by MALDI-TOF mass spectrometry (Sequenom). To
guarantee quality of genotyping, all samples plus a series of duplicates were
genotyped in the same batch.
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Fig. 18 Diagram of MassARRAY iPLEX Sequenom assay protocol
(278).
2.2.4 Statistical analysis
The consistency of genotype frequencies at each SNP locus with
respect to the Hardy-Weinberg equilibrium was tested (279). The
correlation of the allelic frequencies within and among experiments, or
between allele frequency data obtained by SNP array and pyrosequencing
analyses, was tested by the Pearson's coefficient. Differences in allelic
frequencies between case and control groups were analyzed by the Fisher's
exact test or by chi-square analysis when the normal approximation was
appropriate. Technical component was estimated as mean of the variance
86
2. Materials and Methods
between replicates within experiment, whereas the component due to
sampling was obtained by comparison between mean allelic frequencies of
the two experiments. The estimation of number of chromosomes in cases
and controls was carried out using the 2x2 contingency table analysis.
Association between each SNP and disease status, computing odds ratios
and 95% confidence intervals, was assessed using the logistic regression or
the extended Mantel-Haenszel chi-square for linear trend. LD of the SNPs
with the surrounding region was assessed using HapMap data (CEU
population). The Kaplan-Meier product-limit method and the log-rank test
(280, 281) were used to evaluate the effect of the genotypes on overall
survival of lung cancer patients.
2.3 FAMILY-BASED ASSOCIATION STUDY FOR LUNG CANCER
RISK
2.3.1 Genome-wide SNPs analvsis
Genome-wide genotyping was carried out in DNA pools prepared from
cases and controls of the family-based series (see paragraph 2.1.3). 200 ng
of DNA per sample was hybridized using the Infinium II Assay Human610-
Quad BeadChip on the Sentrix BeadChip platform (Ilium ina, see paragraph
2.2.2), which allows analysis of 620,901 genetic markers chosen from the
International HapMap release 23. For each DNA pool, SNP array analysis
was carried out in quadruplicate.
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2.3.2 Individual genotyping
Individual samples were genotyped using MassARRAY (Sequenom)
(see paragraph 2.2.3).
2.3.3 Statistical analysis
Differences between lung cancer cases and their sib controls in allelic
frequencies assessed in SNP array hybridization were analyzed using
random variance t-statistics (282) and BRB ArrayTools developed by Dr.
Richard Simon and Amy Peng Lam
(http://linus.ncLnih.govLBRBArrayTools.html). Differences in allele
frequencies, estimated from SNP-array analysis of DNA pools, between
cases and controls were tested by Fisher's exact test or by chi-square
analysis when the normal approximation was appropriate. The correlation of
the allelic frequencies between SNP array and individual genotypes was
expressed as a Pearson's coefficient. Association analyses were carried out
using PUNK software (223), which included analysis of HWE, family-based
TDT (258) and population-based association analyses between disease
status and genotype/allelotype. A generalized linear model with binomial
errors was used to test the relationship between genetic susceptibility score
and proportion of lung cancer cases; the mean values of genetic
susceptibility scores were also analyzed using the Kruskal-Wallis test. The
age was down-coded to binary dummy variables (age in decades), which
were used as covariates in logistic analyses. Linkage disequilibrium between
SNP markers was evaluated using JUN program, version 1.6.0
(http://www.genepi.org.au/jlin.html) (283).
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2.4 CASE-ONLY ASSOCIATION STUDY FOR LUNG CANCER
PROGNOSIS
2.4.1 Genome-wide SNPs analysis
DNA pools obtained from 600 lung ADCA patients according to their
clinical stage (see paragraph 2.1.3) were analyzed using the Human610-
Quad BeadChip array (Iliumina), as for family-based series (see paragraph
2.3.2). Twelve SNP-array hybridizations were performed for each DNA pool
as described in paragraph 2.2.2.
2.4.2 Individual genotyping
Selected SNPs were genotyped in individual samples using
MassARRAYSequrnom assay (Sequenom) as described in paragraph 2.2.4.
2.4.3 Gene expression profile with microarray analysis
Microarray gene expression analysis was carried out in RNA pool from
120 lung ADCA patients (see paragraph 2.1.3). Each RNA pool was reverse-
transcribed, labelled with biotin and amplified overnight (14 h) using the
Iliumina Total Prep RNA Amplification kit (Ambion) according to the
manufacturer's protocol. A mixture of 1.5 I-1gof the biotinylated cRNA
samples were hybridized according to manufacturer's protocol to Sentrix
Bead Chip HumanHT-12 (experiment A) or to Sentrix Bead Chip
HumanRef_8_v2 (experiment B) (Iliumina). The arrays contain more than
48,000 or 22,000 bead types representing 47,231 or 18,196 unique
sequences, respectively, derived from human genes in the NCBI Reference
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Sequence (RefSeq) Release 38 or 22, respectively. Array chips were
scanned with an Illumina BeadArray Reader. Intensity values of each
hybridization were quality-checked and the data set was normalized using
the cubic spline algorithm in the BeadStudio Version 3 software. A detection
P-value <0.05 was set as a cut-off to filter the reliable genes, yielding a
matrix containing 12,244 genes and 13,035 detectable transcripts,
respectively. Data were analyzed using BRB ArrayTools (see paragraph
2.4.8). Microarray results were validated by quantitative real-time peR
(qRT-PCR) as described in paragraph 2.4.6.
2.4.4 Quantitative Real-Time peR
From each sample, 1 I-Ig of RNA was used to synthesize cDNA by
reverse-transcription using Transcriptor First Strand cDNA Synthesis Kit
(Roche, Basel, Switzerland) with a 1: 1 mix of oligo( dT) and random
hexamer primers, according to the manufacturer's instructions.
Real-time peR analysis was performed using customized TaqMan®
Low Density Arrays on the 7900HT System (Applied Biosystems, Foster
City, CA, USA). TaqMan Gene Expression Assays used, spotted onto a 384-
well card, are listed in Table 8 and in Table 9. Eight cDNA samples were
analyzed per card. Each sample was measured in duplicate in a single RT-
peR run. 2.5 ng of cDNA template, mixed with TaqMan® Universal peR
Master Mix (Applied Biosystems), in a total volume of 100 Ill, was loaded
per sample loading port. Thermal cycling and fluorescence detection was
performed on the microfluidic card sample block in the Applied Biosystems
ABI Prism 7900HT Sequence Detection System (SDS) with ABI Prism
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7900HT SDS Software 2.2 (Applied Biosystems). The thermal cycling
conditions were 2 min at 50°C and 10 min at 94.5 °c, followed by 40
cycles of 30 s at 97 °c and 1 min at 59.7 °C. Relative expression levels
were calculated using the comparative Ct method calibrating the samples
relative to a cDNA pool from normal lung tissue (calibrator). The raw gene
expression values were normalized according to the expression of
hypoxanthine phosphoribosyltransferase 1 (HPRT1, Hs99999909_m1) gene
as endogenous reference (housekeeping) (Table 8 and Table 9).
The amount of a target gene in a sample, normalized to an
endogenous reference and relative to a calibrator, is given by (285): 2-MCt
where Ct, or threshold cycle, is "the fractional cycle number at which the
amount of amplified target reaches a fixed threshold" and 1111Ct= l1Ct(target
geneinsample)- l1Ct(targetgenein calibrator)·The l1Ct value is calculated as Ct(targetgene)-
Ct(housekeeplng)for each samples and for calibrator sample.
Gene symbol Gene name
Table 8. Genes present on the TaqMan® LowDensity Array for
Microarray validation.
Gcoml
MSXl
TMEMI00
SMAD6
IDHl
VIPRl
Sle14Al
ect.s
PlEKH02
SFTPA2B
SBN02
RRP12
TaqMan® Gene
Expression Assay
No.
GRINLlA complex locus
Msh homeobox 1
Transmembrane protein 100
SMADfamily member 6
Isocitrate dehydrogenase 1 (NADP+),
soluble
Vasoactive intestinal peptide receptor 1
Solute carrier family 14 (urea transporter),
member 1 (Kidd blood group)
B-cell ell/lymphoma 3
Pleckstrin homology domain containing,
family 0 member 2
Surfactant protein A2B
Strawberry notch homolog 2 (Drosophila)
Ribosomal RNAprocessing 12 homolog (S.
cerevisiae)
Hs00291311_ml
Hs00427183_ml
Hs00388033_m 1
Hs00178579_ml
Hs00271858_ml
Hs00270351_ml
Hs00210608_ml
Hs00180403_ml
Hs00368811_ml
Hs00359837_ml
Hs00209130_m1
Hs00958380_ml
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DACT1 Dapper, antagonist of beta-catenin, Hs00420410_m1
homolog 1 (Xenopus laevis)
ITlN1 Intelectin 1 (galactofuranose binding) Hs00914745_m1
C200rf114 Chromosome 20 open reading frame 114 HsOl113243_m1
SElE Selectin E Hs00950401_m1
FCN3 ficolin (collagen/fibrinogen domain Hs00892390_m 1
containing) 3 (Hakata antigen)
COLlA1 Collagen, type I, alpha 1 Hs01076777 _m1
DEFA3/DEFA1 defensin, alpha 3, neutrophil-specific/ HsOO414018_m1
defensin, alpha 1
TXNIP thioredoxin interacting protein HsOO197750_m1
lZTS1 leucine zipper, putative tumor suppressor HsOO232762_m1
1
INHBB Inhibin, beta B HsOO173582_m1
HPRT1 Hypoxanthine phosphoribosyltransferase 1 Hs99999909 m1
Table 9. Genes present on the TaqMan@ LowDensity Array for cytokine-
cytokine receptor pathway validation.
TaqMan® Gene
Gene symbol Gene name Expression
Assay No.
CXCl2 chemokine (C-X-C motif) ligand 2 Hs00601975_m1
CCl2 chemokine (C-C motif) ligand 2 Hs00234140_m1
CXCl14 chemokine (C-X-C motif) ligand 14 HsOO171135_m1
tumor necrosis factor receptor superfamily,
TNFRSF12A member 12A HsOO171993_m1
CCl3 chemokine (C-C motif) ligand 3 HsOO234142_m1
colony stimulating factor 3 receptor
CSF3R (granulocyte) HsOl114427_m1
TNFSF10 tumor necrosis factor (ligand) superfamily,
member 10 Hs00234356_m1
TGFB3 transforming growth factor, beta 3 Hs01086000_m1
CSF3 colony stimulating factor 3 (granulocyte) Hs99999083_m 1
Il7R interleukin 7 receptor Hs00233682_m 1
Il1R1 interleukin 1 receptor, type I HsOO991010_m1
Il8 interleukin 8 HsOO174103_m1
CCl21 chemokine (C-C motif) ligand 21 Hs99999110_m1
CX3CR1 chemokine (C-X3-C motif) receptor 1 Hs00365842_m 1
IL6 interleukin 6 HsOO174131_m1
IL1RL1 interleukin 1 receptor-like 1 Hs01073300_m1
CXCR7 chemokine (C-X-C motif) receptor 7 Hs00604567_m1
ICAM1 intercellular adhesion molecule 1 HsOO164932_m1
ICAM4 intercellular adhesion molecule 4 HsOO169941_m1
CXCLl chemokine (C-X-C motif) ligand 1 (melanoma
growth stimulating activity, alpha) Hs00236937 _m1
CCL4Ll chemokine (C-C motif) ligand 4-like 1 Hs00237011_m 1
CXCL13 chemokine (C-X-C motif) ligand 13 Hs00757930_m 1
HPRT1 Hypoxanthine ohosphoribosyltransferase 1 Hs99999909 m1
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2.4.5 Immunohistochemical Analysis
Immunohistochemical staining was performed on paraffin-embedded
tissue sections of lung ADCA and surrounding normal lung tissue retrieved
from the archives of our Department of Pathology. Antibodies used were
anti-SLC14A1 (AV48116; diluted 1: 1500) and anti-SMAD6 (AV100717;
diluted 1:250) from Sigma-Aldrich™ (Sigma-Aldrich™, St. Louis, MO, USA),
and anti-FeN3 (sc-55202; diluted 1:50) from Santa Cruz Biotecnology, Inc
(Santa Cruz, CA, USA). Immunoreactive signals were detected with Chem-
Mate DAB (Dako, Glostrup, Denmark).
2.4.6 Statistic analysis
Differences between stage I and stage>I lung ADCA cases in allelic
frequencies assessed in SNP-array hybridization were analyzed using
random variance t-statistics (282) and BRB Array Tools
(http://linus.nci.nih.gov/BRB-ArrayTools.html). Differences in chromosome
counts between the two groups were tested by Fisher's exact test or by chi-
square analysis when the normal approximation was appropriate. The
correlation between SNP-array and individual genotype allelic frequencies
was expressed as a Spearman's coefficient. Association between clinical
stage (lor >1) and confounding variables was analyzed using ANOVA
(analysis of variance) or logistic analysis, whereas association between
SNPs and clinical stage was analyzed using PLINK software (223), which
included analysis of HWE, LD between SNPs, and population-based
association between prognosis factors and genotype/allelotype. Age at
cancer diagnosis was down-coded to binary dummy variables (age in
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decades), which were used as covariates in logistic regression analyses. The
average genetic risk score of clinical stage> 1 for individuals was calculated
using the "score" procedure of PLINK, i.e., the sum, across the 22
statistically significantly (P <0.01) associated SNPs in the joint analysis, of
the number of minor alleles (0,1 or 2) at any SNP multiplied by the log of
the odds ratio for that SNP. The reliability of the model was assessed by
bootstrap re-sampling with replacement (286). Overall survival was
assessed using Cox regression analysis and the "survival" package in R,
with follow-up cut at 60 months to reduce bias due to mortality caused by
non-cancer-related factors. All statistical tests were 2-sided.
Analyses of gene expression data were performed using BRB Array
Tools version 3.8.1 (http://linus.nci.nih.gov/BRB-ArraYTools.html). Pathway
analyses were carried out using the DAVID (Database for Annotation,
Visualization and Integrated Discovery) Functional Annotation Tool (DAVID
Bioinformatics Resources 6.7, NIAID/NIH, http://david.abcc.ncifcrf.gov/
(287» and the Ingenuity Pathway Analysis tool (IPA, Ingenuity System,
https:llanalysis.ingenuity.com). Differences in mRNA levels determined in
qRT-PCR were assessed by ANOVA on relative quantification (RQ) data.
Correlation between microarray and qRT-PCR results was assessed using
Pearson's correlation coefficient, r. Kruskal-Wallis test was carried out using
R packages.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Primers used for PCR amplification and genotyping of 47 SNPs
SNP Gene
Forward PCR primer' (seq 5'- Reverse PCR primer1 (seq 5'- Pyrosequencing primer
>3') >3') (seq 5'->3')
rs10518668 B-cacttgccttaatcagatggtca tctcccctccttaaataaatgatg aaagcaattcaatttctct
rs11119493 HHAT gtgctctgtattcaaaagccattt B-aaacatcccaaaatatgggtgaga atttgatatttggttaaatt
rs12556578 tgtggtggcaaatattctttgtt B-gctggtgtcacttgctgaataat tccctttttctatttgg
rs12680976 gggatgcagctagagcaatactta B-aactgtgagtcctccaactttgt taatacaaataaaatcagaa
rs1385049 cctgaatcaaacttgcgtaatg B-atgtatcagttcttagccactgga aattccctatgaaaatatta
rs1433184 gagcaaatgtgggatgattcaaag B-acaccatcagcctgttgttttta tgcatttttgtttacaaatt
rs1584586 tgtctggacccaagcttttc B-gaaacggttcatcactaccagtc tcttagttcagttttggtaa
rs17199134 B-tctttttgactcctcatttcttta gataaacttctctcctttttgtaa aatatgattcaaagttaata
rs2038256 atatttttgggtaggcaacagact B-accctctagctttgctgtttgt ggagttgaggaatttcag
rs3797832 B-ttttcaccaggcttaagacattg tcacaataaatgggaaggatga aattaaaagaaaacgaatt
rs3804479 B-agccaaacaaaggtacagtatgc tcataaaagcaagcgagatttcca agcgagatttccaaaa
rs4897493 ctcttttgctttcacacacaagtt B-gatcacaggatacaaagcacacat atggcatttagaagaaaa
rs1877116 B-tctccttctgccaaattctgct gggctgttgacattgagctact gttatctcaagaatacctg
rs2588767 B-gcctaatattagtttggcactgaa gtattgggaagggattcttcaa cagagtcttaaaaaaacgc
rs3130517 tttttgaagactagccatgacact B-gcctctctctgtgggctattaa tccttttaagacttgatgtt
rs2418422 C9orf27 B-gaggaagaggaaatcaggtagaaa ttctccactatcctcttgcatcta ctcttgcatctagtgctt
rs6488007 B-tacggagtttcactttgggatgat tgctagtccacctgaattctctta acttaaccatatttttgaga
rs16918924 B-ggccatctgcttcaccaa tagagtgggcagcctgaaga tgaagaaaattgtaaatgtt
rs8027776 SEC11A B-cactgcgtccagcctaaaaac cgttctgtcccacctctaatg atcatagagtatgtattctt
rs132470 tttcccaaaagaccctaaatagct B-ccatcctggtgtcataaaacatct cactgtgtgttagcagaa
rs4823406 PHF218 caagcatgcagggactagaat B-accccacacacccacatt gaaattcagtgaagaaaaac
rs6654096 GPM68 B-caaagctgccattgcctttta tggaaagattggggttgaagg tcattattgccctgag
rs5945306 ZNF275 aggtctggttgccagtttaggtg B-aaccacatgcctcgctcttt ctaccaaaacttgaagg
rs2172706 B-gatccagagcttgctgaagtga ataccatgtgagggaagagtaacc tcctactctcttctcttcc
rs1470037 8-atgtcagattttcccctacaacaa cactagaagggcaataggcaaga ggcaataggcaagatg
rs1584586 tgtctggacccaagcttttc B-gaaacggttcatcactaccagtc tcttagttcagttttggtaa
rs1428053 gcagaaaaaagagcaaaataaacc B-tggatctgtagtgatagcccattt aatttgtttctttagaatgc
rs1033822 catgcttattcattcaggaacatc 8-agctagccagtattgtgacattga aaaatacactctgtatgagc
rs1520 KIF6 8-gcttccataaactacccaaggata ggctcccttgcattttataaga attcatgaaatataattcac
rs210798 MYB B-ctctgtccatggatttgactacaa tggcaccagctgtttgtaaa tttaataaaaagcacagga
rs4731775 gtcccccaaatggttttttattgt B-tttctttctcttgcctgactgct caatattgtgaaagcat
rs3812278 CNOT4 gcctcagttaaccaaatctaagga B-tgtcatgttggagttggagtttt ttgggataaagtcatttaat
rs7011544 taaaacatagtggggacctccaa B-tgtcattgcacatatcacactcag gggacctccaagaatct
rs302917 B-aaaggattggaggagaaatattca atggtgctgtttttgaaaacttg tggaaataaatttgacaga
rs7907321 CTNNA3 ggggaattgttgtatttgaaagaa B-caatcatgcttcaaattgcttaga tgacgtgtatattttgttat
rs2515373 CNTN5 B-tcttagggggcacgtggt cacagagggtggaatgttga gttgaaattctcctacctc
rs7670329 tctagatgagcaccaataatgcc B-gaatgttgctcatttgaaacagtt gcaccaataatgcctt
rs8062660 B-ccaaactcatgggtgtctgaa agagggataggaaatgtgtcagg gagtaccagctgcca
rs2869832 B-tctgttgcctttcccttctg tggcccaggtttctcctgtt gagaaaatcacgactatcaa
rs2139875 LOC388458 B-gaacttggtaacactgccaacaat cctcagcatcaggcaatatacat tttaatttccagattttcac
rs8113515 gttttaccacattattggcagttg B-cacaaatggctgtctcatctgta aaggcaatttccttt
rs967785 GK B-ccgtagagatcctgtgtgaagtag gcattttgcagggagtgg gggagtggtttagcaa
rs1199508 DGAT2L6 tagcaataaacaagctgattcaaa B-gccacatatggacatcaaattttc ccatctgattttgagactta
rs5949639 B-tccctctgagctttcaagatcact tggggcattaaatgaattaaggt agacaaattactgttattgg
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'For each SNP one peR primer is modified by addition of a biotinylated group at the 5' extremity (8),
rs1933800 gaatgttcccaacacaaagaaat 8-atgatattatgattcgtggagtgc acaccataatagaaccca
rs5943261 acagctttttgcattgtgattacc 8- tctctctcaatcccctatcattct ttttgcattgtgattacc
rs6918015 acacaggaagcagtggctagatga 8-aggcttcaagtgcttctgaatcaa agaggcaaaggccac
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3.RESULTS
3.1 RESULTS OF POPULATION-BASED ASSOCIATION STUDY
FOR LUNG CANCERRISK
3.1.1 Multiple unlinked SNPs are associated with a decreased lung
ADCA risk
SNP-array hybridization design was carried out using a DNA pooling
strategy in a joint analysis of 2 experiments, each conducted in duplicate in
pools of either 200 lung ADCA cases or 200 matched healthy controls
extracted from our series (Table 6). Correlation of the allelic frequencies
between replicates within each experiment was 0.991 in both experiments,
whereas correlation between experiments was 0.984.
Statistical analyses of allelic frequencies of the two independent
experiments pointed to 235 SNPs statistically correlated (P < 0.01) within
and between experiments and significant allelic imbalance between case
and control DNA pools. From these SNPs putative associated with lung
cancer risk, we selected a subset of 47 SNPs to limit costs of the experiment
(Table 10), giving priority to SNPs with the highest statistical association (P
< 1 X 10-7 in at least 1 replica), reduced variation of allele frequency
between the two experiments (coefficient of variation, i.e., standard
deviation/mean allele frequency, ~5%), frequency of the rare allele ~0.20,
and close vicinity « 1 Mb) to another SNPof the 235 SNP list.
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Table 10. 47 SNPs putative associated with lung cancer risk in GWA analysis of the
two experiments.
SNP name Position
P value C
a Chromosome (Mb) b Gene First Second
experiment experiment
rs10518668 1 83,1 1,31 X 10-
13 3,33 X 10-16
rsl1119493 1 210,6 HHAT 1,59 X 10-
12 6,16 X 10-12
rs2172706 1 154,7 KCNN3 * 4,03 X 10-6 8,80 X 10-3
rs1470037 2 81,9 6,59 X 10-
3 2,74 X 10-6
rs1584586 3 150,2 TSC22D2 * 3,54 X 10-11 9,00 X 10-3
rs17199134 4 172,3 7,77 X 10-
16 4,08 X 10-9
rs1877116 4 66,0 1,46 X 10-
3 6,59 X 10-3
rs2588767 4 66,9 1,49 X 10-
3 2,62 X 10-6
rs7670329 4 180,3 1,94 X 10-
6 6,78 X 10-3
rs3797832 5 108,4 FER 1,52 X 10-
10 6,16 X 10-11
rs1428053 5 116,7 9,00 X 10-
3 3,78 X 10-3
rs3804479 6 6,6 LY86 1,11 X 10-
16 9,00 X 10-3
rs4897493 6 131,4 EPB41L2 * 6,63 X 10-10 3,36 X 10-10
rs3130517 6 31,3 1,81 X 10-
6 7,15 X 10-6
rs1033822 6 18,8 8,00 X 10-
8 2,75 X 10-4
rs1520 6 39,5 KIF6 4,10 X 10-
7 5,00 X 10-8
rs210798 6 135,5 MYB 9,00 X 10-
3 1,00 X 10-8
rs6918015 6 151,5 1,34 X 10-
4 5,50 X 10-5
rs4731775 7 130,9 MKLN1 1,82 X 10-
3 5,62 X 10-4
rs3812278 7 135,1 CNOT4 1,14 X 10-
6 6,90 X 10-4
rs12680976 8 140,0 2,54 X 10-
9 4,70 X 10-14
rs1385049 8 51,8 SNTG1 * 1,59 X 10-12 9,00 X 10-3
rs1433184 8 108,5 ANGPTl 2,54 X 10-
11 2,41 X 10-13
rs7011544 8 111,1 9,27 X 10-
3 4,06 X 10-4
rs2418422 9 118,7 C9orf27 4,10 X 10-
3 2,35 X 10-3
rs302917 9 135,6 GTF3C4, DDX31 * 2,00 X 10-8 4,46 X 10-5
rs7907321 10 68,0 CTNNA3 4,77 X 10-
3 2,00 X 10-8
rs2515373 11 99,5 CNTN5 1,00 X 10-
8 7,14 X 10-5
rs6488007 12 31,9 1,21 X 10-
3 2,16 X 10-3
rs16918924 12 31,9 4,15 X 10-
3 1,09 X 10-3
rs2038256 14 29,2 C14orf23, FOXG1B * 2,35 X 10-11 2,83 X 10-12
rs8027776 15 85,3 SECllA 9,05 X 10-
5 8,99 X 10-6
rs8062660 16 59,2 3,73 X 10-
3 1,18 X 10-5
rs2869832 17 63,3 2,04 X 10-
5 4,92 X 10-3
rs2139875 18 4,2 9,00 X 10-
3 2,00 X 10-8
rs8113515 19 43,8 PSG9 * 6,98 X 10-6 1,20 X 10-3
rs132470 22 45,2 ARHGAP8, PRR5 3,71 X 10-
3 3,62 X 10-4
rs4823406 22 45,3 PHF21B 7,30 X 10-
4 9,87 X 10-3
rs12556578 X 62,7 7,08 X 10-
10 1,39 X 10-8
rs6654096 X 14,0 GPM6B 1,41 X 10-
6 4,14 X 10-4
rs5945306 X 152,7 4,07 X 10-
4 3,19 X 10-4
rs967785 X 30,7 GK 3,83 X 10-4 4,17XlO-
3
rs1199508 X 69,4 DGAT2L6 1,00 X 10-7 8,77 X 10-
4
rs5949639 X 95,0 9,00 X 10-3 3,12 X 10-
3
rs1933800 X 97,7 1,90 X 10-5 6,00 X 10-
8
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rs5943261 X 1084 6,15 X 10-3 2,66 X 10-4
a SNPssorted by chromosomeand position; * gene in LDwith relative SNP(HapMap3
GenomeBrowserrelease#2); b Positionin megabasesaccordingto Ensemblrelease59; c P
valuesobtained by the Fisher'sexact test or by chi-squareanalysiswhen the normal
approximationwasappropriate.
The independent confirmation of allele frequency obtained from 300K
SNP assay was carried out using pyrosequencing analysis. Primers designed
(Supplementary Table 1) to analyze the 47 SNPs in the same DNA pools led
to the selection of 16 SNPs, based on strength of association (-log P > 1.5,
Table 11) and concordance between the two experiments, and analyzed in
the individual samples by MassARRAYSequenom Assay (Sequenom).
Table 11. 16 SNP validated in the pyrosequencing analysis on DNA pools.
SNpa Chromosome Mbb Gene P Fisher -logP
rs2172706 1 154,7 KCNN3 * 3.30 x 10-3 2,48
rs1470037 2 81,9 8,85 x 10-5 4,05
rs1877116 4 66,0 1.20 x 10-3 2,92
rs3130517 § 6 31,3 2,45 x 10-4 3,61
rs4897493 6 131,4 EPB41L2 * 1.09 x 10-2 1,96
rs6918015 6 151,5 1.39 x 10-2 1,86
rs4731775 t 7 130,9 MKLN1 6,15 x 10-4 3,21
rs2515373 11 99,5 CNTN5 8,11 x 10-5 4,09
rs16918924 12 31,9 2,69 x 10-4 3,57
rs6488007 12 31,9 1.76 x 10-2 1,75
rs8062660 16 59,2 1.80 x 10-2 1,74
rs2139875° 18 4,2 1.31 x 10-2 1,88
rs8113515° 19 43,8 PSG9 * 4,31 x 10-4 3,37
rs5945306 X 152,7 2,54 x 10-6 5,60
rs967785 X 30,7 GK 2.62 x 10-2 1,58
rs5943261 X 108,4 3.16 x 10-2 1 50
a SNPs sorted by chromosome and position; § failed pre-extend (Sequenom); 0
failed in homogenous mass extension (hME) design (Sequenom); t failed
genotyping; * gene mapping in the LD region with relative SNP (HapMap3
Genome Browser release #2); b Position in megabases according to Ensembl
release 59.
Among these 16 SNPs, 1 SNP failed in the pre-extend analysis, 2 SNP
failed in homogenous mass extension (hME) design, and 1 SNP failed in the
genotyping. Frequency of the rare alleles of the 12 remaining SNPs in
controls ranged from 0.07 to 0.36. None of these SNPs showed significant
deviations from the Hardy-Weinberg equilibrium. Paired analysis for
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possible LD between the 12 SNPs detected a significant LD between
rs6488007 and rs16918924, mapping at a 13.6 kb distance on
chromosomes 12, with a preferential segregation of the rare alleles of the
two SNPs in the same individuals (P<O.OOOl), in both controls (0' = 0.88)
and cases (0' = 0.79). Although these SNPs were linked, their genotypes
matched only partially in the series of controls and cases, indicating that
each of the two SNPs contained a distinct set of genetic information. Thus,
they were maintained in the study and analyzed separately. The SNPs
selection steps are summarized in Fig. 19.
>318,000 ~NPs in GWA
..
DNApool allele frequency analysis
... P~1.0 x lOol; MAF>O.2
235 SNPs
... p~ 1.0 X 1007
47 SNPs
...
Independent confirmation on DNA pools
(Pvroseq uencing)
... -logP> 1.5
16SNPs
~ 17 excluded from MassARRAYgenotyping
Individual genotyping (MassARRAY
Sequenom Assay)
...
12SNPs
... Logistic analysis, P<O.OS
8SNPs
Fig. 19 Schematic representation of SNPs selection in
population-based case-control association study.
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Significant allelic associations with lung ADCA risk were observed for
8 SNPs (P:$0.05); 7 autosomal and one on chromosomes X (Table 12). The
SNPon chromosomes X (rs5945306) showed significant allelic association in
both sexes. None of the 8 SNPs showed statistical associations with the
confounding variables of gender, smoking habit and age, except for SNPs
mapping on chromosomes X, for which logistic analyses were adjusted by
sex.
Table 12. List of 8 SNPs showing significant association with lung ADCA risk
after MassARRAYSequenom assay on individual samples.
SNpa Chromosome Position (Mb) b Gene
rs2172706 1 154,7 KCNN3 *
rs1470037 2 81,9
rs1877116 4 66,0
rs4897493 6 131,4 EPB41L2 *
rs2515373 11 99,5 CNTN5
rs6488007 12 31,9
rs16918924 12 31,9
rs5945306 X 152,7
a SNPs sorted by chromosome and position; b Position in megabases
according to Ensembl release 59; * gene mapping in the LD region with
relative SNP (HapMap3 Genome Browser release #2).
We assessed the lung cancer risk by genotype or allele status testing
a genetic model based on dominant or codominant effects of the rare allele
on this risk. A significant association between the rare allele carrier status
and decreased risk of lung ADCA was found for the 8 SNPs (OR "'0.6-0.8, P
< 0.05; Fig. 20), except for the SNP rs2515373 that shows a borderline
association (OR = 0.73; 95% Cl: 0.52-1.02; Fig. 20). No significant
association was observed between rare allele carrier status and survival rate
of lung ADCA patients at any SNPs.
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SNP elY. Genotype Number of
controls/cases
rs2172706 AA 3081316
GG orAG 2061158
rs1470037 2 TT 3751319
GG orTG 139/95
rs1877116 4 AA 320J326
GG orAG 1931146
rs4897493 6 TT 3871385
CC orTC 132192
rs2516373 11 AA 419J406
GG orAG 102172
rs648eOO7 12 AA 3021281
GG orAG 190/127
rsl6918924 12 AA 3861392
CCor AC 127182
rs5946306 X TT 416/412
CCorTC 96.161
0.5 0.6 0.8 1.0
Per-allele OR (95% Cl)
Fig. 20 Plot of the risk of lung cancer associated with the rare allele carrier status
at each of 8 SNPs identified by genome-wide scan, in a series constituted by
Italian cases and controls. Shaded squares denote odd ratios (ORs). Horizontal
lines represent 95% CIs. The vertical line indicates the null effect (OR=1.0).
3.1.2 The confirmed SNPs point to a polygenic model with additive
and interchangeable effects
We tested the hypothesis of a polygenic model under the assumption
of additive and independent effects of rare alleles of the 8 SNPs that showed
associations with lung ADCA risk. Gender-adjusted allele dosage-response
analysis (i.e., number of alleles versus risk of lung ADCA) evidenced that
risk of lung cancer significantly decreased according to the number of rare
alleles carried (Fig. 21, P = 5.3 x 10-9). In particular, carriers of 2 to 6 rare
alleles showed a statistically significant decreased risk of lung cancer, with a
decreasing trend up to an OR=0.29; (95% Cl 0.13-0.67) for individuals
carrying 5-6 rare alleles (Fig. 21). Overall, carriers of 2 or more rare alleles
(n=344/229, controls/cases) versus carrier of 0 or 1 rare allele
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(n= 137/177, controls/cases) showed about 2-fold lower risk of lung ADCA
(OR=0.52, 95% Cl 0.39 - 0.68, P = 2.8xlO-6).
No. of Number of
rare alleles controls/cases
0 42/56
- 1 95/121
2 143/122
3 100/71
4 74/26
50r6 27/10
0.16 0.25 0.4 0.6 1.0 1.6
Per-carrier OR (95% Cl)
Fig. 21 Plot of the risk of lung cancer associated with the carrier status of
each rare allele of the 8 SNPs reported in Fig. 21.
3.2 RESULTS OF FAMILY-BASED ASSOCIATION STUDY FOR
LUNGCANCERRISK
3.2.1 Multiple unlinked SNPs are associated with lung ADCA risk
Genome-wide analysis of allelic frequencies of each SNP from case
and sib-control DNA pools, deleting SNPs whose minor allele frequency in
both cases and controls was <0.1, revealed 659 SNPs with parametric P-
values s 1.0 x 10-7 (equivalent at a false discovery rate P = 0.0008). For
these 659 SNPs, we estimated the number of chromosomes in cases and
controls and obtained 82 SNPs putatively associated with disease at P s
0.001. All of them were assayed for mass spectrometry analysis on
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~ sib-TOT test, P<O.l
620,901 SNPs in GWA
~
Discordant-sibships DNA pool allele frequency analysis
~ P~LO x 10-7; MAF>0.1
659 SNPs
~ P~O.OOl
82SNPs
~
Discordant-sibships individual genotyping
(MassARRAY Sequenom Assay)
~ 7 SNPs failed MassSpectrometry analysis
75 SNPs
36SNPs
Fig. 22 Schematic representation of SNPsselection in discordant
sib-pairs study.
MassARRAY Sequenom assay (Sequenom): three SNPs failed PCR or
MassEXTEND primer design and, therefore, 79 SNPs were genotyped by
MassARRAY in 80 cases and their respective healthy sib controls. After
MassARRAY genotyping, two SNPs failed genotyping, one SNP was
monomorphic and one SNP showed highly significant deviation from the
Hardy-Weinberg equilibrium (most likely because of bias in genotype calls
due to preferential allele amplification or to technical problems in their
assays), and were therefore removed from the study, reducing the number
of markers to 75 SNPs. The SNPs selection steps are summarized in Fig. 22.
Correlation analysis of the minor allele frequencies estimated in cases
and controls either in DNA pools by SNP array analysis or in individual
samples by MassARRAY for the 75 SNPs associated with lung cancer
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demonstrated the reliability of the pooling approach (r = 0.78, P < 2.2 x 10-
16, Fig 23).
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Single-point analysis using the sib- TDT test (258) indicated that 36 of
o
o
r=O.78, P<2.2e-16
I I I I
0.4
the 75 genotyped SNPs were significantly associated with disease status
0.1 0.2 0.3
(Table 13). The strongest associations were observed for SNPs rsl1833102
0.0
Frequency of the rare allele (DNA pools)
mapping in the carboxypeptidase M (CPM) gene on chromosomes 12,
Fig. 23 Correlation between SNPfrequencies measured by SNP
array analysis of DNApools and frequencies measured by
genotyping of individual samples. Plotted data represent
frequencies of the rare allele of 75 SNPsputatively associated with
lung cancer risk.
rs17120323 in the sarcoglycan zeta (SGCZ) gene on chromosome 8,
rs124457s8 within cadherin 13, H-cadherin (heart) (CDH13) gene on
chromosome 16, and rs325702 mapping in the cyclic nucleotide-gated
channel alpha 4 (CNGA4) gene on chromosome 11.
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Table 13. 36 SNPsshowing statistically significant association with lung cancer risk in the
discordant sibs series.
SNpa Chromosome Position Gene P-value b OR C 95% Cl
(Mb) §
rs639739 1 4,4 0.0124 0.5 0.24 - 1.06
rs12748434 1 52,3 NRDl 0.058 2.30 0.78 - 6.81
rs1261411 1 57,0 PPAP2B 0.0114 1.65 1.01 - 2.69 d
rs2765529 1 119,6 WARS2 0.0482 0.66 0.39 - 1.14
rs6676647 1 119,8 0.0233 0.64 0.37 - 1.09
rsl0931664 2 195,8 0.058 0.57 0.24 - 1.36
rs721377 3 14,4 SLC6A6 * 0.0126 0.33 0.12-0.95d
rs9813644 3 49,9 MSTlR *, CAMKV * 0.0254 3.63 0.74 - 17.80
rs1918071 3 55,0 CACNA2D3 0.072 0.55 0.26 - 1.14
rs1456196 3 117,7 0.0348 1.68 0.78 - 3.60
rs12648320 4 92,3 FAM190A 0.0196 0.54 0.30 - 0.97 d
rs28475332 4 188,4 0.0201 0.41 0.16 - 1.02
rs7713580 5 41,9 0.096 1.56 0.68 - 3.60
rs16889292 6 78,4 0.0339 0.14 0.02 - 1.12
rs12663498 6 151,0 PLEKHG1 0.055 0.49 0.27 - 0.91
rs17160175 t 7 31,5 CCDC129 * 0.033 1.86 0.92 - 3.76
rsll773530 7 31,5 CCDC129 * 0.0164 1.95 0.97 - 3.93
rs4330610 7 85,3 0.059 0.36 0.09 - 1.39
rs17120323 8 14,7 SGCZ 0.0011 e 1.94 1.11 - 3.38 d
rs3019885 8 118,0 SLC30A8 0.052 0.69 0.42 - 1.13
rs12342234 9 13,3 0.0126 1.83 0.88 - 3.81
rs16937762 9 19,8 SLC24A2 0.0196 0.35 0.11 - 1.11
rs12001157 9 72,1 APBAl 0.090 1.63 0.78 - 3.42
rs325702 11 6,3 FAM160A2, CNGA4 0.0045 2.41 1.06 - 5.49 d
rs820900 11 38,2 0.0114 0.31 0.10-0.99d
rs10842402 12 24,9 0.061 0.63 0.33 - 1.19
rs11833102 12 69,3 CPM 0.0006 e 2.44 1.21 - 4.94 d
rs9544359 13 77,3 0.0254 1.91 0.93 - 3.94
rs1958226 14 82,2 0.052 0.55 0.24 - 1.26
rsll074274 15 95,0 MCTP2 0.0348 2.54 0.87 - 7.43
rs12445758 16 83,3 CDH13 0.0016 e 1.93 1.16 - 3.22 d
rs790097 17 71,6 SDK2 0.096 0.48 0.16 - 1.45
rs4426464 19 1,8 ONECUn 0.0067 2.57 1.17-5.65d
rs755032 20 24,0 0.0067 2.04 0.91 - 4.57
rs2516542 22 21,4 TOP3B 0.0076 3.1 1.18-8.11d
rs4823153 22 44,3 0.0046 0.51 0.27 - 0.97
a SNPs sorted by chromosome and position; b DFAM procedure in PLINK toolset, nominal P-
values. SNPs sorted by chromosome and position. c Based on allelic test for association. d
P<0.05, logistic regression procedure in PLINK toolset, based on allelic test for association,
i.e., rare allele versus common allele. e P<0.05 by 20,000 permutations of the whole series
(75 SNPs). t SNP rsl7160175 excluded from the polygenic model due to its high linkage
disequilibrium with rs11773530 (D'= 1.0, r2 = 0.97). § Position in megabases according to
Ensembl release 59; * gene mapping in the LD region with relative SNP (HapMap3 Genome
Browser release #2).
3.2.2 Four SNPs were confirmed in population series
The 36 statistically associated SNPs with lung cancer in the discordant
sibs analysis (Table 13) were replicated in a population-based lung ADCA
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case-control series (Table 1). None of them showed significant deviation
from the Hardy-Weinberg equilibrium, except for rs11074274 (P = 0.005, in
cases only). Unadjusted logistic analysis indicated that 4 SNPs (rs12748434,
rs1261411, rs4330610, and rs301988S) were statistically significant
associated (P<O.OS, Table 14). When adjusted for sex, age and smoking
habit only the last three SNPs were significantly associated in the
population-based series (P < 0.05, Table 14).
Table 14. SNPsshowing statistically significant association with lung
adenocarcinoma risk in the pODulation-basedseries.
SNP a Chromosome Position (Mb) Gene ORb 95% Cl P-value C
§
rs12748434 1 52,3 NRD1 0.70 0.51 - 0.96 0.026
rs1261411 1 57,0 PPAP2B 1.23 1.03 - 1.48 0.024
t
rs4330610 7 85,3 0.57 0.35 - 0.94 0.025
t
rs3019885 8 118,Q SLC30A8 1.21 1.01 - 1.45 0.036
t
a SNPssorted by chromosome and position; bBased on allelic test for association. C
Logistic regression procedure in PLINK toolset; nominal P-values; t Statistically
associated SNPs in adjusted analysis for sex, age and smoking habit; § Position in
megabases according to Ensembl release 59.
Comparison of the cases with early tumour onset (age up to 60 years;
n= 198) versus the whole controls confirmed the association of the SNP
rs301988S on chromosome 8 (P = 0.029) and detected the association of
the SNP rs16937762 on chromosome 9 (P = 0.024).
3.2.3 The polygenic model explains lung cancer risk in discordant
sibships
In the family-based series we tested the previous proposed polygenic
model for the interpretation of individual risk of lung cancer.
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Analysis included a total of 35 SNPs (Table 13) and 151 subjects. SNP
rs17160175 was excluded for its high linkage disequilibrium with
rsl1773530 (0'= 1.0, ~ = 0.97). Five controls and four cases were
removed from the dataset because >80% genotypes were missing.
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Fig. 24 A polygenic inheritance model with additive and
interchangeable effects of rare alleles at lung cancer modifier
loci explains the individual risk of lung cancer in the family-
based series. Scatterplot shows the proportions of subjects that
are cases as a function of genetic susceptibility score and the
fitted line.
To test the model, a score of +1 or -1 was attributed to the rare
allele of each SNP based on its association with increased or decreased lung
cancer risk, respectively. For each subject, the sum of the scores for all 35
SNPswas obtained as a general estimator of the individual genetic risk. The
average estimator was -1.6 ± 0.3 (mean ± standard error) in controls and
2.0 ± 0.3 in cases, respectively (P = 2.0 X 10-11, Kruskal-Wallis test). The
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proportion of lung cancer cases increased at higher genetic susceptibility
scores (Fig. 24; P = 5.9 x 10-9).
Then, we tested the same model in the replication study that has
been carried out in the population-based series, by calculating for each
individual the genetic susceptibility score as we have done in the family-
based series. Applying the same polygenic model in the population-based
series, by using the three confirmed SNPs (Table 14), we found that the
average estimator was 1.25 ± 0.03 in controls and 1.40 ± 0.03 in cases,
respectively (P = 0.0019, Kruskal-Wallis test). Analysis limited only to non-
smoker cases (n=66) versus all controls (n=S03) or versus non-smoker
controls (n=2S) gave similar results.
3.3 RESULTS OF GENOME-WIDE SNPs ANALYSIS IN CASE-
ONLY ASSOCIATION STUDY FOR LUNG CANCER PROGNOSIS
3.3.1 Multiple unlinked SNPs are associated with lung ADCA
prognosis
Analysis to test for possible associations between clinical stage and
confounding variables, such as gender, age at diagnosis and smoking habit,
revealed a relatively weak statistical association between clinical stage and
smoking status, with a borderline significant decrease of ever-smokers in
clinical stage >1 (OR=0.61, 95% Cl 0.39 - 0.95, P=0.030, logistic analysis).
No statistically significant associations were observed between clinical stage
and either age at diagnosis or gender.
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Genome-wide SNP array analysis conducted in 12 replicas of DNA
pools from lung cancer cases at clinical stage I or at higher clinical stages
(Table 3)/ respectively/ allowed the screening of 620/901 SNPs. Analysis of
allelic frequencies of each SNP from DNA pools/ deleting SNPs whose minor
allele frequency was >0.10 in the pools/ revealed 10/571 SNPs at
parametric P-values s 1.0 x 10-5• For these 10/571 SNPs/ using a 2x2
contingency table analysis to reconstructed the number of chromosomes in
the two groups we identified 80 most statistically associated SNPs with
clinical stage at P s 1.0 X 10-4• The SNPs selection steps are summarized in
Fig.25.
620,901 SNPs in GWA
~
DNA pool allele frequency analysis
~ P~LO x 10-s; MAF>0_1
10,571 SNPs
~ p~ 1.0 X 10-4
80SNPs
~
Individual genotyping (MassARRAY
Sequenom Assay)
~ 17 excluded from MassARRAY genotyping
63SNPs
~ Logistic analysis, P<0.05
Fig. 25 Schematic representation of SNPs selection in case-only
GWAS.
110
3. Results
Table 15. 63 SNPs putative associated with lung cancer staging.
SNpa Chromosome Position Gene Pvaluec ORd 95% ICd Pvalue d(Mb)b
rs951774 2 102,9 IL1RL1*,IL1RL2* 1.48 x 10-5 0.67 0.48 to 0.95 2.6 x 10-2
rsl0187901 2 140,6 7.26 x 10-5 0.60 0.39 to 0.93 2.8 x 10-2
rs13390491 2 179,6 TTN 9.33 x 10-5 1.65 1.20 to 2.27 1.8xl0-3
rsl0498217 2 228,0 COL4A4 1.23 x 10-5 0.56 0.37 to 0.84 6.9 x 10-3
rs16843438 2 242,1 TMEM16G 8.48 x 10-6 0.56 0.39 to 0.80 1.6xl0-3
rs2574711 3 11,7 VGLL4 5.28 x 10-5 0.55 0.36 to 0.85 3.5x 10-3
rs7694589 4 30,3 4.45 x 10-5 0.68 0.52 to 0.90 9.4x 10-3
rsll722134 4 73,6 2.79 x 10-5 1.68 1.05 to 2.69 2.5 x 10-2
rs1994854 4 77,8 7.59 x 10.7 0.55 0.40 to 0.77 2.1 x 10-4
rs423997 4 86,3 2.88 x 10-6 1.34 1.05 to 1.72 1.2 x 10-2
rs4505911 5 68,2 5.01 x 10-5 0.45 0.26 to 0.78 4.1xl0-3
rslo900886 5 105,2 2.40 x 10-5 0.54 0.38 to 0.78 1.0xl0-4
rs13189604 5 107,2 FBXL17 3.54 x 10-6 7.3 X 10-1
rs3823111 6 53,5 KLHL31 4.95 x 10-6 2.33 1.26 t04.33 5.0 x 10-3
rs806435 6 88,8 SPACAl 6.59 x 10-6 1.96 1.34 to 2.86 4.8 x 10-4
rs458523 6 95,1 1.72xl0-5 1.54 1.20 to 1.97 5.8 x 10-4
rs565968 6 125,4 IBRDCl 1.24xl0-6 0.78 0.62 to 0.98 4.3x 10-2
rsl0278557 7 15,7 MEOX2 3.42 x 10-5 0.50 0.37 to 0.67 5.0 x 10-6
rsl3438238 7 54,3 4.14x 10-10 3.3 x 10-1
rs2877213 7 54,9 4.02 x 10-5 6.7 X 10-1
rs845559 7 55,2 EGFR 8.98 x 10-6 4.9 X 10-1
rs17819684 7 82,7 PCLO 9.86 x 10.5 1.45 1.12to 1.87 2.4x 10-3
rs2299297 7 104,7 MLL5 6.56 x 10-5 1.64 1.24t02.16 4.2 x 10-4
rs2648 7 128,8 TSPAN33 7.57 x 10-6 2.29 1.43 to 3.68 8.0 x 10-4
rs17125699 8 17,7 3.87 x 10-5 0.52 0.28 to 0.98 4.4x 10-2
rsl0738132 8 98,2 4.54 x 10-7 3.6 X 10-1
rs972519 9 4,5 SLC1Al 7.14 x 10.6 0.60 0.41 to 0.89 7.3 x 10-3
rs824249 9 28,8 1.78x 10-5 0.55 0.37 to 0.82 3.1 x 10-3
rsl0491726 9 114,3 LTB4DH, ZNF483 3.87 x 10-5 1.2 X 10.1
rsl0987191 9 129,0 2.28 x 10-7 0.47 0.29 to 0.77 2.7 x 10-3
rsl1259181 10 14,6 FAM107B 6.87 x 10.5 0.60 0.38 to 0.95 2.2 x 10.
2
rs2797902 10 31,3 ZNF468 * 5.05 x 10-5 1.4 X 10.
1
rsl0832757 11 17,3 NUCB2 3.33 x 10-5 0.54 0.40 to 0.72 4.6 x 10-5
rs7107350 11 21,2 NELLl 5.52 x 10-6 2.01 1.34 to 3.00 7.2x 10-4
rs3808996 11 125,0 SLC37A2 6.72 x 10-5 0.60 0.40to 0.89 1.3 x 10-2
rs3825305 12 63,0 PPM1H 6.13x 10-5 0.50 0.31 to 0.79 3.3 x 10-3
rs9596742 13 53,6 1.01 x 10-5 0.43 0.28 to 0.67 1.3 x 10-4
rs2391875 13 111,5 3.03 x 10-5 0.53 0.37 toO.75 2.0 x 10-
4
rs8020076 14 28,5 6.34 x 10.6 1.66 1.28 to 2.14 8.2 x 10-5
rs718998 14 37,4 SLC25A21 9.70 x 10-5 1.45 1.07 to 1.96 2.0 x 10-2
rs1255641 14 64,0 PPP2R5E 6.62 x 10-5 1.75 1.24 to 2.47 1.1 x 10-3
rsl0520058 15 38,6 SPREDl 7.82 x 10-7 0.35 0.20 to 0.64 5.4 x 10-4
rs2937940 15 86,4 7.86 x 10-5 1.88 1.40 to 2.54 1.9 x 10-
5
rs9927531 16 26,5 7.19x 10.5 1.76 1.23 to 2.51 1.6 x 10-
3
rs1183259 16 60,4 5.28 x 10.5 0.51 0.33 to 0.77 1.8 x 10-3
rs4788587 16 72,0 PKD1L3 2.22 x 10.5 0.66 0.48 to 0.91 1.2 x 10-
2
rsl0514440 16 78,7 WWOX 1.48x 10-5 3.38 1.67 to 6.82 5.4 x 10-4
rs1860444 17 48,9 3.57 x 10-6 3.10 1.71 to 5.63 4.3 x 10-4
rs16950191 17 49,7 CA10 4.69 x 10-5 1.38 1.03 to 1.84 3.2x 10-2
rs12610723 19 3,8 MATK 1.13 x 10-5 2.41 1.36 to 4.26 2.8 x 10.3
rs2287700 19 14,6 PKNl 8.46 x 10-5 1.99 1.21 to 3.26 7.9 x 10.
3
rs4805442 19 30,1 6.30 x 10.5 0.48 0.32 to 0.72 4.3x 10-4
rs6030680 20 41,8 PTPRT 2.28 x 10-6 1.61 1.21 to 2.13 1.1 x 10.3
rs4553110 X 6,5 7.85 x 10-5 0.62 0.44 to 0.88 5.2 x 10-3
rs12687904 X 6,8 4.26 x 10-5 0.51 0.28 to 0.90 1.4 x 10-2
rs4830793 X 12,7 FRMPD4 9.56 x 10-5 2.19 1.25 to 3.81 4.0 x 10-3
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rs7887846 X 22,7 5.58 x 10.5 0.62 0.43 to 0.89 1.3x 10.2
rs5972356 X 31,3 DMD 3.89x 10.7 0.56 0.35 to 0.87 7.4 x 10-3
rs5927730 X 31,4 DMD 4.19x 10.5 0.66 0.47to 0.92 1.8x 10.2
rs5906595 X 48,1 6.65 x 10.5 5.8 X 10-2
rs5969041 X 86,2 7.37x10·5 7.2x10·2
rs404481 X 102,5 TCEAL8 8.31 x 10.5 0.66 0.48 to 0.89 7.8 x 10.3
rs2207031 X 128,0 3.30x10-6 2.24 1.45to 3.47 1.9x10-4
a SNPs sorted by chromosomeand position; • gene in LDwith relative SNP (HapMap3Genome Browser release#2); b Position
in megabasesaccording to Ensembl release59; C P valuesobtained by chi-square analysis from GWA; dOR, odds-ratio obtained
by logistic regressionprocedureof PLINKtoolset, based on allelic test for association, i.e., rare allele versus common allele,
adjustedby age at tumour diagnosis in decades, and smokingstatus; Cl, confidence interval;§SNPs showing statistically
significant(P <0.05) associationwith clinical stage in individualQenotyoinQ.
To validate the SNP-array findings in DNA pools, the 80 SNPs were
selected for genotyping in the individual cases by MassARRAY. Of the 80
SNPs, 2 mitochondrial SNPs, 1 SNP on chromosome Y, and 9 redundant
SNPs in tight LD with closely SNPs «58 kb distance) in the same locus in
the HapMap Caucasian (CEU) population were excluded. One SNP failed PCR
or MassEXTEND primer design and 4 additional SNPs failed genotyping,
reducing the number of markers to 63 SNPs (Table 15).
A good correlation of the minor allele frequencies obtained by
MassARRAYgenotyping in single individuals or by SNP-array analysis in DNA
pools was observed (r=0.79, P<2.2 x 10-16), demonstrating the reliability of
the DNA pooling approach (Fig. 26). None of the selected SNPs showed
significant deviation from the HWE, except for rs565968 (P=0.00076). No
statistically significant LD was observed between any SNP pairs (r2<0.1).
Association analysis using a logistic model adjusted for smoking
status indicated that 54 of 63 SNPs were significantly associated with
clinical stage status (Table 15, P<0.05). The strongest association was
observed for SNP rs10278557 (P=5.0 x 10-6), which maps in the
mesenchyme homeobox 2 (MEOX2) gene on chromosome 7.
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Fig. 26 Correlation between SNP frequencies measured by SNP
array analysis of DNA pools and frequencies measured by
genotyping of individual samples. Plotted data represent
frequencies of the rare allele of 63 SNPs putatively associated
with lung cancer risk.
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The 63 SNPs were then tested in two independent series of 317 lung
ADCA and 257 lung SQCC patients (Table 3). The ADCA series of patients
showed similar phenotypic characteristics as compared to the discovery
series, whereas the SQCCseries had an older age at diagnosis and a higher
frequency of males and of ever-smokers as compared to the ADCA series. A
statistically significant association was found between clinical stage and age
at tumour diagnosis in the SQCC series (P=O.005, Kruskal-Wallis test), but
not in the ADCA series; neither gender nor smoking status was associated
with clinical stage in either of the two series. No statistically significant
deviation (P<O.Ol) from the HWE was observed in the two series for any of
the 63 SNPs.
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In the small independent ADCA series, 3 SNPs (rs7694589,
rs3823111, rs169S0191) were confirmed to be statistically associated with
clinical stage (P<O.OS, logistic analysis, Table 16), while in the lung SQCC
series, 3 other SNPs showed significant association with clinical stage
(rsl0491726, rsl0S200S8, and rs480S442; P<O.OS, logistic analysis
adjusted for age at diagnosis, Table 17).
Table 16. SNPs showing statistically significant association with clinical stage in ADCA
independent series.
SNpa Position Gene Rare/Common OR C 95% Cl C P value CChromosome (Mb) b allele
rs7694589 4 30,3 T/C 2.1 1.38 to 3.06 4.1 x 10-4
rs3823111 6 53,5 KLHL31 T/C 2.7 1.13 to 6.38 2.6 x 10-2
rs16950191 17 497 CAlO A/C 1.6 1.06 to 2.29 2.4 x 10-2
a SNPs sorted by chromosome and position; b Position in megabases according to Ensembl
release 59; C Unadjusted logistic regression procedure in PLINK toolset; P values obtained by
allelic test for association' Cl confidence interval.
Table 17. SNPs showing statistically significant association with clinical stage in SQCC
independent series.
Position Rare/SNpa Chromosome (Mb) b Gene Common
ORc 95% Cl C P value C
allele
rs10491726 9 114,3 LTB4DH, T/C 0.5325 0,29-0,98 0.04266
ZNF483
rs10520058 15 38,6 SPRED1 A/C 0.3582 0,14-0,91 0.03014
rs4805442 19 30 1 A/G 0.475 0,27-083 0.009019
a SNPs sorted by chromosome and position; b Position in megabases according to Ensembl
release 59; C Logistic regression procedure in PLINK toolset, adjusted for age at diagnosis; P
values obtained by allelic test for association' Cl confidence interval.
To test for possible heterogeneity between the ADCA series and to
increase the statistical power of association analyses (288), we carried out a
joint analysis of the GWA and ADCA replication series bringing the total
sample size of 917 lung ADCA patients (Table 3). Logistic analysis in the
whole series adjusted for age at diagnosis and smoking status revealed 22
SNPs showing statistically significant association with clinical stage at
statistical threshold of P<O.Ol (Table 18). The strongest association
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remained for the SNP rs10278557 (P=1.1 x 10-5) mapping in the MEOX2
gene.
Table 18. 22 SNPs associated with lung ADCA clinical stage in the joint analysis of the GWA and
replication ADCA series and used to build up the polygenic model with additive effects of SNP rare
alleles on risk of clinical stage> 1.
SNP a Chromosome Position Gene Rare OR 95% CIe P-value e
(Mb) b Allele e
rs951774 2 102,9 ILIRLl *, ILIRL2* A 0.7 0.5 to 6.9 x 10-
0.9 3
rs13390491 2 179,6 TIN T 1.4 1.1 to 6.3 x 10-
1.8 3
rsl0498217 2 228.0 COL4A4 T 0.7 0.5 to 9.4 x 10-
0.9 3
rs1994854 4 77,8 A 0.7 0.5 to 2.8 x 10-
0.9 3
rs4S0S911 5 68,2 A 0.5 0.3 to 4.0 x 10-
0.8 3
rsl0900886 5 105,2 A 0.7 0.5 to 7.7 x 10-
0.9 3
rs3823111 6 53,S KLHL31 T 2.6 1.6 to 2.1 x 10-
4.3 4
rs806435 6 88,8 SPACAl T 1.8 1.3 to 2.5 x 10-
2.4 4
rsl0278557 7 15,7 MEOX2 A 0.6 0.4 to 1.1 x 10-
0.7 5
rs2299297 7 104,7 MLLS T 1.6 1.3 to 7.5 x 10-
2.0 5
rs824249 9 28,8 T 0.6 0.5 to 9.5 x 10-
0.9 3
rsl0987191 9 129 A 0.5 0.4 to 2.5 x 10-
0.8 3
rsl0832757 11 17,3 NUCB2 A 0.6 0.5 to 5.8 x 10-
0.8 5
rs9596742 13 53,6 A 0.6 0.5 to 7.7 x 10-
0.9 3
rs2391875 13 111,5 A 0.6 0.4 to 8.8 x 10-
0.8 5
rs8020076 14 28,S C 1.3 1.1 to 9.8 x 10-
1.6 3
rsl0520058 15 38,6 SPREDl A 0.5 0.3 to 5.8 x 10-
0.8 3
rs9927531 16 26,S A 1.7 1.3 to 2.5 x 10-
2.3 4
rs10514440 16 78,7 WWOX T 2.4 1.4 to 1.1 x 10-
4.1 3
rs16950191 17 49,7 CA10 A 1.5 1.2 to 1.6 x 10-
1.8 3
rs7887846 X 22,7 A 0.7 0.5 to 7.8 x 10-
0.9 3
rs2207031 X 128 A 1.8 1.2 to 1.4 x 10-
2.5 3
a SNPs sorted by chromosome and position; b Position in megabases according to Ensembl release
59; e Logistic regression procedure in PLINK toolset, based on allelic test for association with
clinical stage, adjusted for age at cancer diagnosis and smoking status. SNPs selected based on P
<0.01 threshold for association.
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3.3.2 Differences in lung ADCA outcome are associated with
patients' genetic profile
Using our polygenic model (289), we evaluate additive effects of
these 22 SNP in modulating individual clinical stage. 81 of 917 patients with
more than 30% missing genotypes were removed from the dataset. For
each patient, the allele-based odds ratio (Table 18) was attributed to the
carrier status of an allele of each SNP associated with clinical stage status,
based on its association with the probability of carrying a stage >1 lung
ADCA. To test the model, a score of +1 was attributed to the carrier status
of a risk allele of each SNP based on its association with increased
probability of developing lung cancer with higher clinical stage. For each
o
o
o
Fig. 27 Genetic risk score in patients with clinical stage I and in
patients with higher clinical stage. The horizontal line within the
box represents the median value of the genetic estimator of
outcome (in base 2 logarithmic units); the upper and lower
boundaries of each box represent 75th and 25th percentile,
respectively; upper and lower bars indicate the relative highest
and lowest values, respectively (P<2.2 x 10-16).
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patient, a genetic risk score was calculated as the sum of the scores for all
22 SNPs to obtain a general estimator of individual outcome. The average
genetic estimator was -7.9 x 10-3 ± 5.4 x 10-4 (mean ± standard error) for
patients with clinical stage I (n=418) and 3.2 x 10-3 ± 5.3 x 10-4 for
patients with higher clinical stage (n=403) (P<2.2 x 10-16, ANOVA analysis,
Fig. 27). The 22 SNPsexplained 20.7% of the phenotypic variance in clinical
staging. Although with a lower size effect as compared to the first series
and to the whole series, the genetic estimator was statistically associated to
clinical stage in the second ADCA series alone (P = 0.0006, ANOVA
analysis), suggesting the predictive value of the 22-SNPs genetic profile on
clinical staging of lung cancer patients.
-
To verify the robustness of the model in our series, since we did not
10
have sufficient available lung ADCA samples for a larger second replication
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Genetic risk score
Fig. 28 Genetic risk of developing a more aggressive lung ADCA
(clinical stage >1) in patients grouped according to the quartiles
of genetic risk score, with the lowest quartile as the reference
group. Bars denote ORs. Vertical lines represent 95% CIs.
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step, we carried out an empirical replication using bootstrap samples
(8=2000 resamplings), as proposed in a recent paper (290). We found that
the difference in the genetic estimator between stage 1 and stage >1
patients was = -11.1 x 10-3,95% confidence interval (Cl) = -12.7 x 10-3 to
-9.7 X 10-3, Pdiff = 0.0005.
Subjects were divided in 4 groups based on the quartiles of the
genetic risk score. Application of the generalized linear model to the quartile
groups, with the lowest quartile as the reference, revealed a significant
association between the genetic estimator and increased probability to
develop a more aggressive lung ADCA cancer (OR= 2.9, 95% Cl 1.9 - 4.6,
P=2.7 x 10-6 for the second quartile, OR= 6.8, 95% Cl 4.4 - 10.7, P<2 x
1.0
co 0.9
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Fig. 29 Kaplan-Meier survival curves in lung ADCApatients grouped
as in Fig 3.9. Follow-up is shown truncated at 60 months (P = 8.0 X
10-8, logrank test).
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10-16 for the third quartile; and OR= 14.5, 95% Cl 9.1 - 23.6, P <2 x 10-16
for the forth quartile group, Fig. 28).
Finally, Kaplan-Meier curves showed statistically significant
association of the genetic risk score, in quartiles, and overall survival (P =
8.0x10-8, log-rank test; Fig. 29).
Use of multivariate Cox proportional hazard models for survival
(adjusted for age and smoking habit) to evaluate the association between
the genetic risk score and overall survival showed that the risk of death for
the quartiles 3 to 4 (HR= 1.5, 95% Cl 1.1 - 2.0, P = 0.016; HR= 2.3, 95%
Cl 1.7 - 3.0, P = 8.7 X 10-8, respectively) was statistically significant higher
from that of the lowest quartile.
3.4 RESULTS OF GENOME-WIDE MICROARRAY ANALYSIS IN
PATIENT-BASED ASSOCIATION STUDY
3.4.1 A gene expression profile of normal lung is associated with
clinicalstage
Preliminarily, we found no statistically significant associations
between gender or age with clinical stage, indicating that either variables do
not modulate clinical staging in our series.
To identify stage-associated genes, we performed a microarray
analysis of 120 normal lung tissues from lung ADCA patients, differentially
grouped in two microarrays experiments. In normal lung, statistically
significant differences in expression levels between clinical stage I and >1,
patients were detected for 55 (Fig. 30 A) in experiment A and for 361 (the
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Fig. 30 Heat map of 55 transcripts (at threshold nominal level of P<l x
10-3) and of top 68 out of 361 transcripts (at threshold nominal level of
P< 1 x 10-5) whose expression levels showed statistically significant
differences in normal lung of stage 1as compared to stage >1patients in
the first experiment (A) and in the second experiment (8). Gene names
are given on the right. Expression levels of the listed genes are indicated
by the color bar (green, low; red, high).
top 68 genes with P < 1 X 10-5 are listed in Fig. 30 B) transcripts in
experiment B (P<O.OOl, see also Supplementary Table 2 and 3 at the end
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of this chapter).
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To validate the results obtained with microarray experiments, we
o
performed qRT-PCR on the 120 individual RNAs samples. We selected a
o
<)
o
r= 0.89, P=2.7x 10-8
0.5
Fold changes obtained with Microanay
Fig. 31 Correlation between microarray gene expression
data obtained on RNA pools and qRT-PCRon individual
RNAsamples for 22 genes.
total of 22 genes, 13 of which were shared by both gene lists (GCOM1,
MSX1, TMEM100, SMAD6, IDH1, VIPR1, SlC14A1, BCl3, PlEKH02,
SFTPA2B, SBN02, RRP12, DACT1), and 2 (TXNIP, lZTS1) and 7 (ITlN1,
C20orfl14, SElE, FCN3, COLlA1, DEFA3, INHBB) genes that showed the
most significant statistical associations in experiment A and B, respectively
(Table 8). The correlation between microarray assay and qRT-PCR in
detected levels was excellent (r=0.89, P=2.7x10·8, Fig. 31), indicating that
microarray analysis detected real variations and that expression data were
reproducible.
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Among the 22 assayed genes, 11 genes showed a statistically
significant difference in expression between stage I and stage > I patients
(P<O.OS, Kruskal-Wallis test, Fig. 32, Table 19).
Table 19. Gene expression results of 22 assayed genes in patients with stage I and higher
clinical stage using qRT-PCR.
Gene symbol RQmean ± SE P-value Fold change aClinical stage I Clinical stage > I
BCl3 0.70 ± 0.06 0.91 ± 0.07 0.052 0.77
C20orfl14 1.68 ± 0.43 0.95 ± 0.23 0.014 * 1.77
COLlA1 0.50 ± 0.07 0.75 ± 0.19 0.698 0.67
DACT1 0.83 ± 0.07 0.94 ± 0.07 0.096 0.88
DEFA3 0.51 ± 0.11 1.25 ± 0.51 0.964 0.41
FCN3 1.49 ± 0.18 0.81 ± 0.11 0.005 * 1.84
GCOM1 1.19 ± 0.14 0.85 ± 0.07 0.116 1.40
IDH1 1.13 ± 0.09 0.88 ± 0.04 0.042 * l.28
INHBB 0.6 ±O 0.08 0.85 ± 0.14 0.198 0.71
ITlN1 0.65 ± 0.21 2.39 ± 1.12 0.610 0.27
lZTS1 0.66 ± 0.09 0.74 ± 0.06 0.045 * 0.89
MSX1 0.63 ± 0.07 0.75 ± 0.06 0.038 * 0.84
PlEKH02 0.93 ± 0.07 1.00 ± 0.04 0.209 0.93
RRP12 0.80 ± 0.04 1.00 ± 0.06 0.051 0.80
SBN02 1.02 ± 0.07 1.03 ± 0.05 0.470 0.99
SElE 0.82 ± 0.11 1.29 ± 0.2 0.040 * 0.64
SFTPA2B 1.45 ± 0.26 1.09 ± 0.15 0.280 1.33
SlC14A1 1.46 ± 0.13 1.03 ± 0.12 0.016 * 1.42
SMAD6 1.34 ± 0.16 0.89 ± 0.11 0.044 * 1.51
TMEM100 1.57 ± 0.23 0.86 ± 0.11 0.005 * 1.83
TXNIP l.18 ± 0.11 0.84 ± 0.06 0.013 * 1.40
VIPR1 1.20 ± 0.17 0.71 ± 0.09 0.040 * 1.69
RQ, relative quantification ." Genes showing statistically significant variation (P<0.05) of
expression between patients with stage I and higher clinical stage patients using Kruskal-
Wallis test. a Clinical stage I vs. clinical stage >1.
Among the statistically significant associated genes, FeN3 (ficolin 3)
and TMEM100 (transmembrane protein 100) showed the stronger
differences between stage I and stage>I patients (fold change> 1.8, Table
19) and the best statistical associations with clinical stage (P=O.OOS, Table
19, Fig. 32).
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Fig. 32 mRNA expression levels (mean ± S.E.) of genes in normal lung tissue of
lung ADCA patients assessed by qRT-PCR by clinical stage. Asterisks indicate
statistically significant differences (P < 0.05) as compared to the reference
group (open bars).
3.4.2 Differential expression profiles of cytokine and cytokine-
related genes according to clinical stage
The gene lists obtained from the two experiments in relationship to
lung cancer stage were uploaded into the IPA tool for gene network search
and into the DAVID Functional Annotation Tool for pathway analysis. The
first list of 55 genes revealed no statistically significant results, whereas the
first network identified by IPA tool uploading the second list of 361 genes
was "Antigen Presentation, Cell-mediated Immune Response, Humoral
Immune Response" (Fig. 33). In addition, in overall analysis of biochemical
pathways (KEGG database in DAVID tool) the best statistically associated
pathway identified in the list of 361 genes was "Cytokine-cytokine receptor
interaction" (hsa04060, P=0.00057; Table 20).
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Table 20. KEGGpathway analysis by DAVID of the 361 statistically differentially expressed
genes between stage I and higher clinical stage patients
KEGGpathway Gene p* Genescount
hsa04060: Cytokine-
5.7 x 10-4
CXCl2,CCl2,CXCl14, TNFRSF12A, CCl3,
cytokine receptor 15 CSF3R, TNFSFIO, INHBB, TGFB3, CSF3,
interaction Il7R, IURl, Il8, CCl21, CX3CRl
hsa04514:Cell adhesion
8 0.015
ICAMl, HLA-DRB5, ClDNl, SElE, HLA-
molecules (CAMs) A29.1, HLA-E, HLA-DMA, VCAMl,
hsa04940:Type I diabetes 4 0.044 HLA-DRB5, HLA-A29.1, HLA-E, HLA-DMA,mellitus
hsa0451O:Focal adhesion 9 0.049
LAMBl, COl3Al, THBS2, PDGFD, COUA2,
COl6A2, BCARl, COLIAl, COL6A3,
* Calculated by the DAVID functional annotation tool, using a modifier Fisher exact test.
Based on this information, we used qRT-PCRon customized TaqMan@
Low Density Arrays (assays listed in Table 9) to analyze the 120 individual
RNAs samples for expression of 22 cytokine-related genes highlighted by
the KEGGbiochemical pathway analysis (Table 20) and by IPA tool analysis.
Analysis of qRT-PCR in normal lung tissue found that the expressions of 6
genes were statistically different between stage I and stage >1 patients
(P<O.OS, Kruskal-Wallis test, Table 21 and Fig. 34), with TNFSF10/TRAIL
(tumour necrosis factor ligand superfamily, member 10) showing the best
statistical association (P=0.007, Table 21, Fig. 34) and IL6 (interleukin 6)
showing the higher modulation (tv1.S-fold up-regulation in stage >1
patients, Table 21).
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Fig. 33 IPA network diagram showing the biological associations of 35 genes
associated with "Antigen Presentation, Cell-mediated Immune Response,
Humoral Immune Response". Genes that showed up-regulation or down-
regulation in our samples are in red or in green, respect~ely. The significance
of the nodes are displayed using various shapes that represent the functional
classes of the gene products as shown in the key.
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Fig. 34 mRNAexpression levels (mean ± S.E.) of cytokine-related genes in normal
lung tissue of lung ADCApatients assessed by qRT-PCRby clinical stage. Data are
given as in Fig. 34.
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Table 21. Gene expression results of 22 cytokine-related genes in patients with stage
I and higher clinical stage using qRT-PCR.
Gene RQmean ± SE P-value
Fold-
symbol Clinical stage I Clinical stage >1
change a
CCL2 0.89 ± 0.11 1.23±0.14 0.020 * 0.72
CCL21 0.93 ± 0.08 1.09 ± 0.08 0.079 0.85
CCL3 1.53 ± 0.17 1.50 ± 0.14 0.834 1.02
CCL4U 2.15 ± 0.28 2.12 ± 0.27 0.629 1.01
CSF3 0.51 ± 0.11 0.64 ± 0.13 0.515 0.80
CSF3R 1.12 ± 0.07 0.92 ± 0.06 0.024 * 1.22
CX3CR1 1.39 ± 0.12 1.04 ± 0.10 0.049 * 1.34
CXCU 0.73 ± 0.11 0.78±0.14 0.946 0.94
CXCLl3 2.09 ± 0.48 1.50 ± 0.34 0.326 1.39
CXCLl4 0.90 ± 0.13 1.24 ± 0.16 0.147 0.73
CXCL2 0.73 ± 0.08 0.83 ± 0.10 0.400 0.88
CXCR7 0.91 ± 0.06 1.00 ± 0.06 0.123 0.91
1CAM1 0.62 ± 0.08 0.79 ± 0.09 0.229 0.78
1CAM4 1.21 ± 0.09 1.24 ± 0.10 0.832 0.98
1UR1 0.85 ± 0.04 0.85 ± 0.05 0.828 1.00
1LlRLl 1.09 ± 0.13 0.84 ± 0.07 0.737 1.30
1L6 0.70 ± 0.10 1.04 ± 0.13 0.032 * 0.67
1L7R 1.S4±0.13 1.11 ± 0.08 0.029 * 1.39
1L8 0.48 ± 0.11 0.68 ± 0.12 0.152 0.71
TGFB3 0.79 ± 0.05 0.92 ± 0.06 0.065 0.86
TNFRSF12A 0.75 ± 0.07 0.90 ± 0.08 0.128 0.83
TNFSF10 1.41 ± 0.10 1.04 ± 0.08 0.007 * 1.36
RQ, relative quantification. * Genes showing statistically significant variation (P<0.05)
of expression between patients with stage I and higher clinical stage patients in using
Kruskal-Wallis test. a Clinical stage I vs. clinical stage >1.
FCN3 TMEM100
.n ~"
.;
e ca 0
to
'~
V V *;;:: s~ ;; * e'"'" '"" ::l0 0
4> l'
.11>
:> :>
~ /' '':::;.... '" ....Cii c:i ,0,\1: Cii cl0:: 0::
Q ~ '"
'" cl, I N T > I N T
Stage Tissue
Stage Tissue
Fig. 35 mRNA expression levels (mean ± S.E.) of FeN3 and TMEM100
assessed by qRT-peR in lung tissue of ADeA patients by stage and type of
tissue (N, normal; T, tumor). Asterisks indicate statistically significant
differences (P < 0.01) as compared to the reference group (open bars).
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3.4.3 Differential expression between normal and tumour tissue
To determine whether the mRNA levels of the 11 modulated genes
between stage I and stage> I (and validated by qRT-PCR) are modulated in
tumour tissue, we compared gene expression levels in 27 matched pairs of
lung ADCA and adjacent normal lung tissue by qRT-PCR. Most of the
assayed genes, i.e., 9 out of 11, showed statistically significant deregulation
in ADCA tissue as compared to normal tissue (P<O.05, Kruskal-Wallis test,
Table 22). All deregulated genes, except for IDH1, showed down-regulation
in ADCA tissue as compared to normal lung tissue (Table 22). FCN3, SELE
and TMEM100 showed ~40-fold lower mRNA levels in lung ADCA than in
normal lung tissue (P<O.OOOl, Table 22, Fig. 35).
Table 22. Gene expression results of 22 assayed genes in lung ADCA tissue and
adjacent normal lung tissue using QRT-PCR.
RQmean ± SE Fold-
Gene symbol
Tumour tissue
P change aNormal tissue
C20orfl14 1.74 ± 0.69 1.27 ± 0.43 0.849 1.37
FeN3 1.59 ± 0.25 0.02 ± 0.01 2.8 x 10-10 • 79.5
IDHl 1.29 ± 0.14 1.73 ± 0.25 0.416 0.75
LZTSl 0.97 ± 0.19 0.35 ± 0.04 9.8 x 10-06 • 2.77
MSXl 0.78 ± 0.17 0.12 ± 0.02 4.0 x 10-09 · 6.50
SELE 1.33 ± 0.37 0.02 ± 0.00 8.1 x 10-09 · 66.5
SLC14Al 1.37±0.17 0.12 ± 0.02 1.3 x 10-09 · 11.4
SMAD6 1.70 ± 0.27 0.15 ± 0.02 1.3 x 10-09 · 11.3
TMEM100 1.60 ± 0.23 0.04 ± 0.02 5.2 x 10-10 • 40.0
TXNIP 1.16 ± 0.16 0.27 ± 0.05 2.6 x 10-08 • 4.30
VIPRl 1.54 ± 0.24 0.05 ± 0.01 2.8 x 10-10 · 30.8
RQ, relative quantification. • Genes showing statistically significant variation
(P<0.05) of expression between lung ADCA and adjacent normal lung tissue using
Kruskal-Wallis test. a Normal tissue vs. tumour tissue.
To select promising candidate genes for further analysis, we decided
to perform validation at the protein level for the 9 genes modulated
between normal tissue and ADCA tissue using immunohistochemistry. Only
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commercial antibodies tested for IHC were selected. Immunohistochemical
staining was performed for FCN3, SLC14Al and SMAD6 on paraffin-
embedded tissue sections of lung ADCA and surrounding normal lung tissue
to determine whether mRNA over-expression was reflected by an increase
of their corresponding proteins in normal and tumour tissue. We confirmed
5..C14A1
. FOJ3
Fig. 36 Immunohistochemical staining of FCN3,SLC14Al and SMAD6
proteins. No or few proteins were detected in tumour tissues (right
panels), whereas a clear staining patterns were observed in normal
tissues for each proteins (left panel).
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differential expression of proteins FCN3, SLC14A1 and SMAD6 between
normal and tumour tissue (Fig. 36).
3.4.4Integration of GWAS and gene expression profiling
By integrating data from GWA with gene expression signatures from
case-only study, we found 6 SNPs, among those with P S 1 X 10-7 in GWA,
that map within genes slightly differentially expressed P<O.OOl, Table 23)
in the second microarray experiment.
Table 23. Integration of GWA data with microarray results.
Ratio
SNpa P-value Chromosome
Position
Gene*
P-value stage=I
GWA (Mb) Microarray vs.
stage>!
rs4340697 1 x 10-7 3 64.60 ADAMTS9 1.45 x 10-4 0.81
rs11140860 < 1 x 10-7 9 72.52 C9orf135 1.72 x 10-5 1.30
rs16927500 < 1 x 10-7 11 35.49 PAMR1 5.30 x 10-4 0.83
rs7305739 < 1 x 10-7 12 13.36 EMPl 3.68 x 10-4 0.80
rs2839531 < 1 X 10-7 21 43.89 RSPHl 1.80 x 10-6 1.36
rs1799969 < 1 x 10-7 19 10.39 ICAM1, 2.99 x 10-4 0.79,0.81
ICAM4*
a SNPs sorted by chromosome and position; b Position in megabases according to
Ensembl release 59; * gene in LD with relative SNP (HapMap3 Genome Browser
release #2)
Focusing on regions where we identified the 54 most associated SNPs
with clinical stage (Table 15), we found detectable expression of 18 of 30
known genes (Table 24) in normal lung tissue of lung ADCA patients, but we
found no statistically significant differences in mRNA expression levels
between the clinical stage I and stage >I patients at any of the 18 genes
(Table 24), suggesting that the SNP candidacy may rest on non-
synonymous variations that are in linkage disequilibrium with the identified
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SNPs, or on splicing alternative variants rather than alteration of transcript
regulation.
Then, we undertook a more direct approach to link GWAS and
microarray and to assess whether GWAS and microarray analyses have
identified similar sets of genes performing DAVID functional annotations
pathway analyses using the SSS unique genes out of 8S4 genes identified
with GWAS among the top 1,334 SNPs (with P :S 1 x 10-7), and the top 361
genes identified in gene expression data.
Table 24. Integration of microarray results with GWA data.
Gene*
Fold change
SNP P-value GWA
microarray
IL1RL1*,IL1RL2* 1.26 rs951774 4.00 x 10-7
VGLL4 0.97 rs2s74711 < 1 x 10-7
MLL5 1.00 rs2299297 < 1 x 10-7
TSPAN33 1.04 rs2648 < 1 x 10-7
SLC1A1 0.88 rs972s19 < 1 x 10-7
LTB4DH, ZNF483 1.07, 1.02 rs10491726 6.00 x 10-7
FAM107B 1.03 rs112s9181 < 1 x 10-7
NUCB2 0.84 rs108327s7 < 1 x 10-7
NELL1 0.99 rs71073s0 < 1 x 10-7
PPM1H 0.95 rs382s30s < 1 x 10-7
PPP2RsE 1.03 rs1255641 < 1 x 10-7
SPRED1 1.04 rs10s200s8 < 1 x 10-7
WWOX 1.08 rs10514440 < 1 x 10-7
MATK 1.05 rs12610723 < 1 x 10-7
PKN1 1.03 rs2287700 < 1 x 10-7
PTPRT 0.96 rs6030680 1 x 10-7
DMD 1.11 rs5972356, rs5927730 < 1 x 10-7, 7 X 10-7
TCEAL8 1.01 rs404481 1 x 10-7
*gene in LD with relative SNP (HapMap3 Genome Browser release #2)
Results of functional annotation clustering sorted by statistically
significance (P < O.OS) can be found in Fig. 37. Interestingly, in both list,
most of the top functional clusters derived from GWAS and microarray data
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are directly or indirectly related to cell adhesion: cell adhesion molecules
and focal adhesion in GWAS results and cell adhesion molecules,
extracellular matrix-receptor interaction, and focal adhesion in gene
expression data.
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Fig. 37 Clustering of functional annotation pathways based on GWAS- (upper panel)
and microarray-dericed genes (lower panel) (with P<O.OS).
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Supplementary Table 2. List of genes differentially expressed between clinical stage I and >1patients in the first
experiment.
Gene symbol
stage=l/ Gene Start Gene End
P-value b stage>1 Gene name Chromosome
ratio
(Mb) C (Mb) c
NBL1 3.32 x 10-4 0.76 Neuroblastoma, suppression of 19.97 19.98
tumorigenicity 1
STK40 6.31 x 10-4 0.83 Serine/threonine kinase 40 36.81 36.85
CITED4 2.27 x 10-4 0.69 Cbp/p300-interacting 41.33 41.33
transactivator, with Glu/Asp-rich
carboxy-terminal domain, 4
SCP2 7.00 x 10.4 1.32 Sterol carrier protein 2 53.39 53.52
TXNIP 2.33 x 10-5 1.37 Thioredoxin interacting protein 145.44 145.44
GPR89A 8.86 x 10-4 1.22 G protein-coupled receptor 89A 145.76 145.83
DEDD 5.02 x 10-4 0.86 Death effector domain containing 1 161.09 161.10
IDH1 1.59 x 10-4 1.33 Isocitrate dehydrogenase 1 2 209.10 209.13
(NADP+), soluble
ITGA9 5.91 x 10-4 0.80 Integrin, alpha 9 3 37.49 37.87
VIPR1 1.79 x 10-4 1.45 Vasoactive intestinal peptide 3 42.S3 42.58
receptor 1
MSX1 8.35 x 10-5 0.71 Msh homeobox 1 4 4.86 4.87
HADH 2.40 x 10-4 1.19 Hydroxyacyl-Coenzyme A 4 108.91 108.96
dehydrogenase
PCDHBS 5.07 x 10-4 0.85 Protocadherin beta 5 5 140.51 140.52
FGF18 7.86 x 10-4 0.83 Fibroblast growth factor 18 5 170.85 170.88
MT01 7.62 x 10-4 1.17 Mitochondrial translation 6 74.17 74.22
optimization 1 homolog (S.
cerevisiae)
IFNGR1 7.86 x 10-4 1.20 Interferon gamma receptor 1 6 137.52 137.54
AEBP1 2.86 x 10-4 0.70 AE binding protein 1 7 44.14 44.15
CLlP2 4.97 x 10-4 0.81 CAP-GLY domain containing 7 73.70 73.82
linker protein 2
ATP6VOE2 3.40 x 10-4 1.20 ATPase, H+ transporting VO 7 149.57 149.58
subunite2
LZTS1 3.38 x 10-5 0.76 Leucine zipper, putative tumor 8 20.10 20.16
suppressor 1
C8orf58 1.53 x 10-4 0.82 Chromosome 8 open reading 8 22.46 22.46
frame 58
CHMP5 9.70x 10-4 1.20 Chromatin modifying protein 5 9 33.26 33.28
GNA14 7.01 x 10-4 1.18 Guanine nucleotide binding 9 80.04 80.26
protein (G protein)
GALNT12 8.77 x 10-4 1.21 UDP-N-acetyl-alpha-D- 9 101.57 101.61
galactosamine:polypeptide N-
acetylgalactosaminyltransferase
12 (GaINAc-T12)
IER5L 3.09x 104 0.73 Immediate early response 5-like 9 131.94 131.94
C10orf73 5.35 x 10-4 1.27 PREDICTED: chromosome 10 10 50.34 50.34
open reading frame 73
C10orf57 4.96 x 10-4 1.19 Chromosome 10 open reading 10 82.17 82.19
frame 57
RRP12 5.31 x 10-4 0.78 Ribosomal RNA processing 12 10 99.12 99.16
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homolog (S. cerevisiae)
PRDX3 2.27 x 10-4 1.25 Peroxiredoxin 3 10 120.93 120.94
SFTPA2B 4.80 x 10-4 1.39 Surfactant, pulmonary- 10 81.32 81.32
associated protein A2B
CCDC86 2.22 x 10.4 0.76 Coiled-coil domain containing 86 11 60.61 60.62
APLP2 6.74 x 10-4 1.21 Amyloid beta (A4) precursor-like 11 129.94 130.01
protein 2
LOC728715 9.81 x 10-4 0.79 PREDICTED: similar to 12 31.26 31.36
hCG38149
FLJ40142 6.54 x 10-4 1.21 FLJ40142 protein 12 110.48 110.51
RNF10 5.94 x 10-4 0.81 Ring finger protein 10 12 120.97 121.02
VPS37B 2.61 x 10-4 0.76 Vacuolar protein sorting 37 12 123.35 123.38
homolog S (S. cerevisiae)
DACT1 5.32 x 10-4 0.81 Dapper, antagonist of beta- 14 59.10 59.12
catenin, homolog 1 (Xenopus
laevis)
GCOM1 6.27 x 10-5 1.40 GRINL 1A combined protein 15 57.88 58.Q7
PLEKH02 3.80 x 10-4 0.80 Pleckstrin homology domain 15 65.13 65.21
containing, family 0 member 2
SMAD6 1.34 x 10-4 1.59 SMAD family member 6 15 66.99 67.07
SOLH 3.05 x 10-4 0.83 Small optic lobes homolog 16 0.58 0.60
(Drosophila)
RAS34 5.24 x 10-4 0.86 RAB34, member RAS oncogene 17 27.04 27.05
family
TMEM100 1.08x10-4 1.55 Transmembrane protein 100 17 53.79 53.80
CYGS 9.47 x 10-4 0.78 Cyloglobin 17 74.52 74.53
SLC14A1 2.04 x 10-4 1.43 Solute carrier family 14 (urea 18 43.30 43.33
transporter), member 1 (Kidd
blood group)
SBN02 4.99 x 10-4 0.70 Strawberry notch homolog 2 19 1.11 1.17
(Drosophila)
MIDN 4.30 x 10-4 0.71 Midnolin 19 1.25 1.26
TRIP10 6.12x10-5 0.72 Thyroid hormone receptor 19 6.74 6.75
interactor 10
PLVAP 5.73x10-4 0.71 Plasmalemma vesicle 19 17.46 17.49
associated protein
BCL3 2.98 x 10-4 0.64 B-cell CLUlymphoma 3 19 45.25 45.26
ITCH 6.80 x 10-4 0.84 Itchy homolog E3 ubiquitin 20 32.95 33.10
protein ligase (mouse)
ZMYND8 7.12 x 10-4 1.16 Zinc finger, MYND-type 20 45.84 45.99
containing 8
ARMCX3 3.76x10-4 1.22 Armadillo repeat containing, X- X 100.88 100.88
linked 3
PSMD10 8.65 x 10-4 1.16 Proteasome (prosome, X 107.33 107.33
macropain) 26S subunit, non-
ATPase,10
SLC25A43 6.42 x 10-4 1.18 Solute carrier family 25, member X 118.53 118.59
43
a Gene sorted by chromosome and position; bp-value obtained by Class Comparison Analysis using BRB ArrayTools
version 3.8.1; c Position in megabases according to Ensemble Release 60.
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Supplementary Table 3. List of genes differentially expressed between clinical stage I and >1patients in the second
experiment.
Gene symbol P-value b stage=l/ Gene name Chromosome Gene Start Gene End
stage> I (Mb) C (Mb) C
ratio
MTE < 1 x 10.7 0.66 Metallothionein E 14.03 14.15
FCN3 < 1 x 10-7 1.53 Ficolin (collagenlfibrinogen 27.7 27.7
domain containing) 3 (Hakata
antigen)
CITED4 1.4X10-6 0.72 Cbp/p300-interacting 41.33 41.33
transactivator, with Glu/Asp-
rich carboxy-terminal domain,
4
GADD45A 9.00 X 10-6 0.79 Growth arrest and DNA- 68.15 68.15
damage-inducible, alpha
ITLN1 < 1 x 10-7 0.35 Intelectin 1 (galactofuranose 160.85 160.85
binding)
SELE < 1 x 10-7 0.58 Selectin E (endothelial 169.69 169.7
adhesion molecule 1)
TPR 3.9 X 10-6 0.77 Translocated promoter region 186.28 186.34
(to activated MET oncogene)
SLC30A1 5 X 10-7 0.7 Solute carrier family 30 (zinc 211.74 211.75
transporter), member 1
LOC652694 6.1 X 10-6 0.71 PREDICTED: similar to Ig 2 0.004 0.005
kappa chain V-I region HK102
precursor
FHL2 3.8 X 10-6 0.72 Four and a half LIM domains 2 2 105.97 106.05
INHBB 3.1 X 10-6 0.73 inhibin, beta B (activin AB beta 2 121.1 121.11
polypeptide) (INHBB).
COL3A1 3 X 10-7 0.72 Collagen, type III, alpha 1 2 189.84 189.88
(Ehlers-Dan los syndrome type
IV, autosomal dominant)
VIPR1 1 X 10-7 1.45 Vasoactive intestinal peptide 3 42.53 42.58
receptor 1
DNHD2 B.9 X 1Q-6 1.34 PREDICTED: dynein heavy 3 55,31 59,53
chain domain 2
CLDN1 4 X 10-6 0.73 Claudin 1 3 190.02 190.04
CXCL2 3.5 X 10-6 0.77 Chemokine (C-X-C motin 4 74.96 74.97
ligand 2
CXCL14 7.2 X 10-6 0.77 Chemokine (C-X-C rnonf) 5 134.91 134.91
ligand 14
LOC649143 1.1 X 10-6 1.46 PREDICTED: similar to HLA 6
class II histocompatibility
antigen, DRB1-9 beta chain
precursor (MHC class I antigen
DRB1*9) (DR-9) (DR9)
SERPINB1 7.6 X 10-6 0.78 Serpin peptidase inhibitor, 6 2.83 2.84
clade B (ovalbumin), member
1
C60rf105 6.9 X 10-6 1.3 Chromosome 6 open reading 6 11.71 11.81
frame 105
HLA-A29.1 5 X 10-7 1.4 Major histocompatibility 6 29.9 29.9
complex class I HLA-A29.1
GSTA2 1 X 10-7 1.41 Glutathione S-transferase A2 6 52.61 52.63
GSTA1 6.4 X 10-6 1.36 Glutathione S-transferase A 1 6 52.66 52.67
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RN7SK < 1 x 10-7 0_6 RNA, 7SK small nuclear 6 52_86 52_86
(RN7SK) on chromosome 6
LOC647169 5 X 10-7 1.4 PREDICTED: similar to Chain 6 52_63 52_64
A, Glutathione Transferase A1-
1 Complexed With An
Ethacrynic Acid Glutathione
Conjugate (Mutant R15k)
IL6 6 X 10-7 0_72 Interleukin 6 (interferon, beta 7 22_77 22_77
2)
IGFBP3 3.9 X 10-6 0.77 Insulin-like growth factor 7 45.95 45.96
binding protein 3
COL1A2 6.4 X 10-6 0.77 Collagen, type I, alpha 2 7 94.02 94.06
NPTX2 5 X 10-7 0.71 Neuronal pentraxin " 7 98.25 98.26
DEFA1 2 X 10-7 0.7 Defensin, alpha 1 8 6.84 6.84
LOC728358 < 1 x 10-7 0.67 Defensin, alpha 1 (DEFA1B) 8 6.85 6.86
DEFA3 < 1 x 10-7 0.61 Defensin, alpha 3, neutrophil- 8 6.87 6.88
specific
EFCA81 6 X 10-7 1.39 EF-hand calcium binding 8 49.62 49.65
domain 1
TMEM70 5.2 X 10-6 0.76 Transmembrane protein 70 8 74.88 74.9
CTHRC1 1 X 10-7 0.71 Collagen triple helix repeat 8 104.38 104.4
containing 1
ENPP2 2 X 10-7 0.69 Ectonucleotide 8 120.57 120.69
pyrophosphatase/phosphodies
terase 2 (autotaxin)
MYC 1.4 X 10-6 0.72 V-myc myelocytomatosis viral 8 128.75 128.75
oncogene homolog (avian)
LY6H 8 X 10-7 0.7 Lymphocyte anijgen 6 8 144.24 144.24
complex, locus H
LCN2 4.8 X 10-6 1.31 Lipocalin 2 9 130.91 130.92
SFTPA28 5.8 X 10-6 1.38 Surfactant, pulmonary- 10 81,31 81,32
associated protein A2B
FJX1 3.1X10-6 0.75 Four jointed box 1 (Drosophila) 11 35_64 35.64
MS4A8B 5.9 X 10-6 1.43 Membrane-spanning 4- 11 60.47 60.48
domains, subfamily A, member
88
PDGFD 6.4 X 10-6 0.78 Platelet derived growth factor 11 103.78 104.04
D
SOCS2 4.1X10-6 0.77 Suppressor of cytokine 12 93.96 93.97
signaling 2
NP 3.4 X 10-6 0.73 Nucleoside phosphorylase 14 20.94 20.95
NLF2 2.3 X 10-6 0.75 PREDICTED: nuclear localized 15 62.46 62.46
factor 2
SMAD6 < 1 x 10-7 1.43 SMAD family member 6 15 66.99 67.07
TNFRSF12A 6 X 10-7 0.68 Tumor necrosis factor receptor 16 3.07 3.07
superfamily, member 12A
MT1E 6.5 X 10-6 0.78 Metallothionein 1E 16 56.66 56.66
MT1M 1 X 10-6 0.74 Metallothionein 1M 16 56.67 56.67
MT1G 4 X 10-7 0.74 Metallothionein 1G 16 56.7 56.7
MT1H 3.2 X 10-6 0.72 Metallothionein 1H 16 56.7 56.71
MT1X 1.7 X 10-6 0.73 Metallothionein 1X 16 56.71 56.72
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C200rf114 <1x10-7 1.82 Chromosome200penreading 20 31.86 31.9
frame 114
C200rf127 3.8 X 10-6 0.75 Chromosome 20 open reading 20 33.81 33.81
frame 127
RSPH1 1.8 X 10-6 1.36 Radial spoke head 1 homolog 21 43.89 43.92
(Chlamydomonas)
IGLL3 2.2 X 10-6 0.68 Immunoglobulin lambda-like 22 23.92 23.98
polypeptide 3
XIST 8 X 10-7 1.59 X (inactive)-specific transcript X 73.04 73.07
(non-protein coding)
CT45-4 9 X 10-7 0.7 Cancer/testis antigen CT45-4 X 134.93 134.95
LOC647460 5.2 X 10-6 0.74 PREDICTED: similar to Ig
kappa chain V-I region HK101
precursor
a Gene sorted by chromosome and position; bp-value obtained by Class Comparison Analysis using BRB ArrayTools
version 3.8.1; c Position in megabases according to Ensemble Release 60.
0.67LOC400578 < 1 x 10-7 PREDICTED: similar to
Keratin, type I cytoskeletal14
(Cytokeratin-14) (CK-14)
(Keratin-14) (K14)
PREDICTED: similar to
Keratin, type I cytoskeletal16
(Cytokeratin-16) (CK-16)
(Keratin-16) (K16)
Solute carrier family 6
(neurotransmitter transporter,
serotonin), member 4
Collagen, type I, alpha 1
Transmembrane protein 100
Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent1
Growth arrest and DNA-
damage-inducible, beta
Prion protein 2 (dublet)
MGC102966 6 X 10-7 0.72
SLC6A4 3 X 10-7 1.47
COL1A1
TMEM100
NFATC1
< 1 x 10-7
1 X 10-7
9.1 X 10-6
0.63
1.45
0.72
GADD458 6.8 X 10-6 0.74
< 1 X 10-7 0.54PRND
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17 16.73 16.74
17 20.4 20.41
17 28.52 28.56
17 48.26 48.28
17 53.8 53.81
18 77.16 77.29
19 2.48 2.48
20 4.7 4.71
4. Discussion
4. DISCUSSION
It is now believed that both cancer initiation risk and later neoplastic
events (tumour growth, invasion, metastatic spread, response to
therapeutic interventions, and survival) may be strongly influenced by
factors predetermined by individual's genetic background. Recent progress
in decoding the human genome has provided information about thousands
of potentially important gene polymorphisms affecting both normal
physiological mechanisms and cancer pathogenesis. These variants act
through their products involved in various regulatory systems and metabolic
chains at different levels of biological organization. It seems likely that
combinations of these common polymorphic gene variants frequently found
in populations may exert regulation of basic processes such as proliferation,
differentiation, and apoptosis, and may influence different stages of
carcinogenesis, as supported by several reports of significant associations
between germ line variations and risk or prognosis of different cancer types.
At the beginning of my project, population-based association studies
were widely-used approach for the identification of common genetic factors
affecting common diseases, such as cancer (291), but only few genome-
wide studies were carried out. In 2006, this research group has reported a
study on >80,000 SNPs that led to the identification of a functional
association between the region containing the PDCD5 (programmed cell
death 5) gene and lung cancer risk in two independent Caucasian
populations (292). In 2007, the same research group reported an
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association between SNPson Kruppel-like factor 6 (KLF6) gene and reduced
risk of lung cancer suggesting its candidacy in modulated lung cancer
susceptibility (293) using one of the first Affimetrix platforms (lOOK SNP
array). These preliminary studies opened new prospects to carry out
additional genome-wide scans in order to investigate the hypothesis of a
polygenic inheritance of susceptibility to lung cancer in humans (294).
At the moment, as at the beginning of my project, no GWASs for the
identification of lung cancer prognostic germ line variations have been
published. However, some studies have suggested the involvement of
genetic elements influencing of neoplastic development and leading to
differences in patients' prognosis, treatment response and survival rates
(141, 142, 292, 295).
4.1 POPULATION-BASED AND FAMILY-BASED ASSOCIATION
STUDIES FOR LUNG CANCER RISK
To address the initial aim of identifying genetic determinants of lung
ADCA risk we have carried out a genome-wide association study (GWAS) in
Italian lung ADCA patients (population-based study) and healthy unrelated
controls and a GWAS in Italian lung patients and their unaffected sibs as
controls (family-based study).
In the population-based GWAS, we decided to focus specifically on
lung ADCA, instead of lung cancer patients in general, to avoid problems
deriving from histotype admixture and because this histotype is most likely
the one where inherited components play the stronger role as suggested by
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its high frequency among young and non-smoker lung cancer patients (94,
296, 297). We used a joint analysis of two independent populations rather
than a replication-based analysis to increase power to detect genetic
association (226). However, although the correlation between the
measurements of allelic frequencies was high, concordance between two
different experiments in the identification of SNPs associated to the risk of
lung ADCA was not high, leading to 235 SNPs only with P values < 0.01 in
both experiments. This result might be due to either technical variance
representing almost one third of the observed variance, or to the wide
genetic differences that make not plausible the comparison of groups of
individuals although taken from the same population. Indeed, the compared
groups differed much more than expected because of the effect of sampling.
We identified 12 SNPs putatively associated with lung cancer risk.
Genotyping of these SNPs in individual samples led to statistical
confirmation of 8 of 12 (67%) SNPs.This result provided evidence that the
screening system was sufficiently accurate to determine real differences in
allele frequency between cases and controls.
The 8 SNPs associated with lung ADCA risk identified several
chromosomal regions putatively associated with lung cancer risk (Table 12).
Most of the 8 SNPs do not have an apparent functional activity but they
most likely represent genetic markers in significant linkage disequilibrium
(LD) with the genomic regions containing the functional variations. Among
these, SNP rs2515373 on Chromosome 11 maps within intron 3 of the
contactin 5 (CNTN5) gene, which encodes a glycosylphosphatidylinositol-
anchored neuronal membrane protein that functions as a cell-adhesion
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molecule. A role for this protein in tumour invasion and metastasis is
possible, since another gene of this same family (contacting 1) encodes a
product that modulates invasion and metastasis of lung ADCA cells (298).
The other SNPs show significant LD with genomic regions containing genes
that may carry functional variations. For instance, SNP rs2172706 maps on
Chromosome 1 at a distance of 10 kb from the 3D-end of the KCNN3 gene
(potassium intermediate/small conductance calcium-activated channel,
subfamily N, member 3), and at a distance of 70 kb from the 50 of the
ADAR gene (adenosine deaminase RNA-specific). A wide LD region (140 kb)
around rs2172706 is observed, preferentially including the ADAR gene and
partially including the 30 region of KCNN3. SNP rs4897493 on Chromosome
6 is in LD with the EPB41L2gene, a member of the protein 4.1 superfamily
involved in linking cell surface glycoproteins to the actin cytoskeleton and
acting in tumour suppression (299). At present, it is unknown whether the
effects of single SNPson lung cancer risk are mediated by encoded proteins
or by non-coding RNAs in LD with the relative SNPs.
These preliminary findings suggest the involvement of multiple
common alleles in the inherited modulation of lung ADCA risk in the general
population. Indeed, the rare allele carrier status at each of the 8 confirmed
SNPs was associated with a significant modulation of lung cancer risk (Fig.
20), suggesting that multiple, and unlinked genetiC loci may control
individual susceptibility to lung cancer in humans. These findings would not
exclude that rare germ line mutations could provide a high risk of lung
cancer in carriers; however, such putative mutations would have a low
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impact on the risk of the disease at the general population level and would
not be detectable by GWAstudies.
The results of this first GWAS are consistent with a polygenic
inheritance model characterized by dominant or co-dominant effects of rare
alleles at 8 unlinked markers. Indeed, we found a significant trend of
decreased lung ADCA risk by the carrier status of two or more rare alleles,
with effects particularly strong for carriers of four or more rare alleles (OR <
0.3; Fig. 21). Thus, the combination of multiple genetiC variants may have a
strong effect on lung ADCA risk. Dosage effects and interchangeability of
rare alleles in the same individual in modulation of lung ADCA risk suggest
that candidate genes act on independent biochemical pathways, as the
known functions of genes in LD with the associated SNPswould predict.
It should also be considered that the 8 SNPs associated with lung
ADCA risk in our study may show different LD in different ethnic groups,
and consequently, may be relevant only in certain populations, because
ethnic-related loci are plausible under the assumption of the polygenic
model.
Our results are in agreement with findings obtained in the well
characterized model constituted by mouse inbred strains, where the
polygenic nature of control of strain susceptibility to carcinogen-induced
lung tumourigenesis has been dearly demonstrated (31, 300). In addition,
we have reported that genetiC variants causing an inhibition of genetiC
susceptibility to lung tumourigenesis are common in inbred strains (301),
consistent with the present findings of the reduction of lung cancer risk by
the rare alleles in humans. Therefore, the same type (polygenic) of genetic
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control of susceptibility to lung tumourigenesis may be operative in both
mammalian species, although the genetic loci involved may differ.
Our results suggest that a polygenic control of susceptibility to lung
cancer may also operate in humans, leading to possible strong effects on
cancer risk of the combination of multiple genetic variants at the individual
level and, consequently, representing an important determinant of lung
cancer risk in the general population.
Since most of the lung cancer cases that we have analyzed consist of
smokers, the identified loci may affect susceptibility to smoking-induced
lung cancer.
Of course, this first analysis would not provide exhaustive coverage of
the genetic components affecting lung cancer risk, but it would represent a
demonstration of the plausibility of the polygenic model of lung cancer risk
in the general population and a first example of how genome-wide screens
could represent a useful approach to dissect the genetic determinants
underlying the susceptibility to common complex diseases. Studies in large
population series are needed to confirm our results that could represent a
first step toward the definition of a genetic profile for the estimation of
individual genetic risk of lung cancer. The future possibility of an estimation
of the individual risk of lung cancer could be helpful for the control of lung
cancer incidence at population level, since high risk individuals may be more
motivated to stop smoking and to undergo early diagnostic procedures
(302).
In the second GWASwe planned to use a sibling-based study design
to detected loci statistically associated with lung cancer risk. Unlike the
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previous GWAS, given the difficult to recruit healthy sibs due to old age at
diagnosis for most of the cases, we included all lung tumour histotypes.
Despite the poor feasibility of the recruitment of healthy sibs controls to
carry out family-based genome-wide association studies in lung cancer, ,
the possible benefits resulting from the appropriate matching of cases and
controls may justify the effort. Even a small size of population (Table 2),
this type of study offers complete robustness to potential population
heterogeneity eliminating problems that are related to case-control studies
with controls from the general population. In particular, an important
advantage of the discordant sibs design is the possibility to exclude the
potential for bias due to population stratification, which is common in
population-based studies (258). Indeed, cases and controls derive from the
same pedigree whose DNA differences may lie in genetic polymorphisms
putatively responsible for the disease status. The effect (lung cancer risk
estimation) detected by the discordant sib pair design (1:1 case:control
ratio) and sib transmission disequilibrium test is due to the combined
presence of linkage and association (258). In addition, even the limited
number of sib-pairs, all cases are non-smokers and younger lung cancer
patients. Thus genetic factors may most likely have played a role in lung
cancer development in these cases, as they did not smoke and suffered
from lung cancer at young age.
In this genome-wide association study using DNA pools, we identified
36 SNPs that showed significant linkage/association in the family-based
series (Table 13). Individual genotyping confirmed the robustness of our
pooling approach (Fig. 23), demonstrating that this method produces
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reliable results and is time- and cost-effective. Of the 36 genetic markers,
13 mapped within genes. The most significantly associated SNPs (P :S
0.0045), i.e., rs11833102, rs17120323, rs1244S758 and rs32S702, mapped
in carboxypeptidase M (CPM), sarcoglycan zeta (SGCZ), cadherin 13, H-
cadherin (heart) (CDH13) and cyclic nucleotide-gated channel alpha 4
(CNGA4) genes, respectively. Overexpression of CPMwas recently reported
to correlate negatively with disease survival in human lung ADCA patients
(303), and aberrant methylation of the CDH13 gene was observed in lung
ADCA (304). Thus, our findings point to the relevance of genetic
components in the modulation of individual lung cancer risk in non-smokers.
Interestingly, we found that one of the associated SNPs (rs12663498,
P = 0.055) maps to 6q25.1, the same locus previously linked to lung cancer
risk in pedigrees with multiple lung cancer members (126). The SNP maps
within the pleckstrin homology domain containing family G (with RhoGef
domain) member 1 (PLEKHG1) gene, which lies 2 Mb from RGS17, the
major candidate gene for the familial lung cancer susceptibility locus (127).
The application of the previously proposed polygenic model to the 35
SNPs associated in the discordant sib-based series showed a highly
statistically significant association between the genetic susceptibility score
and the proportion of lung cancer cases (Fig. 24).
Our single-point analysis confirmed in the population-based series
only 3 of 36 SNPs that were statistically associated in the family-based
series (Tables 14). This result could be expected if we consider the
differences between these two series, i.e., the family-based series is
constituted by young non-smoker lung cancer patients whereas the
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population-based series is constituted by mostly smokers with a higher
median age at tumour diagnosis. In addition, since the results of the family-
based series are not biased by population structure and most of the
detected SNPs presumably represent real associations, the scarce effects of
the same SNPs in the population-based series rest on either the existence of
significant population admixture, masking real associations, or the existence
of phenocopies and a high degree of genetic heterogeneity in the general
population. In the latter case, a model of "private" genetic epidemiology
(305) may account for the genetic effects detected in lung cancer families.
Interesting, in mouse models, our group recently detected a high degree of
genetic heterogeneity affecting genetic susceptibility to skin tumourigenesis
and to inflammatory response, i.e., the same phenotype being linked to
different loci in different mouse lines (306), thus supporting the role of the
"private" genetic epidemiology in an experimental model.
Another aspect that we should take into consideration is the role of
genetic heterogeneity in the predisposition to cancer. Indeed, independent
loci may modulate the risk of sporadic and of familial cancer, as the model
of breast cancer susceptibility demonstrated (307, 308). Also, we should
consider the great impact of the major environmental risk factor, i.e.,
smoking habit, and the difficulty in separating the genetic and
environmental contributions to lung cancer risk. Indeed, a study in
monozygotic and dizygotic twins showed that the possible sharing of the
same environmental risk factors may playa major role in lung cancer risk
(309).
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In 2008, three separate GWASs on several thousand of samples were
published and all three studies found a region on chromosome 15q25
associated with lung cancer risk (130-132). Two of the GWASs identified
polymorphisms directly associated with lung cancer (130, 131), whereas the
third study identified an association between the same genetic region and
nicotine dependence and concluded that the association with lung cancer
goes indirectly through smoking (132).
Even if not included in the 47 SNPs with P < 1 X 10-7 and thus not
considered for further analysis, SNPs of that region (rs12916375) was
included in our initial top list of 235 SNPs (P < 0.01) in population-based
study, indicating that also in our series the chromosome 15q25 region may
be involved in lung ADCA risk in general population. To further test the
candidacy of these region in our population and having already available
DNA pools from our population-based case-control study, we analyzed two
coding polymorphisms reportedly associated with lung cancer risk:
rs1051730, a synonymous change within the CHRNA3 gene (130-132), and
the rs16969968, a D398N polymorphism of the CHRNA5 gene (131).
Because the rs1051730 showed a slightly weaker statistical association with
lung cancer risk as compared with the rs16969968 and because of an
almost complete linkage disequilibrium between these two single-nucleotide
polymorph isms in the European population, only the CHRNA5 polymorphism
was analyzed in individuals of the whole series (Table 1). The frequency of
the A (398Asn) allele differed significantly between controls and cases (0.41
and 0.48, respectively; P = 0.0001) with the homozygosity status of the A
allele significantly associated with lung ADCA risk (OR=1.9, 95% Cl 1.3-
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2.7; P = 0.0003) as well as the heterozygosity status (OR=1.4, 95% Cl
1.0-1.9; P = 0.024) when compared with GG (Asp398Asp) homozygous
subjects. Comparison of subjects carrying the A (398Asn) allele as dominant
effect versus GG (Asp398Asp) homozygous subjects also showed a
significant association of the A allele with lung ADCA risk (OR=1.5, 95% Cl
1.2-2.0; P = 0.002). No significant associations of the CHRNA5 D398N
polymorphism with patients' clinical stage or overall survival were detected.
(310, 311). Our findings in non-smokers discordant sib pairs did not confirm
the previously reported population-based association of lung cancer risk
with the chromosome 15q25 nicotinic receptor locus. These results are
consistent with a recent meta-analysis in >1000 never-smoker cases and
>1800 controls (312) and by a recent pooled analysis (136), showing that
this locus is not associated with lung cancer risk in never-smokers.
Interestingly, a large GWAS in never-smokers found statistically significant
association between lung cancer and a locus at 13q31.3 (137). All these
findings suggest that the genetic factors for risk in smokers and never-
smokers may be different and that lung cancer risk in non-smokers may
have an inherited susceptibility component that may take the place of the
strong role played by the smoking habit in smokers (313), as reviewing in
(314 ).
Subsequent GWASs identified lung cancer susceptibility loci also at
6p21 (133, 134), and 5p15.33 (133, 135), providing further powerful
evidence of a genetic contribution to lung cancer, even if several
discrepancies due to population characteristic such as ethnicity and smoking
(136). In fact, in Asian population the association has not been confirmed
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for the variants in lSq25 reported in the Caucasian studies, due to their
rare allele frequencies, and no variants in 6p21 were replicated in
Caucasians (136). In our two GWA studies, we did not find any associations
among the top SNPs between polymorphisms in 5p1S.33 and 6p21.33 and
lung cancer risk. When we genotyped rs4016181 (in Sp1S.33, CLPTM1L
gene) and rs3117S82 (in 6p21.33, BAT3-MSHSgene) in individual samples
from our population-based case-control study we found a borderline
association with lung ADCA risk only for the SNP in Sp1S.33 locus P=O.02).
Since analysis of candidate genes located in these regions by
individual studies has had only limited success in identifying speclflc
variants that are conclusively associated with lung cancer risk, the
International Lung Cancer Consortium (ILCCO) recently conducted a
genotyping study in a total of 8,431 lung cancer cases and 11,072 controls
of European and Asian ethnic groups (128). This study suggests that only
the SNP rsS60191 (TPS3BP1) of ten variants tested is associated to lung
cancer risk and refuses all other associations focusing on the importance of
consortia and of great case-control studies in replicating or refuting
published genetic associations. Notwithstanding the identification of these
loci (1Sq2S, Sp1S and 6p21) associated with a modulation of lung cancer
risk in particular population, a model explaining the complex genetiCS of
lung cancer predisposition different to our proposed polygenic model is still
waiting to be defined.
148
4. Discussion
4.2 CASE-ONLY ASSOCIATION STUDY FOR LUNG CANCER
PROGNOSIS
Tumour progression is defined as the dynamic stepwise process
through which neoplastic cells evolve towards more malignant
characteristics and more aggressive clinical behaviour (315). This process is
a critical point in clinical cancer management since most cancer deaths still
result from metastasis and the spread of cancer to other parts of the body
begins early in the growth of the primary tumour (316). In the last years,
variations in cancer aggressiveness and malignancy have been mainly
associated with the accumulation of multiple somatic alterations and
epigenetic changes in the neoplastic cells (317). Indeed, most studies
aimed to identify factors that affect cancer patient's outcome/survival are
focused on genetic alterations or transcriptional changes in cancer tissues.
However, such studies have ignored the fact that cancer is a mass of
heterogeneous cells whose growth is dependent upon reciprocal interactions
between genetically transformed cells and the microenvironment in which
they live. Indeed, genetic studies carried out in experimental mouse models
support the biological plausibility of a genetic modulation of cancer
progression (295), suggesting that germ line variations may also playa role
in the control of lung cancer patients' outcome. Although in the last years
several GWA studies have focused on genetic risk for lung cancer, none has
examined the possible genetic modulation of lung cancer staging, that is the
most powerful prognostic factor in cancer patients (318).
To address the hypothesis stating that genetic constitution might also
contribute to tumour development, we planned to investigate the role of
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genetic control in lung cancer progression through case-only association
studies in a group of Italian patients affected by lung ADCA. We collected an
initial relatively large case series containing patients of the same lung
cancer histotype, i.e., ADCA, and of the same ethnicity, which follow-up and
epidemiological data were available. Clinical stage according to the tumour-
node-metastasis (TNM) system (100, 319) is the most powerful prognostic
factor in cancer patients and the main determinant of lung cancer patient's
survival. Thus, in order to look for possible coding SNPs that could explain
the different effects on lung tumour prognosis, we divided our series
according to their clinical staging, comparing stage I and higher clinical
stage patients, and we investigated SNPs with different allele frequencies
between the two groups.
We identified 63 SNPs putatively associated with clinical stage.
Genotyping in individual samples led to statistical confirmation of 54 of 63
(85.7%) SNPs, demonstrating the robustness of our pooling approach (Fig.
26). The most significantly associated SNPs (P :S 5.0 x 10-6), i.e.,
rsl0278557, maps to chromosome 7 in the intronic region of the
mesenchyme homeobox 2 (MEOX2) gene, also known as growth arrest-
specific homeobox (GAX) gene, which encodes a member of a subfamily of
non-clustered, diverged, antennapedia-like homeobox-containing genes.
The encoded MEOX2 protein is a key regulator of vascular-cell function.
MEOX2has been proposed as a candidate tumour suppressor gene in Wilms
tumour, and showed differential expression and aberrant methylation in
lung cancer (320, 321). To test the reproducibility of our results we chose
two smaller lung cancer populations with different lung histological type
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(317 ADCA and 257 SQCC,Table 3). Even though ADCA and SQCC belong
to the same main lung cancer histological group of non-small cell lung
cancer (NSCLC), differences in etiologic, clinical and molecular
characteristics have been widely reported (322). Indeed, one of the loci
recently associated with lung cancer risk, the SplS.33 locus, was found
significantly associated in ADCA subtype but not in squamous cell carcinoma
(212, 213). Also the results of our confirmation analyses identify different
associations between ADCA and SQCC series, reflecting the differences
across histology. In fact, though the loss of statistical power in confirmation
series due to the smaller number of subjects compared to discovery series,
logistic regression analysis of the same 54 SNPs pointed to 3 SNPs
significant associated with clinical stage in ADCA series that were not
confirmed by analysis in SQCCseries. Our findings suggested that several
loci are involved in the modulation of lung tumour progression in general
population and that the involvement is strongly histology-specific.
JOint analysis of the GWA and replication series to increase the
statistical power of the study and to obtain an overall unbiased estimate
(288) identified 22 SNPs that, at nominal statistical P-value <0.01, showed
statistical association with clinical stage (Table 19). Analysis of additive
effects of risk associated to the minor alleles of these 22 SNPs using a
polygenic model (289, 323) in 917 lung cancer patients (Table 3) revealed a
statistically significant association between the general estimator score and
increased risk of higher clinical stage (Fig. 27 and 28) and with risk of death
(Fig. 29), suggesting the complex genetiC control of lung ADCA patients'
clinical prognosis. The predictive value of the genetiC estimator calculated
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on the 22 SNPs genetic profile was statistically associated to clinical stage
also in the second smaller ADCA series only (P=0.0006).
Empirical replication using bootstrap samples from the original data,
rather than replication in independent samples, has been proposed in
association studies since bootstrap samples likely share the same
population structure of original data, whereas an independent series may be
characterized by a different population structure and, thus, lead to false-
negative results on analysis (290). Our empirical replication using bootstrap
samples confirmed the statistically significant difference between stage I
and stage >1 patients in their genetic estimator based on 22 SNPs.
Of the 22 candidate SNPs, ten mapped within genes. Among these,
the most significantly associated SNP in the joint analysis (rsl0278557, P =
1.1 X 10-5, Table 19) maps on chromosome 7 in the intronic region of the
mesenchyme homeobox 2 (MEOX2) gene, described above. Other important
genes are the myeloid/lymphoid or mixed-lineage leukemia 5 (trlthorax
homolog, Drosophila) (MLL5), the sprouty-related, EVHl domain containing
1 (SPRED1, rsl0520058, Table 4), and WW domain containing
oxidoreductase (WWOX, rsl0514440, Table 4) candidacies are also of
interest.
Indeed, MLLSgene belongs to the evolutionarily conserved trithorax
family of human genes that activate and regulate diverse genes, including
homeobox (HOX) genes that are important in oncogenesis and tumour
suppression (324, 325). MLL5 is located on chromosome 7q22, which
frequently is deleted in myeloid leukaemia, and recent studies demonstrate
that MLLSis a key regulator of normal haematopoiesis (326).
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SPRED1 gene negatively regulates the Ras-ERK signalling pathway,
cell motility, and metastasis, and its germ line loss-of-function mutations
cause a neurofibromatosis 1-like syndrome (327, 328).
wwox gene acts as a tumour suppressor in different tumour types
and plays a regulatory role in a wide variety of cellular functions such as
protein degradation, transcription, and RNA splicing (see review in (329».
More recently, WWOXwas found to be often altered or silenced by promoter
methylation in NSCLC(330).
At present, it is unknown whether the observed associations between
SNPs and lung cancer clinical stage underlie effects of non-synonymous or
regulatory variants in linkage disequilibrium with these SNPs. Replication in
large cohorts of patients and on different types of cancer would provide
strong information whether a SNPmay have a role on cancer prognosis and
whether this effect is specific only for a subset of tumour types.
Together, these results indicate for the first time that clinical staging
of lung ADCA can be under genetiC control, with each individual patient
displaying a own tendency toward a low or high clinical stage, modulated by
individual genetiC variations. Indeed, it presented the first effort to identify
whole genomic alterations that determine different outcome in lung cancer
patients and would allow to draw a SNP profile associated with lung cancer
clinical stage and overall survival, representing a first step towards the
possible clinical use of such a profile for the personalized follow-up of
patients at genetiC risk of poor clinical outcome. The significant association
of the 22 SNPs with lung cancer clinical stage and survival opens the
possibility that the functional products of the genes linked to these SNPs
153
4. Discussion
use novel biochemical pathways associated with lung cancer patients'
outcome, and that the identification of these pathways might provide gene
targets for therapies to counter lung cancer progression.
It seems that much of the genetic architecture of complex traits
remains unexplained. A new strategy should be developed for estimating
the degree of false positive finding. In order to analyze the role of genetic
heterogeneity, SNPs panels assembled in the last few years that permit to
identify ethnic and sub-ethnic group, as well as individuals in paternity
testing could be useful (331). The use of these panels has been proposed in
controlling for admixture in association studies (332). Genotyping such a
panel of SNPs in our series would allow identification of genetically-related
subgroups of individuals. In turn, adjusting by genetic clusters may allow
highlighting genetic differences between cases and controls that would be
masked by genetic heterogeneity. Thus, further clarification of the role of
genetic mechanisms in lung cancer patients' outcome may hold the promise
of improved therapy and disease outcome.
It is also known that SNPs in regulatory elements can affect gene
expression levels. Therefore, we planned to analyze whole-genome
expression profiles in normal lung tissue from patients with different clinical
stage, in order to identify transcripts whose expression levels are associated
with lung ADCAprognosis.
The identification of candidate genes by the transcriptional profile
analyses allows tracing possible biochemical pathways that are associated
with lung cancer prognosis. This could overcome the genetic heterogeneity
of this disease, reducing its complex genetic architecture to fewer
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pathways. Over the last years there has been an increase in the use of
microarray technology in cancer research for transcriptional analysis of
primary tumours. Indeed, most of the studies use microarray analysis of
tumor tissues compared with normal tissues for profiling of molecular
characteristics in order to identify possible classifiers for prognosis
(333,334) or to predict for aggressive forms of different stage of cancer
(335). In lung cancer, the microarray analysis has identified gene
expression profiles related to disease recurrence, prognosis and survival in
ADCA (336) and in SQCC patients (337). The number of publications
relating to the use of microarrays for analysis of normal tissue is much
more limited. There are some studies that used normal tissue to generate
gene signatures that discriminated cell populations in sensitive and resistant
to radiotherapy or to identify genes and pathways involved in tissue
response to radiation injury (reviewed in 338). Recently, some studies
analyzed gene expression profiles comparing normal breast tissues from
cancer patients with normal breast tissues from non-cancer patients and
indicated that gene alteration associated with tumor development is already
detected in normal tissue, leading to higher risk for development of a
malignant disease in the breast (339,340).
Under this hypothesis that the dynamic microenvironment in which
cancer grows may influence its aggressiveness and that individual genetiC
constitution may affect the expression profile of normal lung and also
explain differences in the cancer outcome, we performed a genome-wide
transcriptional analysis in normal tissue comparing gene expression profiles
of lung ADCA patients with different stages. Although we cannot exclude
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possible presence of micro-metastases in tumour adjacent normal tissue,
macroscopic analysis in our samples indicated no apparent contamination of
cancer cells. Lung gene expression patterns could be altered by genetic
heterogeneity of human population and by environmental factors, first of all
exposure to cigarette smoke. We attempted to minimize all these
confounding factors by studying a relatively large number of well-
characterized Italian ADeA patients and performing gene expression
analysis only among smokers. Thus, we analyzed expression level of 120
normal tissues from smoker ADeA patients comparing stage I with higher
(Table 4), in order to examine relationships between gene expression
profiles in normal tissue and staging.
In order to verify microarray reproducibility and estimate technical
variability we used a joint analysis of two independent microarray
experiments in RNA pools and we identified a set of 11 stage-associated
genes able to distinguish patients with stage I from patients with higher
stage (Table 21). This gene set included genes that are biologically plausible
contributing to pathogenesis of disease. Indeed, of the two genes whose
transcript levels in normal lung tissue showed the higher modulation
between stage I and stage>I patients and the best statistical association
with patients' clinical stage, FeN3 (ficolin 3) encodes a collagen-like defence
molecule that is involved in the maintenance of tissue homeostasis and of
the innate immune system and acting as recognition molecules in the
complement system (335). FeN3 might playa protective role against the
development of autoimmunity (336) and FeN3 deficiency is associated with
immunodeficiency and with susceptibility to fever, neutropenia, and
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infection (337, 338). Interestingly, susceptibility to infection has been
reported to increase the risk of cancer, including lung cancer (339).
The other best statistically associated and most modulated gene,
TMEMIOO,encodes a transmembrane protein of unknown function(s); in the
developing mouse embryo, TMEMIOO is expressed predominantly in
endothelial cells and thus might be involved in angiogenesis (340).
Among the other genes, C200rfl14 gene, known also as LPLUNC1,
encodes for a protein that is expressed in the upper respiratory tract and
oral cavity, and that may function in host defence (341).
IDHl (isocitrate dehydrogenase 1) gene encodes for a NADP(+)-
dependent isocitrate dehydrogenase, that has a significant role in
cytoplasmic NADPHproduction and in peroxisomal NADPHregeneration and
whose coding mutation at the arginine in 132, that results in loss of the
enzyme's catalytic activity, was associated with malignant gliomas (342)
and thyroid cancers (343).
LZTS1 (leucine zipper, putative tumour suppressor 1) encodes a
tumour suppressor protein ubiquitously expressed in normal tissues and its
expression is often much lower in tumour tissues (344) confirming our
results in ADCA lung tissues. It may have a role in cell-cycle control by
interacting with the Cdkl/cyclinB1 complex and preventing the uncontrolled
cell proliferation. Loss of heterozygosity (LOH) in the LZTS1's locus is a
common characteristic of many types of cancer as ovarian carcinoma (345),
oral squamous cell carcinomas (346) and bladder cancer (347).
MSX1 (msh homeobox 1) encodes a small member of the muscle
segment homeobox gene family that functions as a transcriptional repressor
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during embryogenesis interacting with components of the core transcription
complex (348).
SELEgene encodes for E-selectin, a protein involved in cell adhesion
and responsible for the accumulation of blood leukocytes at sites of
inflammation by mediating the adhesion of cells to the vascular lining. High
serum E-selectin levels had prognostic significance and could be a potential
prognosis factor in NSCLCpatients (349).
SLC14A1 (solute carrier family 14, member 1) gene encodes for a
membrane transporter.
SMAD6 (SMAD family member 6) gene encodes for a signal
transducer, whose expression effects the progression of oesophageal
squamous cell carcinoma (350) and high expression levels are associated to
prognosis and improved survival in oral squamous cell carcinoma patients
(351).
TXNIP (thioredoxin interacting protein), also known as vitamin D3 up-
regulated protein 1 (VDUP1), is a known tumour suppressor gene, that is
involved in redox stress responses (352), regulation of cellular proliferation
(353), and in the differentiation of myeloid and macrophage lineages (354).
Its expression is frequently lost in cancer tissue including breast,
gastrointestinal, renal, and liver tumours (355-358). Our findings of the
down-regulation of TXNIP expression in lung cancer are in agreement with
similar observations reported in small series of NSCLC(359).
VIPR1 (vasoactive intestinal peptide receptor 1) gene encodes for a
small neuropeptide involved in ion flux in lung and intestinal epithelia that
was proposed as tumour suppressor since it was found down-regulated in
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lung adenocarcinoma (360). Most of these genes seem involved in the
control of the response of innate or acquired cellular immunities; therefore,
immunity response as detected in normal lung by transcriptional analysis
may be associated with clinical stage in lung ADCA patients.
Biochemical pathway analysis of the whole transcriptional profile
indicated the involvement of cytokines and cytokine receptors. Overall, the
biochemical pathways of genes in normal lung tissue that were associated
with clinical staging in lung ADCA patients are involved in the control of
inflammation and infection (Table 20). Of the detectable genes, most were
found to be up-regulated in normal tissues from patients with higher clinical
stage, indicating the crucial role of these inflammatory mediators in tumour
growth and progression. It is known that lung tissue samples subjected to
gene profiling may contain an abundance of migratory inflammatory cells
and blood vessels so that analysis of whole lung tissue represents an
amalgam of expression by all of these cell types. However it is interesting
that inflammatory responses were more evidence in normal tissue
surrounding the tumour at advanced stages. These findings are consistent
with reports showing that non-malignant lung stromal areas in advanced-
stage non-squamous cell lung carcinoma contain high levels of neutrophil
infiltration and vascular endothelial cells recruited by chemokines/cytokines
(361-364). Their expression was differentially regulated in the tumour and
lymph node sites during the progression of tumour growth (365). Further
analysis of genes involved in this pathway identified 6 additional genes
whose expression in normal lung was statistically associated with clinical
staging (Table 4). Among these genes, IL6 (interleukin 6) showed the
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stronger modulation (Table 23). This gene encodes a cytokine implicated in
a wide variety of inflammation-associated disease states. Moreover, high
serum IL6 level was found to correlate with tumour invasiveness, size, and
grade and with clinical stage and survival in patients with gastric (366),
colorectal (367), and breast cancer (368).
TNFSF10 (tumour necrosis factor (ligand) superfamily, member 10),
also known as tumour necrosis factor-related apoptosis inducing ligand
(TRAIL), is a member of the TNF superfamily of cytokines that induces
apoptosis in about 50% of investigated tumour cell lines and play an
important role in tumour surveillance (reviewed in (369». TNFSF10/TRAIL
is a key regulator of inflammatory response (370) and its expression has
been implicated in asthma (371), and a specific haplotype of this gene is
associated with risk of asthma (372)
CCL2 (chemokine (C-C motif) ligand 2), also known as monocyte
chemoattractant protein-1 (MCP-l), has been previously demonstrated to
increase tumour growth and bone metastasis through its chemotactic
activity for monocytes/macrophages and basophiles to tumour sites (373).
Monitoring of CCL2concentration in serum may enable prediction of clinical
course of interstitial lung disease (374). CCL2 is also involved in the
advanced stage of atherosclerotic cerebro-vascular disease (375) and is
associated with poor prognosis in associated small vessel vasculitis (376).
In our study, we found that the expression level of these molecules is
just different in the normal tissue from lung cancer patients with different
clinical stage and our observation that a signature is associated with clinical
stage across heterogeneous population of patients is encouraging and it
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could be an important marker of prognosis following further clinical
validation.
We further investigated the expression of the 11 modulated genes
according to clinical stage in tumour tissue, and, interestingly, all of these
genes except for IDHl were down-regulated in lung ADCA tissue as
compared to normal lung (Table 22); such down-regulation in tumour tissue
paralleled the decreased expression levels of the same genes, except SELE,
in normal lung of stage >1 as compared to stage 1 patients (Table 19).
These findings were also confirmed at level of proteins (Fig. 36).
Our findings suggest that clinical staging of lung ADCA patients may
be genetically modulated, at least partially, and that a transcriptional profile
signature associated with clinical staging is detectable in normal lung tissue
of lung ADCA patients. Such a signature may underlie individual genetic
predisposition to low or high clinical stage. Characterization of the identified
candidate genes whose expression is associated with clinical stage might
shed light on the genetic mechanisms underlying individual predisposition to
tumour aggressiveness and might define new genetic targets for drugs
aimed at countering cancer progression.
Our GWAS and microarray analyses both allowed identification of
candidate genes and pathways associated with lung cancer clinical stage.
Each of these two different approaches have several advantages and
weakness, thus by combining data from the two analyses we could identify
a small fraction of genes putatively involved in lung cancer outcome.
To prioritize the discovery of candidate loci associated with lung
cancer prognosis we carried out an integration of data from GWA with gene
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expression signatures from case-only study. We found 6 SNPs, among those
with P ~ 1 X 10-7 in GWA, that map within genes slightly differentially
expressed (P<0.001, Table 23) in the second microarray experiment.
Among these, ADAMTS9 gene encodes a member of the disintegrin and
metalloproteinase with thrombospondin motifs protein family. Members of
the ADAMTS family have been implicated in the cleavage of proteoglycans,
the control of organ shape during development and angiogenesis. In
particular ADAMTS9 contributes to the inhibition of angiogenesis in the
tumour microenvironment (377). Recently, ADAMTS9 has been
characterized as a novel tumour suppressor gene in esophageal squamous
cell carcinoma and has been shown to be epigenetically silenced in
association with lymph node metastases in nasopharyngeal carcinoma
(378). This gene is localized to chromosome 3p14.3-p14.2, an area known
to be lost in hereditary renal tumours (379). Interestingly, the SNP
rs1799969 on chromosome 19 maps within ICAM1 gene and in LD with the
near ICAM4 gene, two genes belonging to the intercellular adhesion
molecule protein family. Both are down-regulated in normal tissue from
higher clinical stage patients. These genes are candidates for additional
studies that could clarify their role and function related to tumour
progression.
When we focused on regions where we identified the 54 most
associated SNPs with clinical stage (Table 15), we found on the Sentrix
Bead Chip HumanRef_8_v2 (Iliumina) detectable expression of 18 of 30
known genes (Table 24) in normal lung tissue of our lung ADCA patients,
but we found no statistically significant differences in mRNA expression
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levels between the clinical stage I and stage >1 patients at any of the 18
genes (Table 24), suggesting that the SNP candidacy may rest on non-
synonymous variations that are in linkage disequilibrium with the identified
SNPs, or on splicing alternative variants rather than alteration of transcript
regulation.
In order to test whether these two approaches identified common
pathways, DAVID functional annotation tool was used for pathways analyses
of GWAS and microarray data. We found that the top GWAS and
differentially expressed genes were enriched in cell adhesion molecules
focusing in different aspects such as focal adhesion, extracellular matrix and
cell adhesion itself. The involvement of cell adhesion system in cancer
progression is now well ascertained (380). In fact, integrins play an
important role in different aspects of tumourigenesis such as cell
proliferation, cell motility, and apoptosis (381), and cadherins were found
involved in tumour cell proliferation through cyclins and cyclin-dependent
kinases (382). In addition, modulation of cell adhesion was found to be
involved in angiogenesis (383) and to play an important role in epithelial-to-
mesenchymal transition that is thought to be a key step in malignant
transformation (384). This result suggest that functional annotation
analyses using candidate genes identified by GWAS and by gene expression
profiling can help to refine the identification of candidate genes or pathways
associated with a certain phenotype.
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CONCLUSIONS
The results showed in the present thesis indicated that genetic
constitution plays an important role in lung cancer susceptibility and
progression. We suggested and confirmed the relevance of a polygenic
model characterized by additive and interchangeable effects of rare alleles
in the modulation of individual risk of lung ADCA identifying multiple
inherited susceptibility alleles linked to lung cancer. Furthermore, we
detected 22 genetiC variants that together explained a large individual
variation in clinical stage and that were also associated with overall survival,
demonstrating that the individual genetiC constitution may affect clinical
stage of lung cancer patients.
In the second part of this thesis I addressed the critical question of
whether a gene expression profile of normal lung tissue can be associated
with clinical stage in lung adenocarcinoma (ADCA) patients. The results of
such analysis pointed to 11 differentially expressed genes, with FCN3 and
TMEMIOOshowing the best statistical association with clinical stage and the
higher modulation. The same FCN3and TMEMIOOgenes were also >40-fold
down-regulated in lung ADCA tissue as compared to normal tissue.
Moreover, analysis of biochemical pathways pointed to a transcriptional
signature involving cytokines and cytokine receptors. In addition, combining
GWAS and microarray data, we identified cell adhesion as a common
biological function and this new approach can help to refine the
identification of candidate genes and/or functions involved in tumour
development.
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These findings provided evidence that clinical stage may be at least
partially genetically determined as reflected in the transcriptional profile of
normal lung tissue and in the germ line polymorph isms.
The elucidation of the molecular events controlling cancer prognosis
and susceptibility could have a great impact on methods for a better
prediction of lung cancer outcome and diagnosis and on adequate
therapeutic choices. In particular, the identification of the genetic variations
and of genes differentially expressed in inherited constitution is essential
knowledge concerning tumour initiation and progression in lung ADCA
cancers. This should help ultimately to identify new potential target areas
for the cancer therapy, design of new efficient drugs to cure cancer with
personalized chemotherapeutic and preventive strategies, based on
individual genetic constitution.
The identification and subsequent functional characterization of the
genetic factors modulating individual risk of lung cancer and/or associated
to patients' prognosis represents an important step toward a better
understanding of the biological and molecular basis of lung cancer
development and progression.
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